AU5065700A - Thiazoloderivatives and pharmaceutical compositions containing them - Google Patents
Thiazoloderivatives and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- AU5065700A AU5065700A AU50657/00A AU5065700A AU5065700A AU 5065700 A AU5065700 A AU 5065700A AU 50657/00 A AU50657/00 A AU 50657/00A AU 5065700 A AU5065700 A AU 5065700A AU 5065700 A AU5065700 A AU 5065700A
- Authority
- AU
- Australia
- Prior art keywords
- formula
- thiophen
- benzo
- dihydroimidazo
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 275
- 239000000203 mixture Substances 0.000 claims description 204
- 239000002904 solvent Substances 0.000 claims description 197
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 150
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 134
- 125000004432 carbon atom Chemical group C* 0.000 claims description 131
- -1 thiazole-2-carboxaldehyde oxime Chemical class 0.000 claims description 114
- 125000005843 halogen group Chemical group 0.000 claims description 81
- 125000000217 alkyl group Chemical group 0.000 claims description 80
- 239000000047 product Substances 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 37
- 238000009835 boiling Methods 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 21
- LVOMAJDUIUCBRF-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carbaldehyde Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C=O)=CSC2=C1 LVOMAJDUIUCBRF-UHFFFAOYSA-N 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000002585 base Substances 0.000 claims description 15
- 208000032841 Bulimia Diseases 0.000 claims description 14
- 208000008589 Obesity Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 235000020824 obesity Nutrition 0.000 claims description 14
- 208000011117 substance-related disease Diseases 0.000 claims description 14
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 13
- 125000001246 bromo group Chemical group Br* 0.000 claims description 13
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 229910052740 iodine Inorganic materials 0.000 claims description 11
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 10
- 239000003638 chemical reducing agent Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 10
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- 208000019901 Anxiety disease Diseases 0.000 claims description 8
- 206010010904 Convulsion Diseases 0.000 claims description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 8
- 208000012902 Nervous system disease Diseases 0.000 claims description 8
- 208000025966 Neurological disease Diseases 0.000 claims description 8
- 230000036506 anxiety Effects 0.000 claims description 8
- 208000010877 cognitive disease Diseases 0.000 claims description 8
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 8
- 206010015037 epilepsy Diseases 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 201000001421 hyperglycemia Diseases 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 206010004716 Binge eating Diseases 0.000 claims description 7
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 7
- 206010013654 Drug abuse Diseases 0.000 claims description 7
- 208000030814 Eating disease Diseases 0.000 claims description 7
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 7
- 206010019196 Head injury Diseases 0.000 claims description 7
- 208000032843 Hemorrhage Diseases 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 206010033664 Panic attack Diseases 0.000 claims description 7
- 208000028017 Psychotic disease Diseases 0.000 claims description 7
- 206010041250 Social phobia Diseases 0.000 claims description 7
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 7
- NJXYNQBZHYKKOI-UHFFFAOYSA-N [3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]methanol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)CO)=CSC2=C1 NJXYNQBZHYKKOI-UHFFFAOYSA-N 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 208000022531 anorexia Diseases 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 230000006399 behavior Effects 0.000 claims description 7
- 125000005605 benzo group Chemical group 0.000 claims description 7
- 208000014679 binge eating disease Diseases 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- 206010061428 decreased appetite Diseases 0.000 claims description 7
- 235000014632 disordered eating Nutrition 0.000 claims description 7
- 206010013663 drug dependence Diseases 0.000 claims description 7
- 230000000926 neurological effect Effects 0.000 claims description 7
- 208000019906 panic disease Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 208000006011 Stroke Diseases 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 125000002524 organometallic group Chemical group 0.000 claims description 6
- 230000004584 weight gain Effects 0.000 claims description 6
- 235000019786 weight gain Nutrition 0.000 claims description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
- 208000020401 Depressive disease Diseases 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 229940124535 smoking cessation aid Drugs 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- YJUSYDAVVNRRJA-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]but-2-yn-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)C#CC)=CSC2=C1 YJUSYDAVVNRRJA-UHFFFAOYSA-N 0.000 claims description 4
- ATYGHWSFFZRFKU-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-bromo-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)Br)=CSC2=C1 ATYGHWSFFZRFKU-UHFFFAOYSA-N 0.000 claims description 4
- QLDFDZWVUGXNPJ-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-ethenyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C=C)=CSC2=C1 QLDFDZWVUGXNPJ-UHFFFAOYSA-N 0.000 claims description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 4
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 4
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000005110 aryl thio group Chemical group 0.000 claims description 4
- 239000013067 intermediate product Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 229940126403 monoamine reuptake inhibitor Drugs 0.000 claims description 4
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 4
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 3
- JAJUKPBMFIUECL-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]butan-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)CCC)=CSC2=C1 JAJUKPBMFIUECL-UHFFFAOYSA-N 0.000 claims description 3
- GVXWRWHEHPYBON-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]ethanol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)C)=CSC2=C1 GVXWRWHEHPYBON-UHFFFAOYSA-N 0.000 claims description 3
- DQVCINHQPHPGMO-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]ethanone Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(=O)C)=CSC2=C1 DQVCINHQPHPGMO-UHFFFAOYSA-N 0.000 claims description 3
- YELGWSUWLGBWTC-UHFFFAOYSA-N 2-bromo-3-(5-chloro-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C12=CC(Cl)=CC=C2SC=C1C1=C(Br)SC2=NCCN12 YELGWSUWLGBWTC-UHFFFAOYSA-N 0.000 claims description 3
- UVUFMJALNDDZOD-UHFFFAOYSA-N 2-bromo-3-(5-methoxy-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C12=CC(OC)=CC=C2SC=C1C1=C(Br)SC2=NCCN12 UVUFMJALNDDZOD-UHFFFAOYSA-N 0.000 claims description 3
- FQICMVANHBIPOM-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(propan-2-yloxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)COC(C)C)=CSC2=C1 FQICMVANHBIPOM-UHFFFAOYSA-N 0.000 claims description 3
- MGZVBYIELZDRPA-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-bromo-6,7-dihydro-5h-[1,3]thiazolo[3,2-a]pyrimidine Chemical compound C1=CC=C2C(C3=C(SC4=NCCCN43)Br)=CSC2=C1 MGZVBYIELZDRPA-UHFFFAOYSA-N 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 3
- NUUBQIMKZKAJIL-UHFFFAOYSA-N S1C2=C(C(=C1)C=1N3C(SC1C=NO)=NCC3)C=CC=C2 Chemical compound S1C2=C(C(=C1)C=1N3C(SC1C=NO)=NCC3)C=CC=C2 NUUBQIMKZKAJIL-UHFFFAOYSA-N 0.000 claims description 3
- LDZUITFMCBWNAT-UHFFFAOYSA-N [3-(1-benzofuran-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]methanol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)CO)=COC2=C1 LDZUITFMCBWNAT-UHFFFAOYSA-N 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000003723 serotonin 1A agonist Substances 0.000 claims description 3
- 230000005586 smoking cessation Effects 0.000 claims description 3
- 125000005504 styryl group Chemical group 0.000 claims description 3
- QPIGXGXRDGXIOR-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]-n-propan-2-ylmethanimine Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C=NC(C)C)=CSC2=C1 QPIGXGXRDGXIOR-UHFFFAOYSA-N 0.000 claims description 2
- BXBNMUMGPWXSBZ-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]but-3-en-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(CC=C)O)=CSC2=C1 BXBNMUMGPWXSBZ-UHFFFAOYSA-N 0.000 claims description 2
- ZJQGNICAUJOFLW-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]pent-4-en-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(CCC=C)O)=CSC2=C1 ZJQGNICAUJOFLW-UHFFFAOYSA-N 0.000 claims description 2
- FQGRDDBPUOVQKN-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]pentan-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)CCCC)=CSC2=C1 FQGRDDBPUOVQKN-UHFFFAOYSA-N 0.000 claims description 2
- RRIAMYOMYITSMB-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]prop-2-en-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(C=C)O)=CSC2=C1 RRIAMYOMYITSMB-UHFFFAOYSA-N 0.000 claims description 2
- ANPWDQQMZFHAIP-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]propan-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)CC)=CSC2=C1 ANPWDQQMZFHAIP-UHFFFAOYSA-N 0.000 claims description 2
- BMJCWHAYLOAJSO-UHFFFAOYSA-N 2-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]propan-2-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(C)(O)C)=CSC2=C1 BMJCWHAYLOAJSO-UHFFFAOYSA-N 0.000 claims description 2
- ACCFGYMZBUOSOA-UHFFFAOYSA-N 2-bromo-3-(7-methoxy-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound COC1=CC=CC2=C1SC=C2C1=C(Br)SC2=NCCN12 ACCFGYMZBUOSOA-UHFFFAOYSA-N 0.000 claims description 2
- VDFKOANEFHDZCN-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(ethoxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)COCC)=CSC2=C1 VDFKOANEFHDZCN-UHFFFAOYSA-N 0.000 claims description 2
- CDXCLKPOPFFADV-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(methoxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)COC)=CSC2=C1 CDXCLKPOPFFADV-UHFFFAOYSA-N 0.000 claims description 2
- OSCMBSILLFHMSR-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(prop-2-ynoxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)COCC#C)=CSC2=C1 OSCMBSILLFHMSR-UHFFFAOYSA-N 0.000 claims description 2
- RILVHTAZUWRQBD-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-chloro-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)Cl)=CSC2=C1 RILVHTAZUWRQBD-UHFFFAOYSA-N 0.000 claims description 2
- INQWVSNWKLOUDT-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-methylsulfanyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)SC)=CSC2=C1 INQWVSNWKLOUDT-UHFFFAOYSA-N 0.000 claims description 2
- LCLXKOYOAYQQNR-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-prop-1-en-2-yl-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(=C)C)=CSC2=C1 LCLXKOYOAYQQNR-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010019909 Hernia Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 239000003377 acid catalyst Substances 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 201000001883 cholelithiasis Diseases 0.000 claims description 2
- 235000019788 craving Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 208000001130 gallstones Diseases 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 208000013403 hyperactivity Diseases 0.000 claims description 2
- 230000002175 menstrual effect Effects 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 230000037323 metabolic rate Effects 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- 208000000689 peptic esophagitis Diseases 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
- 150000004714 phosphonium salts Chemical class 0.000 claims description 2
- 230000035935 pregnancy Effects 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 201000002859 sleep apnea Diseases 0.000 claims description 2
- 239000000779 smoke Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 230000035924 thermogenesis Effects 0.000 claims description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims 2
- MKUWVMRNQOOSAT-UHFFFAOYSA-N but-3-en-2-ol Chemical compound CC(O)C=C MKUWVMRNQOOSAT-UHFFFAOYSA-N 0.000 claims 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Substances CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 101000983970 Conus catus Alpha-conotoxin CIB Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- GRERYAZQWYKFMG-UHFFFAOYSA-N but-3-en-1-ol Chemical compound [CH2]C=CCO GRERYAZQWYKFMG-UHFFFAOYSA-N 0.000 claims 1
- UOGFCIYBLKSQHL-UHFFFAOYSA-N hex-5-en-3-ol Chemical compound CCC(O)CC=C UOGFCIYBLKSQHL-UHFFFAOYSA-N 0.000 claims 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 228
- 239000000243 solution Substances 0.000 description 145
- 239000007787 solid Substances 0.000 description 137
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 133
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 111
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 104
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 94
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 74
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 74
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 66
- 235000002639 sodium chloride Nutrition 0.000 description 59
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 52
- 238000001914 filtration Methods 0.000 description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 46
- 229920006395 saturated elastomer Polymers 0.000 description 40
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 38
- 229910052757 nitrogen Inorganic materials 0.000 description 37
- 239000011780 sodium chloride Substances 0.000 description 37
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 239000000284 extract Substances 0.000 description 33
- 239000000377 silicon dioxide Substances 0.000 description 32
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 30
- 238000003818 flash chromatography Methods 0.000 description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- 239000000725 suspension Substances 0.000 description 27
- 238000010992 reflux Methods 0.000 description 25
- 238000000746 purification Methods 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000011734 sodium Substances 0.000 description 21
- 125000003545 alkoxy group Chemical group 0.000 description 19
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 19
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 18
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 17
- 125000004414 alkyl thio group Chemical group 0.000 description 17
- 239000012312 sodium hydride Substances 0.000 description 17
- 229910000104 sodium hydride Inorganic materials 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- 239000003446 ligand Substances 0.000 description 15
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- YCCXQARVHOPWFJ-UHFFFAOYSA-M magnesium;ethane;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C YCCXQARVHOPWFJ-UHFFFAOYSA-M 0.000 description 11
- 239000002480 mineral oil Substances 0.000 description 11
- 235000010446 mineral oil Nutrition 0.000 description 11
- 229960002748 norepinephrine Drugs 0.000 description 11
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 11
- 239000012279 sodium borohydride Substances 0.000 description 11
- 229910000033 sodium borohydride Inorganic materials 0.000 description 11
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 11
- 230000014759 maintenance of location Effects 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 230000009870 specific binding Effects 0.000 description 9
- PRXNKYBFWAWBNZ-UHFFFAOYSA-N trimethylphenylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)C1=CC=CC=C1 PRXNKYBFWAWBNZ-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000001530 fumaric acid Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000006186 oral dosage form Substances 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 7
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 7
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 125000005016 hydroxyalkynyl group Chemical group 0.000 description 7
- 230000009871 nonspecific binding Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- BKCZXQQTZPBRPV-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=CSC=4N3CCN=4)=CSC2=C1 BKCZXQQTZPBRPV-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 235000011164 potassium chloride Nutrition 0.000 description 6
- 229920002554 vinyl polymer Polymers 0.000 description 6
- ZGTFNNUASMWGTM-UHFFFAOYSA-N 1,3-thiazole-2-carbaldehyde Chemical compound O=CC1=NC=CS1 ZGTFNNUASMWGTM-UHFFFAOYSA-N 0.000 description 5
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 5
- PDQAZBWRQCGBEV-UHFFFAOYSA-N Ethylenethiourea Chemical compound S=C1NCCN1 PDQAZBWRQCGBEV-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 125000004423 acyloxy group Chemical group 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- FLHFTXCMKFVKRP-UHFFFAOYSA-N bromomethylcyclobutane Chemical compound BrCC1CCC1 FLHFTXCMKFVKRP-UHFFFAOYSA-N 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002198 insoluble material Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000003551 muscarinic effect Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 239000012258 stirred mixture Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 102000017911 HTR1A Human genes 0.000 description 4
- 101150015707 HTR1A gene Proteins 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 235000019759 Maize starch Nutrition 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000005567 liquid scintillation counting Methods 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000006201 parenteral dosage form Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 3
- SKEHLMSOHHQWIY-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-bromo-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1=CC=C2C(C3=C(SC4=NCCN43)Br)=CSC2=C1 SKEHLMSOHHQWIY-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
- 241000400611 Eucalyptus deanei Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000008484 agonism Effects 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000007894 caplet Substances 0.000 description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 3
- 210000005257 cortical tissue Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000001055 magnesium Nutrition 0.000 description 3
- 229940091250 magnesium supplement Drugs 0.000 description 3
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- IBXYFQYYVRYALP-UHFFFAOYSA-N molport-003-926-405 Chemical compound Cl[I-](Cl)(Cl)Cl.C[N+](C)(C)CC1=CC=CC=C1 IBXYFQYYVRYALP-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- WTUVGNVEQDDTCM-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-2-bromo-3-phenylmethoxypropan-1-one Chemical compound C=1SC2=CC=CC=C2C=1C(=O)C(Br)COCC1=CC=CC=C1 WTUVGNVEQDDTCM-UHFFFAOYSA-N 0.000 description 2
- VLWUPJUWLHHZIS-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-3-(dimethylamino)propan-1-one;hydrochloride Chemical compound Cl.C1=CC=C2C(C(=O)CCN(C)C)=CSC2=C1 VLWUPJUWLHHZIS-UHFFFAOYSA-N 0.000 description 2
- LBPFBKVAFCBVLQ-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-3-phenylmethoxypropan-1-one Chemical compound C=1SC2=CC=CC=C2C=1C(=O)CCOCC1=CC=CC=C1 LBPFBKVAFCBVLQ-UHFFFAOYSA-N 0.000 description 2
- LJMBFEBDZAOKTD-UHFFFAOYSA-N 1-(7-methoxy-1-benzothiophen-3-yl)ethanone Chemical compound COC1=CC=CC2=C1SC=C2C(C)=O LJMBFEBDZAOKTD-UHFFFAOYSA-N 0.000 description 2
- LSVDHPXBWPECCJ-UHFFFAOYSA-N 1-(7-methoxy-2,3-dihydro-1-benzothiophen-3-yl)-2-phenoxyethanone Chemical compound C1SC=2C(OC)=CC=CC=2C1C(=O)COC1=CC=CC=C1 LSVDHPXBWPECCJ-UHFFFAOYSA-N 0.000 description 2
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- XFUMHENRNCUHOH-UHFFFAOYSA-N 1-fluoro-4-methylsulfanylbenzene Chemical compound CSC1=CC=C(F)C=C1 XFUMHENRNCUHOH-UHFFFAOYSA-N 0.000 description 2
- WFWNTLYUEWAQJX-UHFFFAOYSA-N 1-methoxy-2-(4-phenoxybut-2-ynylsulfanyl)benzene Chemical compound COC1=CC=CC=C1SCC#CCOC1=CC=CC=C1 WFWNTLYUEWAQJX-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- AIUSKKULSAQPEB-UHFFFAOYSA-N 2-bromo-3-(5-methylsulfanyl-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C12=CC(SC)=CC=C2SC=C1C1=C(Br)SC2=NCCN12 AIUSKKULSAQPEB-UHFFFAOYSA-N 0.000 description 2
- YZOGROCAAWYRBU-UHFFFAOYSA-N 2-cyclopropyl-n-methoxy-n-methylacetamide Chemical compound CON(C)C(=O)CC1CC1 YZOGROCAAWYRBU-UHFFFAOYSA-N 0.000 description 2
- IALGRRFZGRXFKT-UHFFFAOYSA-N 2-cyclopropylacetyl chloride Chemical compound ClC(=O)CC1CC1 IALGRRFZGRXFKT-UHFFFAOYSA-N 0.000 description 2
- QKEKNNARIRBOMF-UHFFFAOYSA-N 2-fluoro-5-methylsulfanylbenzaldehyde Chemical compound CSC1=CC=C(F)C(C=O)=C1 QKEKNNARIRBOMF-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- MAZXGTVVVRCULB-UHFFFAOYSA-N 3-(1-benzofuran-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carbaldehyde Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C=O)=COC2=C1 MAZXGTVVVRCULB-UHFFFAOYSA-N 0.000 description 2
- NXPATGQDYTWDNG-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-ethenyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrochloride Chemical compound Cl.C1=CC=C2C(C3=C(SC4=NCCN43)C=C)=CSC2=C1 NXPATGQDYTWDNG-UHFFFAOYSA-N 0.000 description 2
- UZUUVNIERLVVCH-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1=CC=C2C(C3=CSC=4N3CCN=4)=CSC2=C1 UZUUVNIERLVVCH-UHFFFAOYSA-N 0.000 description 2
- KFGPZSUBOWPPMR-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-6,7-dihydro-5h-[1,3]thiazolo[3,2-a]pyrimidine Chemical compound C1=CC=C2C(C3=CSC4=NCCCN43)=CSC2=C1 KFGPZSUBOWPPMR-UHFFFAOYSA-N 0.000 description 2
- ITJNARMNRKSWTA-RLXJOQACSA-N 3-(2-methoxyphenoxy)-3-phenyl-n-(tritritiomethyl)propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC([3H])([3H])[3H])OC1=CC=CC=C1OC ITJNARMNRKSWTA-RLXJOQACSA-N 0.000 description 2
- SRYQCAVJRROBBI-UHFFFAOYSA-N 3-(5-chloro-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C12=CC(Cl)=CC=C2SC=C1C1=CSC2=NCCN12 SRYQCAVJRROBBI-UHFFFAOYSA-N 0.000 description 2
- NFGPFCPZPMBJMV-UHFFFAOYSA-N 3-(5-chloro-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carbaldehyde Chemical compound C12=CC(Cl)=CC=C2SC=C1C1=C(C=O)SC2=NCCN12 NFGPFCPZPMBJMV-UHFFFAOYSA-N 0.000 description 2
- GMPXFKLYBVWGLP-UHFFFAOYSA-N 3-(5-methoxy-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C12=CC(OC)=CC=C2SC=C1C1=CSC2=NCCN12 GMPXFKLYBVWGLP-UHFFFAOYSA-N 0.000 description 2
- PMZJSVBYQJFOQA-UHFFFAOYSA-N 5-methylsulfanyl-1-benzothiophene Chemical compound CSC1=CC=C2SC=CC2=C1 PMZJSVBYQJFOQA-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 102100028661 Amine oxidase [flavin-containing] A Human genes 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- NECFGSDKKIGJNO-UHFFFAOYSA-N Cl.OCC1=C(N2CCN=C2S1)c1csc2ccccc12 Chemical compound Cl.OCC1=C(N2CCN=C2S1)c1csc2ccccc12 NECFGSDKKIGJNO-UHFFFAOYSA-N 0.000 description 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- GUUVPOWQJOLRAS-UHFFFAOYSA-N Diphenyl disulfide Chemical compound C=1C=CC=CC=1SSC1=CC=CC=C1 GUUVPOWQJOLRAS-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- LZCOQTDXKCNBEE-XJMZPCNVSA-N N-methylscopolamine Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-XJMZPCNVSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010040108 Serotonin syndrome Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- YBWSXPROZCISEK-UHFFFAOYSA-N [3-(5-chloro-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]methanol Chemical compound C1=C(Cl)C=C2C(C3=C(SC4=NCCN43)CO)=CSC2=C1 YBWSXPROZCISEK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- PQLAYKMGZDUDLQ-UHFFFAOYSA-K aluminium bromide Chemical compound Br[Al](Br)Br PQLAYKMGZDUDLQ-UHFFFAOYSA-K 0.000 description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000005018 aryl alkenyl group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- WHNPUKSXIKNEMZ-UHFFFAOYSA-N ethyl 3-(1-benzothiophen-3-yl)-2-bromo-3-oxopropanoate Chemical compound C1=CC=C2C(C(=O)C(Br)C(=O)OCC)=CSC2=C1 WHNPUKSXIKNEMZ-UHFFFAOYSA-N 0.000 description 2
- WLQCZVDIQFJHTC-UHFFFAOYSA-N ethyl 3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carboxylate Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(=O)OCC)=CSC2=C1 WLQCZVDIQFJHTC-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 238000001030 gas--liquid chromatography Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940087646 methanolamine Drugs 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- LLNXPQUESDTQIN-UHFFFAOYSA-N methyl 5-methylsulfanyl-1-benzothiophene-2-carboxylate Chemical compound CSC1=CC=C2SC(C(=O)OC)=CC2=C1 LLNXPQUESDTQIN-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 230000000407 monoamine reuptake Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000966 norepinephrine reuptake Effects 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- LJZPPWWHKPGCHS-UHFFFAOYSA-N propargyl chloride Chemical compound ClCC#C LJZPPWWHKPGCHS-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- PTMFUWGXPRYYMC-UHFFFAOYSA-N triethylazanium;formate Chemical compound OC=O.CCN(CC)CC PTMFUWGXPRYYMC-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- SQDDGOVNJMIFFT-UHFFFAOYSA-N 1,1-bis(diethoxyphosphoryl)-n,n-dimethylmethanamine Chemical compound CCOP(=O)(OCC)C(N(C)C)P(=O)(OCC)OCC SQDDGOVNJMIFFT-UHFFFAOYSA-N 0.000 description 1
- DDGHBOLOCQWPKE-UHFFFAOYSA-N 1,3-thiazole;hydrobromide Chemical compound [Br-].C1=CSC=[NH+]1 DDGHBOLOCQWPKE-UHFFFAOYSA-N 0.000 description 1
- VMXJAXJZOXXFOH-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-2-cyclopropylethanone Chemical compound C=1SC2=CC=CC=C2C=1C(=O)CC1CC1 VMXJAXJZOXXFOH-UHFFFAOYSA-N 0.000 description 1
- ZTTZKDDWXHQKSY-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)ethanone Chemical compound C1=CC=C2C(C(=O)C)=CSC2=C1 ZTTZKDDWXHQKSY-UHFFFAOYSA-N 0.000 description 1
- DISWDTIMRONVJU-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]-2-methylpropan-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)C(C)C)=CSC2=C1 DISWDTIMRONVJU-UHFFFAOYSA-N 0.000 description 1
- SNZQXQLEUUCMHL-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]prop-2-yn-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(C#C)O)=CSC2=C1 SNZQXQLEUUCMHL-UHFFFAOYSA-N 0.000 description 1
- UOWIYNWMROWVDG-UHFFFAOYSA-N 1-dimethoxyphosphorylpropan-2-one Chemical compound COP(=O)(OC)CC(C)=O UOWIYNWMROWVDG-UHFFFAOYSA-N 0.000 description 1
- DSPXASHHKFVPCL-UHFFFAOYSA-N 1-isocyanocyclohexene Chemical compound [C-]#[N+]C1=CCCCC1 DSPXASHHKFVPCL-UHFFFAOYSA-N 0.000 description 1
- DSCJETUEDFKYGN-UHFFFAOYSA-N 2-Methoxybenzenethiol Chemical compound COC1=CC=CC=C1S DSCJETUEDFKYGN-UHFFFAOYSA-N 0.000 description 1
- MIMUGAJISMFUGL-UHFFFAOYSA-N 2-bromo-3-(5-methylsulfanyl-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C12=CC(SC)=CC=C2SC=C1C1=C(Br)SC2=NCCN12 MIMUGAJISMFUGL-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
- IPZFRXRLIVTZIX-UHFFFAOYSA-N 3-(1-benzofuran-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=CSC=4N3CCN=4)=COC2=C1 IPZFRXRLIVTZIX-UHFFFAOYSA-N 0.000 description 1
- UARZGTRHSJQGFS-WLHGVMLRSA-N 3-(1-benzothiophen-3-yl)-2-(2-methylprop-2-enyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.c1cccc2c1scc2C1=C(CC(=C)C)SC2=NCCN21 UARZGTRHSJQGFS-WLHGVMLRSA-N 0.000 description 1
- OREBWIBJEFJQTB-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(cyclobutylmethoxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C=1SC2=CC=CC=C2C=1C=1N2CCN=C2SC=1COCC1CCC1 OREBWIBJEFJQTB-UHFFFAOYSA-N 0.000 description 1
- BIOUJAYKDDMMKR-WLHGVMLRSA-N 3-(1-benzothiophen-3-yl)-2-(cyclopropylmethoxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C=1SC2=CC=CC=C2C=1C=1N2CCN=C2SC=1COCC1CC1 BIOUJAYKDDMMKR-WLHGVMLRSA-N 0.000 description 1
- OLMGCVNDAHKFMQ-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(ethoxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1=CC=C2C(C3=C(SC4=NCCN43)COCC)=CSC2=C1 OLMGCVNDAHKFMQ-UHFFFAOYSA-N 0.000 description 1
- VBLYSIACCYOMIG-WLHGVMLRSA-N 3-(1-benzothiophen-3-yl)-2-(prop-2-ynoxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.c1cccc2c1scc2C1=C(COCC#C)SC2=NCCN21 VBLYSIACCYOMIG-WLHGVMLRSA-N 0.000 description 1
- VVDZEYDXPTXINV-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-cyclopropyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1CC1C(S1)=C(C=2C3=CC=CC=C3SC=2)N2C1=NCC2 VVDZEYDXPTXINV-UHFFFAOYSA-N 0.000 description 1
- SDJCTHBPRIXHBO-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-phenylsulfanyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound N=1CCN(C=2C=3C4=CC=CC=C4SC=3)C=1SC=2SC1=CC=CC=C1 SDJCTHBPRIXHBO-UHFFFAOYSA-N 0.000 description 1
- TWZWVQFMKXUFBH-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carbonitrile Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C#N)=CSC2=C1 TWZWVQFMKXUFBH-UHFFFAOYSA-N 0.000 description 1
- HJWYKXQANGRSIE-UHFFFAOYSA-N 3-(5-methylsulfanyl-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C12=CC(SC)=CC=C2SC=C1C1=CSC2=NCCN12 HJWYKXQANGRSIE-UHFFFAOYSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- SRWDQSRTOOMPMO-UHFFFAOYSA-N 3-bromo-1-benzothiophene Chemical compound C1=CC=C2C(Br)=CSC2=C1 SRWDQSRTOOMPMO-UHFFFAOYSA-N 0.000 description 1
- USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- JSSBZHNLEZWWCQ-UHFFFAOYSA-N 4-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]but-3-en-2-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C=CC(O)C)=CSC2=C1 JSSBZHNLEZWWCQ-UHFFFAOYSA-N 0.000 description 1
- IDEODNHVORFHQO-UHFFFAOYSA-N 4-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]but-3-en-2-one Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C=CC(=O)C)=CSC2=C1 IDEODNHVORFHQO-UHFFFAOYSA-N 0.000 description 1
- ZEVUHRJDTWDODR-UHFFFAOYSA-N 4-chlorobut-2-ynoxybenzene Chemical compound ClCC#CCOC1=CC=CC=C1 ZEVUHRJDTWDODR-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- XOHDYBSXKQFZGS-UHFFFAOYSA-N 5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CSC2=NCCN21 XOHDYBSXKQFZGS-UHFFFAOYSA-N 0.000 description 1
- IHRTXCVCVNBWQN-UHFFFAOYSA-N 5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carbaldehyde Chemical compound C1CN=C2SC(C=O)=CN21 IHRTXCVCVNBWQN-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- NZVFVVMOZAWNTM-UHFFFAOYSA-N 5-methylsulfanyl-1-benzothiophene-2-carboxylic acid Chemical compound CSC1=CC=C2SC(C(O)=O)=CC2=C1 NZVFVVMOZAWNTM-UHFFFAOYSA-N 0.000 description 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710185917 Amine oxidase [flavin-containing] A Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- HRJNDJQHIYBUNK-UHFFFAOYSA-N Br.COc1cccc2c(csc12)C1=C(Br)SC2=NCCN12 Chemical compound Br.COc1cccc2c(csc12)C1=C(Br)SC2=NCCN12 HRJNDJQHIYBUNK-UHFFFAOYSA-N 0.000 description 1
- FDTMBOBAMHPBJB-UHFFFAOYSA-N Br.COc1cccc2c(csc12)C1=CSC2=NCCN12 Chemical compound Br.COc1cccc2c(csc12)C1=CSC2=NCCN12 FDTMBOBAMHPBJB-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UNIAEKUKEWFLRQ-UHFFFAOYSA-N C(C)OC(CC1=C(N2C(S1)=NCC2)C=2C1=C(SC2)C=CC=C1)=O Chemical compound C(C)OC(CC1=C(N2C(S1)=NCC2)C=2C1=C(SC2)C=CC=C1)=O UNIAEKUKEWFLRQ-UHFFFAOYSA-N 0.000 description 1
- YRZWULXCOBDGTD-UHFFFAOYSA-N C(C=CC(=O)O)(=O)O.S1C2=C(C(=C1)C=1N3C(SC1C(C)(O)C)=NCC3)C=CC=C2 Chemical compound C(C=CC(=O)O)(=O)O.S1C2=C(C(=C1)C=1N3C(SC1C(C)(O)C)=NCC3)C=CC=C2 YRZWULXCOBDGTD-UHFFFAOYSA-N 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical class [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 241000506654 Haemulon album Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000694718 Homo sapiens Amine oxidase [flavin-containing] A Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- RNXYXIKLWRRZNU-UHFFFAOYSA-N Kynuramine Natural products NCCCC(=O)C1=CC=CC=N1 RNXYXIKLWRRZNU-UHFFFAOYSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- AVRWEULSKHQETA-UHFFFAOYSA-N Thiophene-2 Chemical compound S1C=2CCCCCC=2C(C(=O)OC)=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AVRWEULSKHQETA-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- JPKKQJKQTPNWTR-KQAYXBCTSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2r)-3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1.C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 JPKKQJKQTPNWTR-KQAYXBCTSA-N 0.000 description 1
- LFWGTOBIQYBPRP-UHFFFAOYSA-N [3-(1-benzothiophen-3-yl)-3-oxopropyl]-trimethylazanium Chemical compound C1=CC=C2C(C(=O)CC[N+](C)(C)C)=CSC2=C1 LFWGTOBIQYBPRP-UHFFFAOYSA-N 0.000 description 1
- YXWJCIUFDHSOSG-UHFFFAOYSA-N [3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]-(2-methoxyphenyl)methanol Chemical compound COC1=CC=CC=C1C(O)C(S1)=C(C=2C3=CC=CC=C3SC=2)N2C1=NCC2 YXWJCIUFDHSOSG-UHFFFAOYSA-N 0.000 description 1
- REGJBZFQCZNLEL-WLHGVMLRSA-N [3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]methanol;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=C2C(C3=C(SC4=NCCN43)CO)=CSC2=C1 REGJBZFQCZNLEL-WLHGVMLRSA-N 0.000 description 1
- JBFAFQDHPBMWJR-UHFFFAOYSA-N [3-(1-benzothiophen-3-yl)-6,7-dihydro-5h-[1,3]thiazolo[3,2-a]pyrimidin-2-yl]methanol Chemical compound C1=CC=C2C(C3=C(SC4=NCCCN43)CO)=CSC2=C1 JBFAFQDHPBMWJR-UHFFFAOYSA-N 0.000 description 1
- OTVQDZVMUBSAPX-UHFFFAOYSA-N [3-(5-chloro-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]methyl formate Chemical compound C12=CC(Cl)=CC=C2SC=C1C1=C(COC=O)SC2=NCCN12 OTVQDZVMUBSAPX-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005002 aryl methyl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- AIPRAPZUGUTQKX-UHFFFAOYSA-N diethoxyphosphorylmethylbenzene Chemical compound CCOP(=O)(OCC)CC1=CC=CC=C1 AIPRAPZUGUTQKX-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- ZJMVBGLGQKBNAJ-UHFFFAOYSA-N ethyl 3-(1-benzothiophen-3-yl)-3-oxopropanoate Chemical compound C1=CC=C2C(C(=O)CC(=O)OCC)=CSC2=C1 ZJMVBGLGQKBNAJ-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- JHYNXXDQQHTCHJ-UHFFFAOYSA-M ethyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC)C1=CC=CC=C1 JHYNXXDQQHTCHJ-UHFFFAOYSA-M 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- QLPVTIQQFGWSQQ-UHFFFAOYSA-N kynuramine Chemical compound NCCC(=O)C1=CC=CC=C1N QLPVTIQQFGWSQQ-UHFFFAOYSA-N 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- IJMWREDHKRHWQI-UHFFFAOYSA-M magnesium;ethene;chloride Chemical compound [Mg+2].[Cl-].[CH-]=C IJMWREDHKRHWQI-UHFFFAOYSA-M 0.000 description 1
- FCPRDUXJWIUVPZ-UHFFFAOYSA-M magnesium;methoxybenzene;bromide Chemical compound [Mg+2].[Br-].COC1=CC=CC=[C-]1 FCPRDUXJWIUVPZ-UHFFFAOYSA-M 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- QBNOPZJAURRQCE-UHFFFAOYSA-M magnesium;prop-1-yne;bromide Chemical compound [Mg+2].[Br-].CC#[C-] QBNOPZJAURRQCE-UHFFFAOYSA-M 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- VMESOKCXSYNAKD-UHFFFAOYSA-N n,n-dimethylhydroxylamine Chemical compound CN(C)O VMESOKCXSYNAKD-UHFFFAOYSA-N 0.000 description 1
- BCXCABRDBBWWGY-UHFFFAOYSA-N n-benzyl-n-methylprop-2-yn-1-amine;hydrochloride Chemical compound Cl.C#CCN(C)CC1=CC=CC=C1 BCXCABRDBBWWGY-UHFFFAOYSA-N 0.000 description 1
- OYVXVLSZQHSNDK-UHFFFAOYSA-N n-methoxy-n-methylacetamide Chemical compound CON(C)C(C)=O OYVXVLSZQHSNDK-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960004239 pargyline hydrochloride Drugs 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CCOXWRVWKFVFDG-UHFFFAOYSA-N pyrimidine-2-carbaldehyde Chemical compound O=CC1=NC=CC=N1 CCOXWRVWKFVFDG-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- CURCMGVZNYCRNY-UHFFFAOYSA-N trimethylazanium;iodide Chemical compound I.CN(C)C CURCMGVZNYCRNY-UHFFFAOYSA-N 0.000 description 1
- 238000007514 turning Methods 0.000 description 1
- 201000007912 type 1 diabetes mellitus 10 Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Description
WO 00/71549 PCT/EP00/04279 1 THIAZOLODERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM The present invention relates to certain novel substituted dihydroimidazo[2,1 b]thiazole and dihydro-5H-thiazolo[3,2-a]pyrimidine compounds which have affinity 5 for 5-HT1A receptors and which inhibit neuronal reuptake of 5-hydroxytryptamine and/or noradrenaline, to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, obsessive 10 compulsive behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, stress, as an aid to smoking cessation and in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke, 15 brain trauma, cerebral ischaemia, head injuries and haemorrhage. WO 98/41528 discloses that compounds of formula A
R
3 S Ar / NA R N 4 R R2 20 including pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers, in which: Ar is phenyl, naphthyl or benzo[b]thiophenyl, each of which may be optionally 25 substituted by one or more substituents selected from a) halo, b) an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, c) an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo, d) an alkylthio group containing 1 to 3 carbon atoms optionally substituted by one or more halo, e) a phenoxy group optionally substituted by one or more halo or f) 30 phenyl optionally substituted by one or more halo;
R
1 and R 2 , which may be the same or different, independently are a) H, b) an alkyl group containing 1 to 6 carbon atoms, c) an alkenyl group containing 3 to 6 carbon WO 00/71549 PCT/EP00/04279 2 atoms, d) a cycloalkyl group containing 3 to 7 carbon atoms, e) a cycloalkylmethyl group in which the ring contains 3 to 7 carbon atoms, f) an aryl or heteroaryl group optionally substituted by one or more substituents selected from i) halo, ii) an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, iii) 5 an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo, iv) an alkylthio group containing 1 to 3 carbon atoms optionally substituted by one or more halo, g) an arylalkyl or heteroarylalkyl group in which the alkyl chain contains 1 to 3 carbon atoms and in which the aryl or heteroaryl group may optionally be substituted by one or more substituents selected from i) halo, ii) an 10 alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, iii) an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo, iv) an alkylthio group containing 1 to 3 carbon atoms optionally substituted by one or more halo; or R, and R 2 form an alkylene chain optionally substituted by one or more alkyl groups each containing 1 to 3 carbon atoms, such 15 that, together with the atoms to which they are attached, they form a 5 or 6 membered ring,
R
3 is a) H, b) an aryl or heteroaryl group optionally substituted by one or more substituents selected from i) halo, ii) an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, iii) an alkoxy group containing 1 to 3 20 carbon atoms optionally substituted by one or more halo, iv) an alkylthio group containing 1 to 3 carbon atoms optionally substituted by one or more halo, c) an arylmethyl group in which the aryl is optionally substituted by one or more substituents selected from i) halo, ii) an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, iii) an alkoxy group containing 1 to 3 25 carbon atoms optionally substituted by one or more halo, iv) an alkylthio group containing 1 to 3 carbon atoms optionally substituted by one or more halo; or d) an alkoxyalkyl group containing 3 to 6 carbon atoms; and
R
4 and R 5 , which may be the same or different, independently are an alkyl group containing 1 to 3 carbon atoms, or R 4 and R 5 together with the atom to which they 30 are attached form a cycloalkyl ring containing 3 to 6 carbon atoms; are useful in the treatment of depression, anxiety, Parkinson's disease, obesity, cognitive disorders, seizures, neurological disorders such as epilepsy, and as neuroprotective agents to protect against conditions such as stroke. The 35 compounds of the present invention are not disclosed or suggested in this document.
WO 00/71549 PCT/EP00/04279 3 Sharpe C.J and Shadbolt R.S. (Journal of Medicinal Chemistry, 1971, Vol 14 No.10, p977-982) disclose certain dihydroimidazo[2,1-b]thiazole compounds having antidepressant activity. However, the document also states that these compounds 5 were generally less active and more toxic than the imidazolines also disclosed in the document. The compounds of the present invention are not disclosed or suggested in this document. WO 97/02269 discloses that compounds of formula B 10 4S NN B R 4. S N (R1)g A A
R
s including pharmaceutically acceptable salts thereof in which A is S(O)p or O; 15 pis0,1or2; gis0,1,2,3, or4; n is 2 or 3;
R
1 is a) halo, b) an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, c) an alkoxy group containing 1 to 3 carbon atoms optionally 20 substituted by one or more halo, d) an alkylthio group, an alkylsulphinyl group or an alkylsulphonyl group each containing 1 to 3 carbon atoms optionally substituted by one or more halo, e) hydroxy, f) an acyloxy group containing 1 to 3 carbon atoms, g) a hydroxyalkyl group containing 1 to 3 carbon atoms, h) cyano, i) an alkanoyl group containing 1 to 6 carbon atoms, j) an alkoxycarbonyl group containing 2 to 6 carbon 25 atoms, k) a carbamoyl group or a carbamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, I) a sulphamoyl or sulphamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, or m) an amino group optionally substituted by one or two alkyl groups each containing 1 to 3 carbon atoms; R 1 being 30 the same or different when g is 2, 3 or 4; WO 00/71549 PCT/EP00/04279 4
R
2 , R 3 and R 4 independently are H or an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo; and
R
5 is a) halo, b) an alkyl group containing 1 to 3 carbon atoms optionally substituted 5 by one or more halo, c) an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo, d) an alkylthio group, an alkylsulphinyl group or an alkylsulphonyl group each containing 1 to 3 carbon atoms optionally substituted by one or more halo, e) hydroxy, f) an acyloxy group containing 1 to 3 carbon atoms, g) a hydroxyalkyl group containing 1 to 3 carbon atoms, h) cyano, i) an alkanoyl group 10 containing 1 to 6 carbon atoms, j) an alkoxycarbonyl group containing 2 to 6 carbon atoms, k) a carbamoyl group or a carbamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, I) a sulphamoyl or sulphamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, m) an amino group optionally 15 substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, or n) H ; have affinity for 5-HT1A receptors and inhibit neuronal reuptake of 5-hydroxytryptamine and/or noradrenaline. These compounds are stated to be useful in the treatment of CNS disorders. However, these compounds exhibit activity 20 as monoamine oxidase inhibitors and/or have affinity for other receptors, for example muscarinic receptors, and are therefore likely to cause undesired side effects. Surprisingly the present invention provides compounds with unexpectedly superior selectivity and efficacy. The compounds of the present invention are not disclosed or suggested in WO 97/02269. 25 US4,160,768 discloses that 3-(2-benzofuranyl)-5,6-dihydroimidazo[2,1 b]thiazole is useful as an anti-inflammatory agent. This document does not disclose or suggest the compounds of the present invention. 30 The present invention provides compounds of Formula I R4 S ( r " / I (CR2R3)n (R) R A Rs WO 00/71549 PCT/EP00/04279 5 including pharmaceutically acceptable salts thereof in which A is S or O; 5 g is 0,1, 2, 3 or 4; n is 2 or 3; 10 R 1 is a) halo, b) an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, c) an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo, d) an alkylthio group, an alkylsulphinyl group or an alkylsulphonyl group each containing 1 to 3 carbon atoms optionally substituted by one or more halo, e) hydroxy, f) an acyloxy group containing 1 to 3 carbon atoms, g) 15 a hydroxyalkyl group containing 1 to 3 carbon atoms, h) cyano, i) an alkanoyl group containing 1 to 6 carbon atoms, j) an alkoxycarbonyl group containing 2 to 6 carbon atoms, k) a carbamoyl group or a carbamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, I) a sulphamoyl or sulphamoylmethyl group each optionally N-substituted by one or two 20 alkyl groups each containing 1 to 3 carbon atoms, or m) an amino group optionally substituted by one or two alkyl groups each containing 1 to 3 carbon atoms; R 1 being the same or different when g is 2, 3 or 4;
R
2 and R 3 are each H; 25
R
4 represents a hydroxyalkyl group containing 1 to 6 carbon atoms, anc-hydroxy(2 Cl- 3 alkoxyphenyl)methyl group, a hydroxyalkenyl group containing 3 to 6 carbon atoms in which hydroxy is not attached directly to either carbon of the double bond, a hydroxyalkynyl group containing 3 to 6 carbon atoms in which hydroxy is not 30 attached directly to either carbon of the triple bond, a hydroxycycloalkyl group containing 3 to 6 carbon atoms, an alkenyl group containing 2 to 8 carbon atoms, an arylalkenyl group containing 8 to 10 carbon atoms, a cycloalkyl group containing 3 to 6 carbon atoms, a C 3
-
7 alkynylalkoxyC 1 -3alkyl group, a C 4
-
7 cycloalkylalkoxyC 1
-
3 alkyl group, a C1-3alkoxyC 1 -3alkyl group, a C 1
-
3 alkylthioC 1
-
3 alkyl group, a C1-3alkoxy group, 35 a C 1 -3alkylthio group, an arylthio group, a C1.6 alkanoyl group, a C3-6 WO 00/71549 PCT/EP00/04279 6 alkoxycarbonylalkyl group, cyano, halo, a C 14 alkyliminomethyl group, a Cj. 4 alkylaminoalkyl group or a hydroxyiminomethyl group;
R
5 is H or halo. 5 In a preferred aspect the present invention provides compounds of Formula I RS NN R 4" S N
-
__.)9 I-- (C R 2R 3)n (Ri)g A A Rs5 including pharmaceutically acceptable salts thereof in which 10 A is S or O; g is 0,1,2,3, or4; n is 2 or 3; 15
R
1 is a) halo, b) an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, c) an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo, d) an alkylthio group, an alkylsulphinyl group or an alkylsulphonyl group each containing 1 to 3 carbon atoms optionally substituted by 20 one or more halo, e) hydroxy, f) an acyloxy group containing 1 to 3 carbon atoms, g) a hydroxyalkyl group containing 1 to 3 carbon atoms, h) cyano, i) an alkanoyl group containing 1 to 6 carbon atoms, j) an alkoxycarbonyl group containing 2 to 6 carbon atoms, k) a carbamoyl group or a carbamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, I) a 25 sulphamoyl or sulphamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, or m) an amino group optionally substituted by one or two alkyl groups each containing 1 to 3 carbon atoms; R 1 being the same or different when g is 2, 3 or 4; 30 R 2 and R 3 are each H; WO 00/71549 PCT/EP00/04279 7
R
4 represents a hydroxyalkyl group containing 1 to 6 carbon atoms, a hydroxyalkenyl group containing 3 to 6 carbon atoms in which hydroxy is not attached directly to either carbon of the double bond, a hydroxyalkynyl group containing 3 to 6 carbon atoms in which hydroxy is not attached directly to either carbon of the triple bond, a 5 hydroxycycloalkyl group containing 3 to 6 carbon atoms, an alkenyl group containing 2 to 8 carbon atoms, a cycloalkyl group containing 3 to 6 carbon atoms, a
C
1
-
3 alkoxyC 1
-
3 alkyl group, a C1.
3 alkylthioC 1 -3alkyl group, a C 1
.
3 alkoxy group, a
C
1
-
3 alkylthio group, a C1-6 alkanoyl group, halo, a C 1
-
4 alkyliminomethyl group or a hydroxyiminomethyl group; and 10
R
5 is H or halo. It will be understood that the term halo, when used herein, includes fluoro, chloro, bromo and iodo. It will be understood that in alkyl groups, alkenyl groups, 15 alkynyl groups, alkylthio groups and alkoxy groups containing more than two carbon atoms the alkyl group may be straight or branched. Aryl is used to indicate phenyl optionally substituted by one or more of the following:a C1- 3 alkyl group, a C1-3 alkoxy group or halo. 20 In a first group of preferred compounds of the present invention A is S. In a second group of preferred compounds of the present invention A is O. Preferably g is 0 or 1 and R, is a) halo, b) an alkyl group containing 1 to 3 25 carbon atoms optionally substituted by one or more halo, or c) an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo. Preferably R, is in the 5-position of the benzo[b]thiophene ring. More preferably g is 0 or 1 and R 1 is halo or an alkoxy group containing 1 to 3 carbon atoms. Most preferably g is 0 or 1 and R, is chloro or methoxy. 30 Preferably n is 2. Preferably R 2 and R 3 are each H. 35 Preferably R 4 represents a hydroxyalkyl group containing 1 to 6 carbon atoms, a hydroxyalkenyl group containing 3 to 6 carbon atoms in which hydroxy is WO 00/71549 PCT/EP00/04279 8 not attached directly to either carbon of the double bond, a hydroxyalkynyl group containing 3 to 6 carbon atoms in which hydroxy is not attached directly to either carbon of the triple bond, an alkenyl group containing 2 carbon atoms optionally substituted by one or more C1- 2 alkyl groups , a C1-4 alkyliminomethyl group or a 5 hydroxyiminomethyl group. More preferably R 4 represents a hydroxyalkyl group containing 1 to 5 carbon atoms, a hydroxyalkenyl group containing 3 to 5 carbon atoms in which hydroxy is not attached directly to either carbon of the double bond, a hydroxyalkynyl group containing 3 to 4 carbon atoms in which hydroxy is not attached directly to either carbon of the triple bond or an alkenyl group containing 2 10 carbon atoms optionally substituted by one or more methyl groups. Most preferably
R
4 represents hydroxymethyl or vinyl. Hydroxymethyl is especially preferred for R 4 . Preferred values of R 4 are hydroxymethyl, 1-hydroxyethyl, 1-hydroxy-1 methylethyl; 1-hydroxypropyl, 1-hydroxy-2-methylpropyl, 1-hydroxybutyl, 1-hydroxy 15 3-methylbutyl, 1-hydroxypentyl, 1-hydroxypropenyl, 1-hydroxybut-3-enyl, 1-hydroxy 2-methylpropenyl, 1 -hydroxy-2-methylbut-3-enyl, 1 -hydroxypent-4-enyl, 1 hydroxypropynyl, 1-hydroxybut-2-ynyl, methoxymethyl, ethoxymethyl, methylthio, bromo, chloro, vinyl, allyl, 1-methylvinyl, formyl, acetyl,N-(1-methylethyl)iminomethyl, and hydroxyiminomethyl. More preferably R 4 is hydroxymethyl, 1-hydroxyethyl, 1 20 hydroxy-l1-methylethyl; 1-hydroxypropyl, 1-hydroxy-2-methylpropyl, 1-hydroxybutyl, 1-hydroxy-3-methylbutyl, 1-hydroxypentyl, 1-hydroxypropenyl, 1-hydroxybut-3-enyl, 1-hydroxy-2-methylpropenyl, 1-hydroxy-2-methylbut-3-enyl, 1-hydroxypent-4-enyl, 1 hydroxypropynyl, 1-hydroxybut-2-ynyl, vinyl, 1 -methylvinyl, acetyl, N-( 1 methylethyl)iminomethyl, and hydroxyiminomethyl. Most preferably R 4 is 25 hydroxymethyl or vinyl. Hydroxymethyl is especially preferred. Preferably R5 is H. Preferably n is 2. 30 In a preferred group of compounds of Formula I, A is S, g is 0 or 1; n is 2; R 1 is halo or an alkoxy group containing 1 to 3 carbon atoms; R 2 and R 3 are each H;
R
4 represents a hydroxyalkyl group containing 1 to 5 carbon atoms, a hydroxyalkenyl group containing 3 to 5 carbon atoms in which hydroxy is not attached directly to 35 either carbon of the double bond, a hydroxyalkynyl group containing 3 to 4 carbon atoms in which hydroxy is not attached directly to either carbon of the triple bond or WO 00/71549 PCT/EP00/04279 9 an alkenyl group containing 2 carbon atoms optionally substituted by one or more methyl groups; and R 5 is H. In a preferred group of compounds of Formula I, preferably g is 0 or 1 and R 1 5 is chloro or methoxy. More preferably R 1 is in the 5-position of the benzo[b]thiophene ring. In a further preferred aspect the present invention provides compounds of Formula la 10 R4 S N (R-) N (CH 2
)
n Ia A including pharmaceutically acceptable salts thereof in which A is S or O; 15 g is 0, 1,2, 3 or 4; n is 2 or 3; 20 R 1 is a) halo, b) an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, c) an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo, d) an alkylthio group, an alkylsulphinyl group or an alkylsulphonyl group each containing 1 to 3 carbon atoms optionally substituted by one or more halo, e) hydroxy, f) an acyloxy group containing 1 to 3 carbon atoms, g) 25 a hydroxyalkyl group containing 1 to 3 carbon atoms, h) cyano, i) an alkanoyl group containing 1 to 6 carbon atoms, j) an alkoxycarbonyl group containing 2 to 6 carbon atoms, k) a carbamoyl group or a carbamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, I) a sulphamoyl or sulphamoylmethyl group each optionally N-substituted by one or two 30 alkyl groups each containing 1 to 3 carbon atoms, or m) an amino group optionally substituted by one or two alkyl groups each containing 1 to 3 carbon atoms; R 1 being the same or different when g is 2, 3 or 4; and WO 00/71549 PCT/EP00/04279 10
R
4 represents a hydroxyalkyl group containing 1 to 6 carbon atoms, an a-hydroxy(2 C1-3 alkoxyphenyl)methyl group, a hydroxyalkenyl group containing 3 to 6 carbon atoms in which hydroxy is not attached directly to either carbon of the double bond, a 5 hydroxyalkynyl group containing 3 to 6 carbon atoms in which hydroxy is not attached directly to either carbon of the triple bond, an alkenyl group containing 2 to 8 carbon atoms, an arylalkenyl group containing 8 to 10 carbon atoms, a cycloalkyl group containing 3 to 6 carbon atoms, a C 3
.
7 alkynylalkoxyC 1
-
3 alkyl group, a C4 7 cycloalkylalkoxyC 1 -3alkyl group, a C 1 -3alkoxyC1- 3 alkyl group, a C 1
-
3 alkylthioC 1
,
3 alkyl 10 group, a C 1 3 alkoxy group, a C 13 alkylthio group, an arylthio group, a C 1
.
6 alkanoyl group, a 03-6 alkoxycarbonylalkyl group, cyano, halo, a C1-4alkyliminomethyl group, a Cl- 4 alkylaminomethyl group or a hydroxyiminomethyl group. In a first group of preferred compounds of the present invention A is S. 15 Preferably n is 2 in this group of compounds. Preferably g is 0 or 1 in this group of compounds. Preferably R 1 is halo, an alkoxy group containing 1 to 3 carbon atoms, or an alkylthio group containing 1 to 3 carbon atoms. In a second group of preferred compounds of the present invention A is O. 20 Preferably n is 2 in this group of compounds. Preferably g is 0 or 1 in this group of compounds. Preferably R 1 is halo, an alkoxy group containing 1 to 3 carbon atoms, or an alkylthio group containing 1 to 3 carbon atoms. In compounds of Formula I and Formula la preferred values of R 1 are methyl, 25 ethyl, propyl, isopropyl, cyclopropyl, methoxy, ethoxy, isopropoxy, bromo, chloro, fluoro, iodo, trifluoromethyl, trifluoromethoxy, methylthio, methylsulphinyl, methylsulphonyl, hydroxy, formyloxy, acetoxy, hydroxymethyl, 1-hydroxyethyl, 1 hydroxy-1-methylethyl, 1-hydroxypropyl, cyano, formyl, acetyl, methoxycarbonyl, ethoxycarbonyl, carbamoyl, carbamoylmethyl, sulphamoyl, sulphamoylmethyl, 30 amino, methylamino, dimethylamino, ethylamino or diethylamino. More preferably
R
1 is methoxy, chloro or methylthio. In compounds of Formula I and Formula la preferred values of R 4 are cyclopropyl, methoxy, ethoxy, bromo, chloro, fluoro, iodo, trifluoromethyl, 35 trifluoromethoxy, hydroxymethyl, 1-hydroxyethyl, 1-hydroxy-1 -methylethyl; 1- WO 00/71549 PCT/EP00/04279 11 hydroxypropyl, 1-hydroxy-2-methylpropyl, 1-hydroxybutyl, 1-hydroxy-3-methylbutyl, 1-hydroxypentyl, 1-hydroxypropenyl, 1-hydroxybut-3-enyl, 1-hydroxy-2 methylpropenyl, 1-hydroxy-2-methylbut-3-enyl, 1-hydroxypent-4-enyl, 3-hydroxybut 1 -enyl, 1 -hydroxypropynyl, 1 -hydroxybut-2-ynyl, a-hydroxy-2-methoxybenzyl, 5 methoxymethyl, ethoxymethyl, isopropoxymethyl, cyclopropylmethoxymethyl, cyclobutylmethoxymethyl, prop-2-ynyloxymethyl, methylthio, phenylthio, vinyl, allyl, prop-1-enyl, 2-methylprop-2-enyl, 1-methylvinyl, styryl, formyl, acetyl, cyano, ethoxycarbonylmethyl, N-(1-methylethyl)iminomethyl, N-methylaminomethyl and hydroxyiminomethyl. More preferably R 4 is hydroxymethyl, 1-hydroxyethyl or vinyl. 10 Most preferably R 4 is hydroxymethyl or vinyl. In especially preferred compounds of Formula la, A is S or O; g is 0 or 1, n is 2; R 1 represents halo, an alkoxy group containing 1 to 3 carbon atoms or an alkylthio group containing 1 to 3 carbon atoms; and R 4 represents a hydroxyalkyl group 15 containing 1 to 4 carbon atoms, an a-hydroxy(2-C 1
-
3 alkoxyphenyl)methyl group, a hydroxyalkenyl group containing 3 to 4 carbon atoms in which hydroxy is not attached directly to either carbon of the double bond, a hydroxyalkynyl group containing 3 to 4 carbon atoms in which hydroxy is not attached directly to either carbon of the triple bond, an alkenyl group containing 2 to 3 carbon atoms, a 20 C 1
-
3 alkylthio group, a C1-2 alkanoyl group or a hydroxyiminomethyl group. In the remainder of this description the term "compounds of Formula I" means compounds of Formula I or compounds of Formula la. Similarly the term "a compound of Formula I" means a compound of Formula I or a compound of Formula 25 Ia. Compounds of Formula I may exist as salts with pharmaceutically acceptable acids. The present invention includes all such salts. Examples of such salts include hydrochlorides, hydrobromides, sulphates, methanesulphonates, nitrates, maleates, 30 formates, acetates, citrates, fumarates, tartrates leg (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures], succinates, oxalates, benzoates and salts with amino acids such as glutamic acid. Such salts are prepared by methods known to those skilled in the art as illustrated in the Examples.
WO 00/71549 PCT/EP00/04279 12 Certain compounds of Formula I may exist in different tautomeric forms or as different geometric isomers, and the present invention includes each tautomer and/or geometric isomer of compounds of Formula I and mixtures thereof. 5 Certain compounds of Formula I may exist in different stable conformational forms which may be separable. For example, if a bulky group is present there may be restricted rotation about one or more single bond or bonds due to steric hindrance. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit 10 separation of different conformers. The present invention includes each conformational isomer of compounds of Formula I and mixtures thereof. Certain compounds of Formula I and their salts may exist in more than one crystal form and the present invention includes each crystal form and mixtures 15 thereof. Certain compounds of Formula I and their salts may also exist in the form of solvates, for example hydrates, and the present invention includes each solvate and mixtures thereof. Certain compounds of Formula I contain one or more chiral centres, and exist 20 in different optically active forms. When compounds of Formula I contain one chiral centre, the compounds exist in two enantiomeric forms and the present invention includes both enantiomers and mixtures of enantiomers. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts which may be separated, for example, by crystallisation; 25 formation of diastereoisomeric derivatives or complexes which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support for example silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is converted into another chemical 30 entity by one of the separation procedures described above, a further step is required to liberate the desired enantiomeric form. Alternatively, specific enantiomers may be synthesised by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer into the other by asymmetric transformation. 35 WO 00/71549 PCTIEP00/04279 13 When a compound of Formula I contains more than one chiral centre it may exist in diastereoisomeric forms. The diastereoisomeric pairs may be separated by methods known to those skilled in the art, for example chromatography or crystallisation and the individual enantiomers within each pair may be separated as 5 described above. The present invention includes each diastereoisomer of compounds of Formula I and mixtures thereof. Specific compounds of Formula I are: 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazole-2-carboxaldehyde; 10 [3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]methanol; 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazole-2-carboxaldehyde oxime; 15 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yl]ethanol; 3-(benzo[b]thiophen-3-yl)-2-bromo-5,6-dihydroimidazo[2,1 -b]thiazole; 20 3-(benzo[b]thiophen-3-yl)-2-bromo-6,7-dihydro-5H-thiazolo[3,2-a]pyrimidine; 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]-1 -methylethanol; 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]propan-1 -ol; 25 2-bromo-3-(5-methoxybenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[ 2 ,1 -b]thiazole; 2-bromo-3-(5-chlorobenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazole; 30 3-(benzo[b]thiophen-3-yl)-2-ethoxymethyl-5,6-dihydroimidazo[2,1 -b]thiazole; 1 -[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]prop-2-en-1 -ol; 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]but-2-yn-1 -ol; 35 3-(benzo[b]thiophen-3-yl)-2-vinyl-5,6-dihydroimidazo[2,1 -b]thiazole; 2-allyl-3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazole; 40 [3-(benzo[b]furan-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yl]methanol; N-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-ylmethylidene]-1 methylethylamine; 45 3-(benzo[b]thiophen-3-yl)-2-chloro-5,6-dihydroimidazo[2,1 -b]thiazole; 2-acetyl-3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazole; 3-(benzo[b]thiophen-3-yl)-2-(methoxymethyl)-5,6-dihydroimidazo[2,1 -b]thiazole; 50 WO 00/71549 PCTIEPOO/04279 14 3-(benza[b]thiophen-3-y)-2-(mfethylthio)-5,6-dihydraimidazol2, 1 -b~thiazole; 3-(benza[b]thiaphen-3-yl)-2-(1 -methylvinyl)-5,6-dihydraimlidazo[2,1 -b]thiazale; 5 1 -[3-(benzo[b]thiophen-3-y)-5,6-dihydrimidazo[2, 1 -b]thiazal-2-yl]-2-methyiprapal-1 al ; 1 -[3-(benza[b~thiophen-3-y)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]butan-1 -ak 10 1 -[3-(benza[b]thiophen-3-y)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yl]-2-methylbut-3-efl 1-al ; 1 -[3-(benzo[b]thiaphen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yI]-3-methylbutan-1 al; 15 1 -[3-(benza[b]thiaphen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazal-2-yi]pentan-1 -al; 1 -[3-(benza[b~thiaphen-3-yl)-5 ,6-dihydroimidaza[2, 1-b]thiazol-2-yI]prop-2-yn-1-al; 20 1 -[3-(benza jb]thiaphen-3-yl)-5,6-dihydraimlidazo[2, 1-blthiazol-2-yl]but-3-en-l1-al; 1 -[3-(benza[b]thiaphen-3-yl)-5,6-dihydrimidazo[2, 1 -b]thiazol-2-yI]-2-methylprap-2 en-i-al; 25 1 -[3-(benza[b]thiaphen-3-yl)-5,6-dihydrimidaza[2, 1 -b]thiazal-2-yI]pent-4-en-1 -al; [3-(benza[b]thiaphen-3-yl)-5,6-dihydraimidazat2, 1 -b~thiazaI-2-yI](2 methaxyphenyl)methanal; 30 3-(benza[b]thiaphen-3-yl)-2-prap-1 -enyl-5,6-dihydraimidaza[2, 1 -b]thiazale; [3(ez~~hohn3y)67dhdo5-haoo32aprmdn2y~ehnl 3-(benza[b]thiaphen-3-yl)-5,6-dihydraimidaza[2, 1 -b]thiazale-2-carbanitrile; 35 3-(benza[b]thiaphen-3-yl)-2-styryI-5,6-dihydraimidaza[ 2 , 1 -b]thiazale; 3-(5-chlarabenza[b]thiaphen-3-yl)-5 ,6-dihydraimidaza[2, 1 -b]thiazale-2 carbaxaldehyde; 40 [3-(5-chlarabenza[b]thiaphen-3-y)-5,6-dihydrimidaza[2, 1 -b]thiazal-2-ylllmethanal; 3-(benza[b]thiaphen-3-y)-2-(phenylthia)-5,6-dihydraimidaza[ 2 ,1 -bjthiazale; 45 [3-(benza[b]thiaphen-3-yl)-5,6-dihydrimidaza[2, 1 -b]thiazal-2-yl]-N methylmethylamine; 3-(benza[b]thiaphen-3-yl)-2-cyclaprapyl-5,6-dihydraimidaza[ 2 , 1 -b]thiazale; 50 3-(benza[b]thiaphen-3-yl)-2-iada-5,6-dihydrimidaza[2, 1 -b]thiazale; 4-[3-(benza[b]thiaphen-3-y)-5,6-dihydrimidaza[2,1 -b]thiazal-2-yl]but-3-en-2-al; 3-(benza[b~thiaphen-3-yl)-2-(2-mlethylprap-2-elyl)-5,6-dihydraimidaza[ 2 ,I -b]thiazale;I WO 00/71549 PCT/EP00/04279 15 ethyl [3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]acetate; 2-bromo-3-[5-(methylthio)benzo[b]thiophen-3-yl]-5,6-dihydroimidazo[2,1 -b]thiazole; 5 {3-[5-(methylthio)benzo[b]thiophen-3-yl]-5,6-dihydroimidazo[2,1 -b]thiazol-2 yl}methanol; 3-(benzo[b]thiophen-3-yl)-2-cyclopropylmethoxymethyl-5,6-dihydroimidazo[2, 1 10 b]thiazole; 3-(benzo[b]thiophen-3-yl)-2-prop-2-ynyloxymethyl-5,6-dihydroimidazo[2,1 -b]thiazole; 2-bromo-3-(7-methoxybenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazole; 15 3-(benzo[b]thiophen-3-yl)-2-isopropoxymethyl-5,6-dihydroimidazo[2,1-b]thiazole; and 3-(benzo[b]thiophen-3-yl)-2-cyclobutylmethoxymethyl-5,6-dihydroimidazo[2, 1 b]thiazole 20 including pharmaceutically acceptable salts thereof and individual enantiomers, racemates or other mixtures of enantiomers. The present invention also includes pharmaceutical compositions comprising 25 a therapeutically effective amount of a compound of Formula I or a salt thereof together with a pharmaceutically acceptable diluent or carrier. As used hereinafter, the term "active compound" denotes a compound of Formula I or a salt thereof. In therapeutic use, the active compound may be 30 administered orally, rectally, parenterally or topically, preferably orally. Thus the therapeutic compositions of the present invention may take the form of any of the known pharmaceutical compositions for oral, rectal, parenteral or topical administration. Pharmaceutically acceptable carriers suitable for use in such compositions are well known in the art of pharmacy. The compositions of the 35 invention may contain 0.1-99% by weight of active compound. The compositions of the invention are generally prepared in unit dosage form. Preferably the unit dosage of active ingredient is 1-500 mg. The excipients used in the preparation of these compositions are the excipients known in the pharmacist's art. 40 Compositions for oral administration are the preferred compositions of the invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, syrups and aqueous or oil suspensions. The excipients WO 00/71549 PCT/EP00/04279 16 used in the preparation of these compositions are the excipients known in the pharmacist's art. Tablets may be prepared by mixing the active compound with an inert diluent such as calcium phosphate in the presence of disintegrating agents, for example maize starch, and lubricating agents, for example magnesium stearate, and 5 tableting the mixture by known methods. The tablets may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention. Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate. Similarly, capsules, for example hard or soft gelatin capsules, containing the active 10 compound with or without added excipients, may be prepared by conventional means and, if desired, provided with enteric coatings in a known manner. The tablets and capsules may conveniently each contain 1 to 500 mg of the active compound. Other compositions for oral administration include, for example, aqueous suspensions containing the active compound in an aqueous medium in the 15 presence of a non-toxic suspending agent such as sodium carboxymethylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil. Preferably the compositions of the invention are administered orally in the 20 known pharmaceutical forms for such administration. Dosage forms suitable for oral administration may comprise tablets, pills, capsules, caplets, multiparticulates including: granules, beads, pellets and micro-encapsulated particles; powders, elixirs, syrups, suspensions and solutions. 25 Solid oral dosage forms, for example tablets, may be prepared by mixing the pharmaceutical composition of the present invention with one or more of the following ingredients or mixtures thereof: inert diluents, for example calcium carbonate, calcium sulphate, compressible sugar, confectioner's sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate 30 dihydrate, glyceryl palmitostearate, hydrogenated vegetable oil, kaolin, lactose, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, microcrystalline cellulose, polymethacrylates, potassium chloride, powdered cellulose, pregelatinized starch, sodium chloride, sorbitol, starch, sucrose, sugar spheres, talc and tribasic calcium phosphate; 35 disintegrating agents, for example alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, croscarmellose sodium, WO 00/71549 PCTIEP00/04279 17 crospovidone, guar gum, magnesium aluminium silicate, methylcellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate, starch including maize starch and agar; 5 lubricating agents, for example calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulphate, sodium stearyl fumarate, stearic acid, talc and zinc stearate; binders, for example acacia, alginic acid, carbomer, carboxymethylcellulose sodium, 10 dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, liquid glucose, magnesium aluminium silicate, maltodextrin, methylcellulose, polymethacrylates, povidone, pregelatinized starch, sodium alginate, starch including maize starch, zein, sugars (such as sucrose, molasses and lactose), and natural and synthetic gums 15 (such as extract of Irish moss, polyethylene glycol, waxes, microcrystalline cellulose and polyvinylpyrrolidone); colouring agents, for example conventional pharmaceutically acceptable dyes; sweetening and flavouring agents; preservatives; 20 one or more pharmaceutically acceptable couple or couples (such as those comprising an acid and a carbonate or bicarbonate salt), which effervesces to aid dissolution when the solid dosage form is added to water; and other optional ingredients known in the art to permit production of oral dosage forms by known methods such as tabletting. 25 Solid oral dosage forms may be formulated in a manner known to those skilled in the art so as to give a sustained release of the active compound. Film coated, solid oral dosage forms comprising compositions of the present invention may be advantageous, depending on the nature of the active compound. Various 30 materials, for example shellac and/or sugar, may be present as coatings, or to otherwise modify the physical form of the oral dosage form. For example tablets or pills may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate and/or hydroxy propyl methylcellulose phthalate. 35 WO 00/71549 PCT/EP00/04279 18 Capsules and/or caplets (for example hard or soft gelatin capsules) comprising the active compound (with or without added excipients such as a fatty oil), may be prepared by conventional means and, if desired, provided with enteric coatings in a known manner. The contents of the capsule and/or caplet may be 5 formulated using known methods to give sustained release of the active compound. Liquid oral dosage forms comprising compositions of the present invention may be an elixir, suspension and/or syrup (for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non 10 toxic suspending agent [such as sodium carboxymethylcellulose] and/or oily suspensions containing the active compound in a suitable vegetable oil [such as arachis oil and/or sunflower oil]). Liquid oral dosage forms may also comprise one or more sweetening agent, flavouring agent, preservatives and/or mixtures thereof. 15 The active compound may be formulated into granules with or without additional excipients. The granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example water) before ingestion. The granules may contain disintegrants (for example a pharmaceutically acceptable effervescent couple formed from an acid and a carbonate or bicarbonate salt) to 20 facilitate dispersion in the liquid medium. Preferably each of the above oral dosage forms may contain from about 1 mg to about 1000 mg, more preferably from about 5 mg to about 500 mg (for example 10 mg, 50 mg, 100 mg, 200 mg, or 400 mg) of the active compound. 25 Compositions of the invention suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with hard fat, semi-synthetic glyceride, cocoa butter and/or polyethylene glycol bases. 30 Pharmaceutical compositions may also be administered parenterally (for example subcutaneously, intramuscularly, intradermally and/or intravenously [such as by injection and/or infusion] in the known pharmaceutical dosage forms for parenteral administration (for example sterile suspensions in aqueous and/or oily media and/or sterile solutions in suitable solvents, preferably isotonic with the blood 35 of the intended patient). Parenteral dosage forms may be sterilised (for example by micro-filtration and/or using suitable sterilising agents [such as ethylene oxide]).
WO 00/71549 PCT/EP00/04279 19 Optionally one or more of the following pharmaceutically acceptable adjuvants suitable for parenteral administration may be added to parenteral dosage forms: local anaesthethetics, preservatives, buffering agents and/or mixtures thereof. Parenteral dosage forms may be stored in suitable sterile sealed containers (for 5 example ampoules and/or vials) until use. To enhance stability during storage the parenteral dosage form may be frozen after filling the container and fluid (for example water) may be removed under reduced pressure. Pharmaceutical compositions may be administered nasally in known 10 pharmaceutical forms for such administration (for example sprays, aerosols, nebulised solutions and/or powders). Metered dose systems known to those skilled in the art (for example aerosols and/or inhalers) may be used. Pharmaceutical compositions may be administered to the buccal cavity (for 15 example sub-lingually) in known pharmaceutical forms for such administration (for example slow dissolving tablets, chewing gums, troches, lozenges, pastilles, gels, pastes, mouthwashes, rinses and/or powders). Compositions for topical administration may comprise a matrix in which the 20 pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally. A suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or a wax, for example paraffin wax or beeswax, together 25 with a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol. Alternatively the active compounds may be dispersed in a pharmaceutically acceptable cream or ointment base. The amount of active compound contained in a topical formulation should be such that a therapeutically effective amount of the compound is delivered during the period of time for which the topical formulation is 30 intended to be on the skin. The compounds of the present invention may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body. Internal sources 35 include implanted reservoirs containing the compound to be infused which is continuously released for example by osmosis and implants which may be (a) liquid WO 00/71549 PCT/EP00/04279 20 such as a suspension or solution in a pharmaceutically acceptable oil of the compound to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compound to be 5 infused. The support may be a single body containing all the compound or a series of several bodies each containing part of the compound to be delivered. The amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time. 10 In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling. 15 In the compositions of the present invention the active compound may, if desired, be associated with other compatible pharmacologically active ingredients. The present invention also comprises a compound of Formula I for use as a medicament. 20 The pharmaceutical compositions containing a therapeutically effective amount of a compound of Formula I may be used to treat depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, obsessive-compulsive 25 behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, stress in mammals particularly humans, and as an aid to smoking cessation in human beings. In addition such compositions may be used in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy 30 and/or conditions in which there is neurological damage such as stroke, brain trauma, cerebral ischaemia, head injuries and haemorrhage. Whilst the precise amount of active compound administered in such treatment will depend on a number of factors, for example the age of the patient, the severity of the condition and the past medical history, and always lies within the sound discretion of the administering 35 physician, the amount of active compound administered per day is in the range 1 to WO 00/71549 PCT/EP00/04279 21 1000 mg preferably 5 to 500 mg given in single or divided doses at one or more times during the day. In yet another aspect, the present invention provides the use of a compound 5 of Formula I in the manufacture of a medicament for use in the treatment of depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent 10 diabetes mellitus, hyperglycaemia, hyperlipidaemia, stress, as an aid to smoking cessation and in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke, brain trauma, cerebral ischaemia, head injuries and haemorrhage. 15 The present invention also provides a method of treating depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, 20 hyperlipidaemia, stress and seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke, brain trauma, cerebral ischaemia, head injuries and haemorrhage which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof. 25 The present invention also provides a method of reducing the craving to smoke in human beings which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof. The present invention also provides a method of reducing weight gain after smoking 30 cessation in human beings which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof. In addition the compounds of the present invention may be useful in the treatment or prevention of metabolic diseases and conditions arising therefrom, for 35 example non exercise activity thermogenesis and increased metabolic rate, sexual dysfunction, sleep apnoea, premenstrual syndrome, urinary incontinence, WO 00/71549 PCTIEP00/04279 22 hyperactivity disorders, hiatial hernia and reflux esophagitis, pain, especially neuropathic pain, weight gain associated with drug treatment, chronic fatigue syndrome, osteoarthritis and gout, cancers associated with weight gain, menstrual dysfunction, gallstones, orthostatic hypotension and pulmonary hypertension. 5 The compounds of the present invention may be useful in preventing cardio vascular disease, and in reducing platelet adhesiveness, in aiding weight loss after pregnancy and in aiding weight loss after smoking cessation. 10 The compounds of the present invention are particularly useful in treating obesity and related co-morbid conditions, for example, diabetes, hyperglycaemia and hyperlipidaemia. It is known that monoamine reuptake inhibitors which are used to treat obesity are often associated with cardiovascular side effects, for example, increased heart rate and increased blood pressure. The compounds of the present 15 invention reduce the cardiovascular side effects which might be expected to occur from the administration of a monoamine reuptake inhibitor particularly a noradrenaline reuptake inhibitor. Whilst not wishing to be bound by theory it is likely that the combination of 5-HT1A agonism in the compounds of the present invention reduces the cardiovascular side effects which might have arisen from their 20 monoamine reuptake inhibition particularly their noradrenaline reuptake inhibition. In another aspect the present invention provides a method of reducing the cardiovascular side effects of an anti-obesity drug comprising incorporating into the compound 5-HT1A agonism. 25 In another aspect the present invention provides the use of a compound which is a 5-HT1A agonist and which is a monoamine reuptake inhibitor particularly a noradrenaline reuptake inhibitor in the treatment of obesity and related co-morbid conditions without causing cardiovascular side effects. 30 The beneficial properties of especially preferred compounds of the present invention in reducing cardiovascular side-effects may be demonstrated in rat telemetry studies in which heart rate, blood pressure, body temperature and locomotor activity are recorded continuously over time. Suitable methods are 35 described in: WO 00/71549 PCT/EP00/04279 23 Brockway, BP, Mills, PA & Azar, SH (1991) A new method for continuous chronic measurement of blood pressure, heart rate and activity in the rat via radio-telemetry. Clinical and Experimental Hypertension - Theory and Practice A1 3(5), 885-895 and Guiol, C, Ledoussal, C & Surge, J-M (1992) A radiotelemetry system for chronic 5 measurement of blood pressure and heart rate in the unrestrained rat. Validation of method. Journal of Pharmacological and Toxicological Methods 28, 99-105. The 5-HT1A agonism of especially preferred compounds of the present invention may be determined by electrophysiology by methods known to those 10 skilled in the art. Processes for the preparation of compounds of Formula I will now be described. The processes may be performed on an individual basis, or by multiple parallel synthesis, also known as High Speed Analoguing. The processes are 15 preferably carried out at atmospheric pressure. Compounds of Formula I may be prepared by methods disclosed in WO 97/02269. Additionally compounds of Formula I may be prepared by methods described below. 20 Compounds of Formula I may be prepared by dehydrating a compound of Formula II RS R4O S N HO (R) I - (CR 2
R
3 )n A
R
5 25 in which A, R 1 , R 2 , R 3 , R 4 , R 5 , g and n are as hereinbefore defined, optionally in the presence of an acid, for example acetic or sulphuric acid, at a temperature in the range 0-200 0 C; preferably in the range 20-150 0 C. Compounds of Formula II may be prepared by reacting a compound of 30 Formula III WO 00/71549 PCT/EP00/04279 24 H S (CR 2
R
3 )n l N S::< (CR 2R3)n II
/N
j / H in which R 2
,R
3 and n are as hereinbefore defined, with a compound of Formula IV
CO.CHR
4 .Z (Ri)gI IV 5 A R 5 in which Z is a leaving group, for example a halo such as bromo, and A, R 1 , R 4 , R 5 and g are as hereinbefore defined, at a temperature in the range 0-200oC, in the presence of a solvent, for example ethanol and optionally in the presence of an acid, for example acetic acid; preferably by heating at a temperature in the range 200C to 10 the boiling point of the solvent used. Compounds of Formula I may also be prepared directly by reacting a compound of Formula III with a compound of Formula IV at a temperature in the range of 0-2000C, optionally in the presence of an acid, for example acetic acid, and 15 optionally in the presence of a solvent, for example ethanol, without isolation of the intermediate of Formula II; preferably by heating at a temperature in the range 20-1500C. Compounds of Formula I in which R 4 represents halo may be prepared by 20 reacting a compound of Formula V S N (R)g
(CR
2
R
3 )n A
R
s 25 in which A, R 1 , R 2 , R 3 , R 5 , n and g are as hereinbefore defined, with a halogenating agent for example bromine, phenyltrimethylammonium tribromide, iodine rmonochloride or benzyltrimethylammonium tetrachloroiodate at a temperature in the WO 00/71549 PCT/EP00/04279 25 range -50-2000C optionally in the presence of a solvent, for example dichloromethane, tetrahydrofuran or acetone. Compounds of Formula I in which R 4 represents a group of Formula 5 -CH(OH)Rx in which Rx is a C1.5 alkyl group, an alkenyl group containing 2-5 carbon atoms, an alkynyl group containing 2-5 carbon atoms or (2-C 1
-
3 alkoxyphenyl) may be prepared by reacting a compound of Formula VI O S R N VI / L(CR2R3) n (R,)g R :111 A R 10 in which A, R 1 , R 2 , R 3 , R 5 , n and g are as hereinbefore defined and Ry is H with an organometallic reagent, for example a compound of formula RxMgX or RxLi in which Rx is as hereinbefore defined and X is halo, for example bromo, in the presence of a solvent, for example tetrahydrofuran or ether, at a temperature in the range of -500C to the boiling point of the solvent used. 15 Compounds of Formula I in which R 4 represents a group of Formula -CH(OH)Ry in which Ry is a C1- alkyl group, an alkenyl group containing 2-5 carbon atoms, an alkynyl group containing 2-5 carbon atoms or (2-C 1
-
3 alkoxyphenyl) may be prepared by reacting a compound of Formula VI in which A, R 1 , R 2 , R 3 , FR, g and n 20 are as hereinbefore defined and Ry is a C1.-5 alkyl group, an alkenyl group containing 2-5 carbon atoms, an alkynyl group containing 2-5 carbon atoms or (2-C1_ 3 alkoxyphenyl) with a reducing agent, for example sodium borohydride, in the presence of a solvent, for example ethanol, at a temperature in the range of 0OC to the boiling point of the solvent used. 25 Compounds of Formula I in which R 4 is hydroxymethyl may be prepared by reacting a compound of Formula VI in which A, R 1 , R2, R 3 , R 4 , R 5 , g and are as hereinbefore defined and Ry is H with a reducing agent, for example sodium borohydride, in a solvent, for example methanol, at a temperature in the range of 30 -500C to the boiling point of the solvent used.
WO 00/71549 PCT/EP00/04279 26 Compounds of Formula I in which R 4 is hydroxyiminomethyl may be prepared by reacting a compound of Formula VI in which A, R 1 , R 2 , R 3 , R 5 , g and n are as hereinbefore defined and Ry is H with hydroxylamine or a salt thereof optionally in the presence of a solvent, for example an alcohol, eg ethanol, at a temperature in 5 the range of 0-2501C. Compounds of Formula I in which R 4 is cyano may be prepared by reacting a compound of Formula VI in which A, R 1 , R 2 , R 3 , R 5 , n and g are as hereinbefore defined and Ry is H with hydroxylamine or a salt thereof in the presence of formic 10 acid at a temperature in the range of 0-250 0 C. Compounds of Formula I in which R 4 represents a C 1
-
4 alkyliminomethylene group may be prepared by reacting a compound of Formula VI in which A, R 1 , R 2 ,
R
3 , R 5 , n and g are as hereinbefore defined and Ry represents H with an amine of 15 Formula RaNH 2 wherein Ra represents a C1-4 alkyl group optionally in the presence of a solvent, for example ethanol, optionally in the presence of an acid catalyst, for example acetic acid, at a temperature in the range 0-2500C. Compounds of Formula I in which R 4 represents a C 1 -4alkylaminomethylene 20 group may be prepared by reacting a compound of Formula I in which R 4 represents a C1-4alkyliminomethylene group, and A, R 1 , R 2 , R 3 , Rs, n and g are as hereinbefore defined, with a reducing agent, for example sodium borohydride, in the presence of a solvent, for example an alcohol e.g. ethanol, at a temperature in the range 00C to the boiling point of the solvent used. 25 Compounds of Formula I in which R 4 represents a C1-4alkylaminomethylene group may be prepared directly from a compound of Formula VI in which A, R 1 , R 2 ,
R
3 , R5, n and g are as hereinbefore defined and Ry represents hydrogen by reaction with an amine of formula RaNH 2 wherein Ra represents a C1-4 alkyl group and a 30 reducing agent, for example sodium triacetoxyborohydride, in the presence of a solvent, for example tetrahydrofuran, at a temperature in the range 0oC to the boiling point of the solvent used. Compounds of Formula I in which R 4 represents a group of formula 35 -C(OH)RxRy in which Rx and Ry are each independently a C 1
.
5 alkyl group may be WO 00/71549 PCT/EP00/04279 27 prepared by reacting a compound of Formula VI in which Ry is a C1.5 alkyl group, and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, with an organometallic reagent, for example a compound of formula RxMgX or RxLi in which Rx is as hereinbefore defined and X is halo, for example bromo, in the presence of a solvent, for example 5 tetrahydrofuran or ether, at a temperature in the range of -500C to the boiling point of the solvent used. Compounds of Formula I in which R 4 represents a group of formula -C(OH)RxRy in which Rx and Ry are the same C1-2 alkyl group may be prepared by 10 reacting a compound of Formula VI, as hereinbefore defined except that Ry is ORz in which Rz is a Cs- 6 alkyl group, with an organometallic reagent, for example a compound of formula RxMgX or RxLi in which Rx is as hereinbefore defined and X is halo, for example bromo, in the presence of a solvent, for example tetrahydrofuran or ether, at a temperature in the range of -50oC to the boiling point of the solvent used. 15 Compounds of Formula I in which R 4 represents a 02-6 alkenyl group in which the double bond is attached to the carbon alpha to the thiazole ring or a styryl group may be prepared by reacting compounds of Formula VI, in which Ry represents hydrogen or a C1-4 alkyl group, and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously 20 defined, with a phosphonium salt of formula RzPh 3 P+Br- in which Rz represents a C1-5 alkyl group or a benzyl group in the presence of a base for example n butyllithium, in a solvent for example, an ether, e.g. tetrahydrofuran, at a temperature in the range -780C to the boiling point of the solvent used. 25 Compounds of Formula I in which R 4 represents a 02-6 alkanoyl group may be prepared by reacting a compound of Formula I in which R 4 represents halo, for example bromo or chloro, and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, or a compound of Formula V with a compound of formula RbMgX or RbLi in which Rb is a C1.6 alkyl group and X is halo, for example bromo or chloro, in the presence of a 30 solvent for example an ether, eg diethyl ether or tetrahydrofuran, at a temperature in the range -780C to the boiling point of the solvent used, and then reacting the product obtained with an acylating agent for example a compound of Formula RcCON(CH 3
)OCH
3 in which Rc represents a C1-5 alkyl group in a solvent, for example an ether e.g. tetrahydrofuran, at a temperature in the range 00C to the WO 00/71549 PCTIEP00/04279 28 boiling point of the solvent used. Compounds of Formula VI may be prepared in a similar manner. Compounds of Formula 1 in which R 4 represents a C1-3 alkoxyC 1
-
3 alkyl group 5 may be prepared by reacting a compound of Formula I in which R 4 represents a hydroxyC 1
-
3 alkyl group, and A, R 1 , R 2 , R 3 , Rs, n and g are as previously defined, with a C1-3 alkylating agent, for example a C1.3 alkyl halide e.g. a C1-3 alkyl iodide in the presence of a base, for example sodium hydride, in a solvent, for exampleN,N dimethylformamide, at a temperature in the range of -50 to 150 0 C. 10 Compounds of Formula I in which R 4 represents a 04 7 cycloalkylalkoxyC 1
.
3 alkyl group may be prepared by reacting a compound of Formula I in which R4 represents a hydroxyC 1
-
3 alkyl group, and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, with a C4-7Cycloalkylalkylating agent, for example a 15 04-7 cycloalkylalkyl halide e.g. a 04-7 cycloalkylalkyl iodide in the presence of a base, for example sodium hydride, in a solvent, for example N,N-dimethylformamide, at a temperature in the range of-50 to 1500C. Compounds of Formula I in which R 4 represents a C 3
.
7 alkynylalkoxyC 1 -3alkyl 20 group may be prepared by reacting a compound of Formula I in which R 4 represents a hydroxyC 1
.
3 alkyl group, and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, with a C3.7 alkynylalkylating agent, for example a C3.7 alkynylalkyl halide e.g. a 03.7 alkynylalkyl iodide in the presence of a base, for example sodium hydride, in a solvent, for example N,N-dimethylformamide, at a temperature in the range of -50 to 25 1500C. Compounds of Formula I in which R 4 represents a C1-3 alkylthioC1- 3 alkyl group may be prepared by reacting a compound of Formula I in which R 4 represents a mercaptoC 1
-
3 alkyl group, and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, 30 with a C1.3 alkylating agent, for example a C1-3 alkyl halide e.g. a C1.3 alkyl iodide in the presence of a base, for example sodium hydride or sodium hydroxide, in a solvent, for example N,N-dimethylformamide, at a temperature in the range of -50 to 1500C.
WO 00/71549 PCT/EP00/04279 29 Compounds of Formula I in which R 4 represents a C1-3 alkylthio group or an arylthio group and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined may be prepared by reacting a compound of Formula I in which R 4 represents halo or a compound of Formula V with a metallating agent, for example a compound of 5 formula RMgX or RLi in which R is a C 1
-
6 alkyl group and X is halo, for example chloro, bromo or iodo, in a solvent, for example an ether or a mixture of ethers, eg tetrahydrofuran, or diethyl ether, at a temperature in the range of -1000C to the boiling point of the solvent used to give an intermediate complex, which is reacted with a disulphide of formula RdS-SRd in which Rd is a 01-3 alkyl group or an aryl 10 group, at a temperature in the range of -1000C to the boiling point of the solvent used. Compounds of Formula I in which R 4 represents a C1-3 alkoxy group and A,
R
1 , R 2 , R 3 , Rs, n and g are as previously defined may be prepared by reacting a 15 compound of Formula I in which R 4 represents halo, for example bromo or iodo, with an C1-3 alkoxide salt, for example a sodium or potassium salt, optionally in the presence of a solvent, for example a C1-3 alcohol or dimethylformamide, optionally in the presence of a catalyst, for example a copper (I) salt, at a temperature in the range of 0-350oC. 20 Compounds of Formula I in which R 4 represents a 03.6 alkenyl group in which the double bond is not attached to the carbon alpha to the thiazole ring may be prepared by reacting a compound of Formula I in which R 4 represents halo, for example bromo or chloro, and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, 25 or a compound of Formula V with a compound of formula RbMgX or RbLi in which Rb is a C1-6 alkyl group and X is halo, for example bromo or chloro, in the presence of a solvent for example an ether, eg diethyl ether or tetrahydrofuran, at a temperature in the range -780C to the boiling point of the solvent used, and then reacting the product obtained with an alkenylating agent, for example a C 3
-
6 alkenylmethyl halide 30 e.g. a C 3
-
6 alkenylmethyl iodide, in a solvent, for example an ether e.g. tetrahydrofuran, at a temperature in the range 00C to the boiling point of the solvent used.
WO 00/71549 PCT/EP00/04279 30 Compounds of Formula I in which R 4 is a C 3
-
6 alkoxycarbonylalkyl group may be prepared by reacting compounds of Formula VI, in which Ry represents hydrogen and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, with a phosphonate of formula Me 2 NCH[PO(ORz) 2 ]2 in which Rz represents a C1-4 alkyl group in the 5 presence of a base, for example sodium hydride, in a solvent for example an ether, e.g. 1,4-dioxane, at a temperature in the range -780C to the boiling point of the solvent used, then subjecting the resulting intermediate product to partial hydrolysis in the presence of an acid, for example hydrochloric acid. 10 Compounds of Formula I in which R 4 is a C 4
-
6 hydroxyalkenyl group in which the double bond is attached to the carbon alpha to the thiazole ring may be prepared by reacting compounds of Formula VI, in which Ry represents hydrogen and A, R 1 ,
R
2 , R 3 , Rs, n and g are as previously defined, with a compound of Formula (RzO) 2 POCH2CORc in which Rz represents a C1-2 alkyl group and Rc represents a 15 C1-3 alkyl group in the presence of a base, for example sodium hydride, in a solvent for example an ether, e.g. tetrahydrofuran, at a temperature in the range -780C to the boiling point of the solvent used, then subjecting the resulting intermediate product to reaction with a reducing agent, for example sodium borohydride, in a solvent, for example ethanol, at a temperature in the range -20 0 C to the boiling point 20 of the solvent used. Compounds of Formula Ill are commercially available or may be prepared by methods known to those skilled in the art.Compounds of Formula IV may be prepared by methods known to those skilled in the art as specified in the individual 25 Examples described herein. The ability of compounds of Formula I to interact with 5-hydroxytryptamine (5-HT) receptors has been demonstrated for the products of Examples 1 to 56 by the following test which determines the ability of the compounds to inhibit tritiated ligand 30 binding to 5-HT receptors in vitro and in particular to 5-HT1A receptors. Hippocampal tissue from the brains of male Sprague-Dawley rats (Charles River; weight range 150-250 g) was homogenised in ice-cold 50 mM Tris-HCI buffer (pH 7.7 when measured at 25 0 C, 1:40 w/v) and centrifuged at 40,000 g at 4 0 C for 10 35 minutes. The pellet was rehomogenised in the same buffer, incubated at 37 0 C for 10 WO 00/71549 PCT/EP00/04279 31 minutes and centrifuged at 40,000 g at 40C for 10 minutes. The final pellet was resuspended in 50 mM Tris-HCI buffer (pH 7.7) containing 4 mM CaCI2, 0.1% L-ascorbic acid and 10 pM pargyline hydrochloride (equivalent to 6.25 mg wet weight of tissue/ml) and used immediately in the binding assay. 5 Membranes (400 il; equivalent to 2.5 mg wet weight of tissue/tube) were incubated with 50 pl of [ 3 H]8-hydroxy-2-(dipropylamino)tetralin
([
3 H]8-OH-DPAT) at a single concentration of 1 nM and 50 pl of distilled water (total binding) or 50 pl of test compound (at a single concentration of 10
-
6 M or at 10 concentrations ranging from 10 10-11-10 -3 M) or 50 pl of 5-HT (10 prM, non-specific binding) at 250C for 30 minutes. The incubation was terminated by rapid filtration under vacuum through Skatron 11734 filters using a Skatron Cell Harvester. Filters were washed with ice-cold 50 mM Tris-HCI buffer, pH 7.7 (at 25 0 C, wash setting 9,9,0). The scored filter paper discs were punched out into vials, scintillation fluid added and radioactivity 15 determined by liquid scintillation counting. The ability of compounds of Formula I to interact with 5-hydroxytryptamine (5-HT) reuptake sites has been demonstrated for the products of Examples 1 to 56 by the following test which determines the ability of compounds to displace the 20 standard ligand, [ 3 H]citalopram, from 5-HT reuptake sites in vitro. Frontal cortical tissue from the brains of male Charles River rats weighing 150-250 g was homogenised in ice-cold 50 mM Tris-HCI, pH 7.4 (when measured at 250C) containing 120 mM sodium chloride and 5 mM potassium chloride (Tris buffer; 25 1:30 w/v) and centrifuged at 40,000 g for 10 minutes. The supernatant was discarded and the pellet rehomogenised in Tris buffer, 1:60 w/v, and centrifuged at 40,000 g for 10 minutes. This step was repeated a further time. The final pellet was resuspended in 50 mM Tris-HCI, pH 7.4 containing 120 mM sodium chloride and 5 mM potassium chloride (equivalent to 3.125 mg wet weight of tissue/ml) and used 30 immediately in the binding assay. All centrifugations were performed at 40C. Membranes (400 pl; equivalent to 1.25 mg wet weight of tissue/tube) were incubated with 50 pl [ 3 H]citalopram at a single concentration of 1.3 nM and 50 pl.1 of distilled water (total binding) or 50 pil of test compound (at a single concentration of 35 10-6 M or at 10 concentrations ranging from 10-11"-10-3 M) or 50 pli of paroxetine WO 00/71549 PCT/EP00/04279 32 (0.5 pM; non-specific binding) for 1 h at 270C. Membrane bound radioactivity was recovered by filtration under vacuum through Skatron 11734 filters presoaked in 0.5% PEI using a Skatron Cell Harvester. Filters were then washed in ice-cold 50 mM Tris-HCI buffer, pH 7.4 (at 250C, wash setting 9,9,0). The scored filter paper 5 discs were punched out into vials, scintillation fluid added and radioactivity determined by liquid scintillation counting. The ability of compounds of Formula I to interact with noradrenaline (NA) reuptake sites has been demonstrated for the products of Examples 1 to 33 by the 10 following test which determines the ability of compounds to displace the standard ligand, [ 3 H]nisoxetine, from noradrenaline reuptake sites in vitro. Frontal cortical tissue from the brains of male Charles River rats weighing 150-250 g was homogenised in ice-cold 50 mM Tris-HCI, pH 7.4 (at 25 0 C) containing 15 120 mM sodium chloride and 5 mM potassium chloride (Tris buffer; 1:60 w/v) using a Kinematic polytron (speed setting 6 for 10 seconds) and centrifuged at 40,000 g for 10 minutes. The supernatant was discarded and the pellet rehomogenised in Tris buffer, 1:60 w/v, and centrifuged at 40,000 g for 10 minutes. This step was repeated twice more so that, in total, the brain tissue was homogenised and centrifuged four 20 times. The final pellet was resuspended in 50 mM Tris-HCI, pH 7.4 containing 300 mM sodium chloride and 5 mM potassium chloride (equivalent to 18.75 mg wet weight of tissue/ml) and used immediately in the binding assay. All centrifugations were performed at 40C. 25 Membranes (400 il; equivalent to 7.5 mg wet weight of tissue/tube) were incubated with 50 p.l [ 3 H]nisoxetine at a single concentration of 0.6 nM and 50 p.I of distilled water (total binding) or 50 pl of test compound (at a single concentration 10-6 M or at 10 concentrations ranging from 10--1110.3 M) or 50 p.l of mazindol (1 p.M; non-specific binding) for 4 h at 40C. Membrane bound radioactivity was recovered 30 by filtration under vacuum through Skatron 11734 filters using a Skatron cell harvester. Filters were rapidly washed with ice-cold 50 mM Tris-HCI, pH 7.4 containing 120 mM sodium chloride and 5 mM potassium chloride (wash setting 9,9,0). The scored filter paper discs were punched out into vials, scintillation fluid added and radioactivity determined by liquid scintillation counting. 35 WO 00/71549 PCT/EP00/04279 33 The ability of compounds of Formula 1 to interact with muscarinic receptors has been demonstrated for the products of Examples 1-56 by the following test which determines the ability of compounds to displace the standard ligand, [3H]N-methylscopolamine, from muscarinic receptors in vitro. 5 Frontal cortical tissue from the brains of male Charles River rats weighing 150-250 g was homogenised in ice-cold 20 mM HEPES buffer, pH 7.5 (measured at 250C) containing 100 mM sodium chloride and 10 mM magnesium chloride (1:10 w/v) using a Polytron PT3100 (speed setting 21,700rpm, 3 x 5 seconds) and 10 centrifuged at 49,500 g for 30 minutes at 40C. The supernatant was discarded and the pellet rehomogenised in 20 mM HEPES buffer, pH 7.5 containing 100 mM sodium chloride and 10 mM magnesium chloride (equivalent to 12.5 mg wet weight of tissue/ml). Membranes were stored at -80oC until required. 15 Membranes were thawed, diluted 1:10 in ice-cold 20 mM HEPES buffer, pH 7.5 containing 100 mM sodium chloride and 10 mM magnesium chloride and homogenised using a Polytron PT3100 as above. Diluted membranes (200 pl; equivalent to 0.25 mg wet weight of tissue/tube) were incubated with 200 pl of 20 mM HEPES buffer, pH 7.5 containing 100 mM sodium chloride and 10 mM 20 magnesium chloride and 50 pl of [ 3 H]N-methylscopolamine at a single concentration of 0.15 nM and 50 pl of distilled water (total binding) or 50 pl of test compound (at a single concentration of 10-6M or at 10 concentrations ranging from 10-11- 10 - 3 M) or 50 pl of atropine sulphate (1 pM; non-specific binding) for 30 min at 300C. Membrane bound radioactivity was recovered by filtration under vacuum through 25 Skatron 11734 filters using a Skatron cell harvester. Filters were rapidly washed with ice-cold 20 mM HEPES buffer, pH 7.5 (wash 1,2 at setting 5,5). The scored filter paper discs were punched out into vials, scintillation fluid added and radioactivity determined by liquid scintillation counting. 30 For each of these tests measuring the ability of compounds of Formula I to displace standard ligands from 5-HT1A receptors and 5-hydroxytryptamine (5-HT) and noradrenaline (NA) reuptake sites and muscarinic receptors in vitro, the percentage displacement of specific binding of tritiated ligand by 10-6 M test compound was calculated in the following way. 35 WO 00/71549 PCT/EP00/04279 34 Firstly, specific binding of tritiated ligand in the absence (A) and presence (B) of test compound was determined: In the absence of compound: 5 A (dpm) = Total binding (dpm) - Non-specific binding (dpm) In the presence of compound (10-6 M): 10 B (dpm) = Binding at 10-6M (dpm) - Non-specific binding (dpm) The specific binding of tritiated ligand in the presence (B) of compound was then converted to a percentage of specific binding of tritiated ligand in the absence (A) of compound: 15 % Specific binding at 10
-
6 M = B (dpm) / A (dpm) x 100 The percentage displacement of specific binding of tritiated ligand by the test compound (10 -6 M) was then obtained by subtraction of the percentage specific 20 binding in the presence of compound from the percentage specific binding in the absence of compound, which is taken as the maximum binding and so equals 100%: % Displacement at 10 -6 M = 100 - % Specific binding at 10 -6 M. 25 In some cases, displacement curves were then produced for compounds which displaced 50% of specific binding of the tritiated ligand at 10 -6 M using a range of concentrations of the compound. The Ki was then calculated by fitting the following simultaneous equations (which are derived from the Feldman equations) by robust non-linear regression to data from three experiments simultaneously: WO 00/71549 PCT/EP00/04279 35 [F, = ILT, - B Ki'=
K
i 1 + , Kd ab= CkrI -L+K,' i 2
F
2 = -ab + ab 2 + K,'L
N
K F Non - specific data B CKrF + Nk F Otherwise
K,,F
2 jKd, + F + * F Ki where B is the concentration of bound ligand-receptor complex. This is calculated for each observation as: DPM 5 B= Specific activity x Volume of incubation L is the concentration of compound [L]tot is the concentration of the tritiated ligand used, calculated as: [L], Mean DPM for Total DPM added samples x Dilution n" Specific activity x Volume of incubation Kd is the equilibrium dissociation constant for the ligand. 10 F, and F 2 are the concentrations of free ligand and free compound respectively. r, is the total concentration of the receptor in the first experiment. This must be multiplied by CK for subsequent experiments (C1=1). NK is the non-specific binding constant. 15 The results obtained in the above tests for 5-HT1A binding and 5-HT and NA uptake, and muscarinic binding for the final products of Examples 1 - 56 hereinafter are given in Table 1 below. Kis are in nM and are means of three independent determinations. % Figures are for % displacement at 10-6 M for a single 20 determination.
WO 00/71549 PCT/EP00/04279 36 TABLE 1 Example 5-HT 5-HT1A NA uptake Muscarinic No. uptake 1 51% 1% 58% 0% 2 13 398 3.7 19% 3 201 200 12 28% 4 26 72% 6.2 0% 5 11 162 3.1 16% 6 7.7 378 3.5 9% 7 18 492 8.9 338 8 79% 48% 85% 87% 9 114 119 17 17% 10 73% 19% 94% 16% 11 97% 8% 61% 39% 12 93% 18% 87% 54% 13 101 89 2.0 15 14 82% 39% 3.1% 16% 15 60 269 8.1 4% 16 27 510 3.8 418 17 16 162 2.7 10.4 18 2.0 14% 46 11% 19 59% 8% 57% 19% 20 5.0 623 9.3 420 21 62% 13% 93% 22% 22 93 283 2.2 49 23 27 71 1.1 63 WO 00/71549 PCT/EP00/04279 37 Example 5-HT 5-HT1A NA uptake Muscarinic No. uptake 24 98 245 5.6 353 25 74% 34% 99% 51% 26 61% 57% 99% 33% 27 64% 43% 99% 49% 28 73% 48% 97% 48% 29 55% 42% 99% 35% 30 58% 42% 99% -5% 31 53% 62% 101% 28% 32 69% 54% 100% 36% 33 55% 48% 101% 28% 34 76 234 61 23% 35 36.5 347 2.2 245 36 62% 68% 104% 95% 37 189 30% 146 20% 38 50% 5% 84% 16% 39 73% 64% 64% 64% 40 75% 62% 44% 16% 41 2.9 110 7.5 28% 42 100% 65% 101% 31% 43 57% 60% 102% 99% 44 53% 4% 86% 32% 45 8.8 28 1.6 7.9 46 94% 92% 100% 88% 47 53% 65% 97% 39% 48 23 24.3 4.1 3.9 WO 00/71549 PCT/EP00/04279 38 Example 5-HT 5-HT1A NA uptake Muscarinic No. uptake 49 77% 61% 102% 73% 50 98% 46% 82% 81% 51 2.1 251 17 39% 52 66% 86% 103% 97% 53 64% 71% 101% 100% 54 54% 97% 101% 2% 55 60% 85% 101% NT 56 61% 81% 101% 96% Ki values are n=1, mean of n=2 or mean of n=3. NT = Not tested. 5 The ability of compounds of the invention to inhibit monoamine oxidase A activity is demonstrable by the following test. The assay was performed using the following general procedure in which the tissue source was human placenta: 10 Enzyme Substrate Incubation Reaction Method of detection product MAO-A(h) Kynuramine 30min/30 0 C 4-OHquinoline Spectrophotometry (0.15mM) The compounds were tested at 1 and 10micromolar in duplicate. 15 Ref: Weyler, W. and Salach, J.I. (1985) Purification and properties of mitochondrial monoamine oxidase type A from human placenta. J. Biol. Chem., 260: 13199 13207. The combination of inhibition of monoamine oxidase activity and 5-HT 20 reuptake inhibition may cause serotonin syndrome (Sternbach, H. Serotonin syndrome. Am. J. Psychiatry 148, 705-713, 1991) which is highly undesirable.
WO 00/71549 PCT/EP00/04279 39 Acute feeding studies Animals and environment 5 Experiments were performed on male Sprague-Dawley rats (300-450 g at the start of the experiment) which were obtained from Charles River (Margate). Animals were individually-housed in polypropylene cages with metal grid floors at a temperature of 21+1 oC and 55% humidity. Polypropylene trays were placed below 10 each cage. Animals were maintained on a reverse phase light-dark cycle. Lights were off from 09.30 h to 17.30 h during which time the room was illuminated by red light. Animals had free access to a powdered rat diet and tap water at all times. The diet was contained in glass feeding jars (10 cm diameter; 8 cm deep) with aluminium lids. Each lid had a hole (3 cm diameter) cut in it to allow access to the food. 15 Animals were accustomed to these conditions for at least two weeks before experimentation. Test procedure 20 On the day prior to testing, the animals were randomly allocated to treatment groups containing 6-8 rats, weighed and their food intakes over a 6 h period were measured. These baseline readings were taken to ensure that the body weights and food intakes of the different groups of rats were not significantly different before drug treatment. On the test day, animals were given vehicle or one of three doses of the 25 test drug. All drugs were dosed orally at the onset of the dark phase since rats consume most of their food during this period. Feeding jars were weighed (to the nearest 0.1g) at the time of drug administration and 1, 2, 4, 6 and 24 h after dosing. At each reading, the trays below the cages were examined for spiltfood which was then returned to the feeding jar. However, spillage of food from the feeding jars was 30 generally negligible. All drug doses are expressed as the free base. Drugs were dissolved in deionised water or suspended in 0.4% cellosize using a sonic bath.
WO 00/71549 PCT/EP00/04279 40 Data analysis Variations in body weight were accounted for by expressing the results as g/kg rat weight (treatment group means + s.e.mean). ED 50 values (the dose of a 5 drug required to reduce food intake to 50% of the control values) were calculated from a logistic sigmoid curve using a dedicated computer program. Statistical comparisons between mean group intakes were made using analysis of variance and Dunnett's test (two-tailed). 10 Especially preferred compounds of Formula la have surprisingly lower affinity for muscarinic receptors compared to the Examples of WO97/02269 and/or have significantly reduced MAOA inhibitory activity compared to compounds exemplified in WO97/02269. For example, Example 1 of WO97/02269 has a muscarinic receptor binding Ki of 130 nM. Muscarinic affinity may cause undesired side-effects, for 15 example dry mouth, blurred vision, sweating, palpitations, constipation and aggravation of narrow angle glaucoma (Blackwell, B. Adverse effects of antidepressant drugs. Part 1 Monoamine oxidase inhibitors and tricyclics. Drugs 21, 202-219, 1981). Obviously it is desirable for compounds to have minimal affinity for muscarinic receptors. 20 Particularly preferred compounds of the present invention have superior activity in acute feeding studies compared to the compounds exemplified in WO 97/02269. 25 The invention is illustrated by the following Examples which are given by way of example only. The final product of each of these Examples was characterised by one or more of the following procedures: high performance liquid chromatography; elemental analysis, nuclear magnetic resonance spectroscopy, mass spectroscopy and infrared spectroscopy. 30 Examples Example 1 35 Triethylamine (75 ml) was added dropwise at < 10 oC to a stirred suspension of 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[ 2 ,1-b]thiazole hydrobromide (50 g; WO 00/71549 PCT/EP00/04279 41 prepared in a manner similar to that described in WO 97/02269) in dichloromethane (400 ml), then the mixture was stirred at ambient temperature for 1 hour. Water (300 ml) was added, then the organic phase was separated, washed with water (2 x 100 ml) and saturated aqueous sodium chloride solution (100 ml), dried (Na 2 SO4), and 5 the solvent removed in vacuo to leave 3-(benzo[b]thiophen-3-yl)-5,6 dihydroimidazo[2,1-b]thiazole as a pale yellow solid (34 g) which was used without further purification. n-Butyllithium (2.5 M solution in hexanes; 17.5 ml) was added dropwise under 10 nitrogen at -70 'C to a stirred solution of 3-(benzo[b]thiophen-3-yl)-5,6-dihydro imidazo[2,1-b]thiazole (10.14 g) in tetrahydrofuran (260 ml), then the mixture was stirred at -70 OC for 20 minutes, allowed to warm to 0 oC, and stirred at 0 OC for 30 minutes. Dimethylformamide (2.86 ml) was added, and the mixture was stirred at ambient temperature for 20 minutes. Saturated aqueous sodium chloride solution 15 (200 ml) and ether (400 ml) were added, then the organic phase was separated, washed with water (100 ml) and saturated aqueous sodium chloride solution (100 ml), dried (Na 2 SO4), and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using a 10:1 mixture of dichloromethane and methanol as eluant. Appropriate fractions were combined and the solvents 20 removed in vacuo. The residue was heated under reflux for 5 minutes with propan 2-ol (100 ml), then the mixture was filtered while hot and allowed to cool to ambient temperature. The resulting solid was collected by filtration and driedin vacuo at 60 oC to give 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[ 2 ,1-b]thiazole-2-carbox aldehyde as a yellow solid (1.4 g), m.p. 206 °C. 25 Example 2 A mixture of 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole-2 30 carboxaldehyde (0.198 g), sodium borohydride (0.026 g) and methanol (20 ml) was stirred at ambient temperature under nitrogen for 1 hour, then water (2 ml) was added and the mixture was concentrated in vacuo to remove methanol. The residue was partitioned between water (30 ml) and ethyl acetate (50 ml), then the organic phase was separated, washed with saturated aqueous sodium chloride solution (20 35 ml), dried (Na 2
SO
4 ), and the solvent was removed in vacuo to leave [3- WO 00/71549 PCT/EP00/04279 42 (benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]methanol as a yellow solid (0.077 g), m.p. 168 - 170 oC. 5 Example 3 A mixture of 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole-2 carboxaldehyde (0.44 g), hydroxylamine hydrochloride (0.118 g) and ethanol (30 ml) was heated under reflux for 2.75 hours, then cooled to ambient temperature. The 10 resulting solid was collected by filtration and suspended in dichloromethane (50 ml). Triethylamine (3 ml) was added, then the resulting solution was washed with water (20 ml) and saturated aqueous sodium chloride solution (20 ml), dried (MgSO4), and the solvent was removed in vacuo to leave 3-(benzo[b]thiophen-3-yl)-5,6-dihydro imidazo[2,1-b]thiazole-2-carboxaldehyde oxime as a white solid (0.07 g), 15 m.p. 226-2280C. Example 4 20 Methylmagnesium bromide (3 M solution in ether; 1.2 ml) was added dropwise at 00C under nitrogen to a stirred solution of 3-(benzo[b]thiophen-3-yl)-5,6 dihydroimidazo[2,1-b]thiazole-2-carboxaldehyde (0.286 g) in tetrahydrofuran (30 ml), then the mixture was stirred at ambient temperature for 15 minutes. Water (5 ml) and ethyl acetate (70 ml) were added, then the organic phase was separated, 25 washed with water (20 ml) and saturated aqueous sodium chloride solution (20 ml), dried (Na 2
SO
4 ), and the solvents were removed in vacuo. The residue was triturated with ether (30 ml) and the resulting solid was collected by filtration and driedin vacuo at 1000C to give 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl] ethanol as an off-white solid (0.213 g), m.p. 174-1760C. 30 Example 5 A suspension of [3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol 2-yl]methanol (0.5 g) in ethanol (25 ml) was heated under reflux until all of the solid 35 had dissolved. Ethereal hydrogen chloride solution (1 M; 2 ml) was added, then the mixture was heated under reflux for 3 minutes and allowed to cool to ambient WO 00/71549 PCT/EP00/04279 43 temperature. The resulting solia was collected by filtration, washed with ether (20 ml) and dried in vacuo at 600C to give 3-(benzo[b]thiophen-3-yl)-5,6-dihydro imidazo[2,1-b]thiazole-2-methanol hydrochloride as a white solid (0.32 g), m.p. 240-2500C (decomposes). Ethereal hydrogen chloride solution (1 M; 2ml) was 5 added to the filtrate remaining from isolation of the above solid, and the mixture was stirred at ambient temperature for 18 hours. The resulting solid was collected by filtration, washed with ether (20 ml) and dried in vacuo at 600C to give a second crop of [3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yl]methanol hydro chloride as a white solid (0.1 g), m.p. 240-2500C (decomposes). 10 Example 6 A mixture of 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole hydrobromide (200 g; prepared in a manner similar to that described in 15 WO 97/02269), saturated aqueous sodium carbonate solution (1000ml) and dichloromethane (2000 ml) was stirred vigorously at ambient temperature for 1.5 hours, then the organic layer was separated, washed with water (500 ml), dried (MgSO 4 ) and the solvent was removed in vacuo. The process was repeated on the same scale, and the two products were combined to give 3-(benzo[b]thiophen-3-yl) 20 5,6-dihydroimidazo[2,1-b]thiazole as a pale yellow solid (264.3 g), which was used without further purification. Bromine (55.5 ml) was added dropwise at 0-5 0C over 1.75 hours to a stirred solution of 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole (264.3 g) in 25 dichloromethane, then the mixture was stirred at 00C for 30 minutes and at ambient temperature for 1 hour. The resulting solid was collected by filtration, washed with dichloromethane (300 ml) and dried in vacuo at 700C to give 3-(benzo[b]thiophen-3 yl)-2-bromo-5,6-dihydroimidazo[2,1-b]thiazole hydrobromide as a pale yellow solid (431 g) which was used without further purification. 30 3-(Benzo[b]thiophen-3-yl)-2-bromo-5,6-dihydroimidazo[2,1-b]thiazole hydro bromide (170 g) was added in portions under nitrogen at 0-80C over 1 hour to a stirred solution of ethylmagnesium chloride [2.0 M solution in ether (620 ml)] in tetrahydrofuran (1700 ml), then the mixture was stirred at 30C for 1.5 hours. 35 Dimethylformamide (136 ml) was added at 3-8 oC over 30 minutes, then the mixture WO 00/71549 PCT/EP00/04279 44 was stirred at ambient temperature for 2 hours, cooled to 80C and quenched by the cautious addition of saturated aqueous ammonium chloride solution (600 ml) and water (350 ml). Ethyl acetate (1500 ml) was added, the mixture was stirred at ambient temperature for 18 hours, and the resulting solid (Fraction 1) was collected 5 by filtration. The organic layer of the filtrate was separated, washed with saturated aqueous sodium chloride solution (500 ml), dried (MgSO 4 ), and the solvents were removed in vacuo. The residue was dissolved in hot propan-2-ol (1000 ml) and the solution was filtered while hot then allowed to stand at ambient temperature for 20 hours. The resulting solid was collected by filtration, washed with propan-2-ol 10 (100 ml) and dried in vacuo at 700C to give 3-(benzo[b]thiophen-3-yl)-5,6-dihydro imidazo[2,1-b]thiazole-2-carboxaldehyde as a yellow solid (19.4 g), m.p. 2060C. A mixture of the solid Fraction 1, dichloromethane (2100 ml), 2 M hydrochloric acid (250 ml) and water (1000 ml) was stirred at ambient temperature for 15 minutes, then triethylamine (80 ml) was added. The dichloromethane layer was separated, 15 and further product was isolated from the aqueous layer by extraction into dichloromethane (500 ml). The combined dichloromethane solutions were dried (MgSO 4 ), and the solvent was removed in vacuo to give further 3-(benzo[b]thiophen 3-yl)-5,6-dihydroimidazo[2,1-b]thiazole-2-carboxaldehyde as a yellow solid (63.0 g), m.p. 2080C. 20 Sodium borohydride (12.5 g) was added in portions over 10 minutes to an ice-cold stirred suspension of 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b] thiazole-2-carboxaldehyde (63 g) in methanol (1200 ml), then the mixture was stirred at 50C for 30 minutes, at ambient temperature for 4 hours, and at reflux temperature 25 for 20 minutes. The mixture was cooled to ambient temperature over 1 hour then water (200 ml) was added and stirring at ambient temperature was continued for 1 hour. The resulting solid was collected by filtration, washed with water (200 ml), ethanol (200 ml) and ether (200 ml), then dried in vacuo at 600C to give [3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]methanol as an off 30 white solid (52.1 g) which was used without purification. A stirred suspension of [3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 b]thiazol-2-yl]methanol (52.1 g) in methanol (2200 ml) was heated under reflux until virtually all of the solid had dissolved. The heat source was removed, and a solution 35 of fumaric acid (21 g) in methanol (250 ml) was added over 1 minute. The mixture WO 00/71549 PCT/EP00/04279 45 was stirred for 10 minutes and allowed to stand at ambient temperature for 1 hour, then it was cooled in ice for 3 hours. The resulting solid was collected by filtration, washed with ice-cold methanol (200 ml), and dried in vacuo at 600C for 3 hours and at 800C for 2 hours to give a white solid which was shown by nmr spectroscopy to be 5 solvated by 1 equivalent of methanol. This solid was combined with a second sample of product (5.2 g; also solvated by methanol) prepared in a manner similar to that described above, and the combined material was ground using a pestle and mortar, then dried in vacuo at 90 0 C and 133Pa for 15 hours to give [3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]methanol fumarate 10 (solvated by 0.05 equivalent of methanol) as a white solid (53.4 g), m.p. 258-262oC (decomposes). Example 7 15 Phenyltrimethylammonium tribromide (3.0 g) was added in portions under nitrogen at 00C to a stirred suspension of 3-(benzo[b]thiophen-3-yl)-5,6-dihydro imidazo[2,1-b]thiazole (2.0 g) in tetrahydrofuran (50 ml), then the mixture was stirred at 00C for 1 hour and at ambient temperature for 18 hours. Water (50 ml) and triethylamine (50 ml) were added, and the organic phase was separated, washed 20 with saturated aqueous sodium chloride solution (50 ml), dried (MgSO 4 ), and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using a 9:1 mixture of ethyl acetate and methanol as eluant. Appropriate fractions were combined and the solvents were removed in vacuo to leave 3-(benzo[b]thiophen-3-yl)-2-bromo-5,6-dihydroimidazo[2,1-b]thiazole as a yellow 25 solid (1.0 g), m.p. 196-2000C. Example 8 Phenyltrimethylammonium tribromide (0.75 g) was added in portions under 30 nitrogen at 00C to a stirred suspension of 3-(benzo[b]thiophen-3-yl)-6,7-dihydro-5H thiazolo[3,2-a]pyrimidine (0.5 g; prepared in a manner similar to that described in WO 97/02269)) in tetrahydrofuran (15 ml), then the mixture was stirred at 00C for 4 hours and allowed to warm to ambient temperature. Water (50 ml) and triethylamine (50 ml) were added, and the organic phase was separated, washed with saturated 35 aqueous sodium chloride solution (50 ml), dried (MgSO 4 ), and the solvents were WO 00/71549 PCTIEP00/04279 46 removed in vacuo. The residue was purified by flash chromatography over silica using a 9:1 mixture of ethyl acetate and methanol as eluant. Appropriate fractions were combined and the solvents were removed in vacuo to leave 3 (benzo[b]thiophen-3-yl)-2-bromo-6,7-dihydro-5H-thiazolo[3,2-a]pyrimidine as a pale 5 yellow solid (0.2 g), m.p. 200-2020C. Example 9 Sodium hydride (60% dispersion in mineral oil; 1.35 g) was added in portions 10 at ambient temperature under nitrogen to a stirred solution of 3-acetyl benzo[b]thiophen (2.9 g) in diethyl carbonate (50 ml), then the mixture was stirred at 800C for 1.5 hours and poured onto a mixture of water (300 ml) and acetic acid (5 ml). The product was extracted into ether (3 x 150 ml), then the combined extracts were washed with water (2 x 50 ml) and saturated aqueous sodium chloride 15 solution (50 ml), dried (MgSO 4 ), and the solvent was removed in vacuo. The residue was purified by flash chromatography over silica in Biotage Flash 40i ® equipment using a 9:1 mixture of hexane and ethyl acetate as eluant. Appropriate fractions were combined and the solvents were removed in vacuo to leave ethyl 3 (benzo[b]thiophen-3-yl)-3-oxopropanoate as a brown oil (1.5 g) which was used 20 without further purification. Phenyltrimethylammonium tribromide (2.15 g) was added in portions at 00C under nitrogen to a stirred solution of ethyl 3-(benzo[b]thiophen-3-yl)-3-oxo propanoate (1.5 g) in tetrahydrofuran (30 ml), then the mixture was stirred at 0oC for 25 30 minutes and at ambient temperature for 1.5 hours. The resulting solid was removed by filtration and washed with tetrahydrofuran (30 ml). The filtrate and washings were combined and the solvent was removed in vacuo. The residue was purified by flash chromatography over silica in Biotage Flash 40i equipment using a 9:1 mixture of petroleum ether (b.p. 60-80 OC) and ethyl acetate as eluant. 30 Appropriate fractions were combined and the solvents were removed in vacuo to leave ethyl 3-(benzo[b]-thiophen-3-yl)-2-bromo-3-oxopropanoate as a brown solid (1.7 g), m.p. 81-830C. A mixture of ethyl 3-(benzo[b]thiophen-3-yl)-2-bromo-3-oxopropanoate 35 (1.7 g), 2-imidazolidinethione (0.53 g) and ethanol (30 ml) was heated under reflux for 10 minutes, then acetic acid (15 ml) was added and the mixture was heated WO 00/71549 PCT/EP00/04279 47 under reflux for 18 hours. The solvents were removed in vacuo and the residue was triturated with ethanol (20 ml). The resulting solid was collected by filtration, washed with ethanol (10 ml) and ether (20 ml), then dried in vacuo at 600C to give ethyl 3 (benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole-2-carboxylate as an off 5 white solid (1.15 g), m.p. 209-2110C. A mixture of ethyl 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b] thiazole-2-carboxylate (0.4 g), triethylamine (2 ml) and dichloromethane (15 ml) was stirred at ambient temperature for 20 minutes, then it was diluted with 10 dichloromethane (40 ml), washed with water (2 x 20 ml) and saturated aqueous sodium chloride solution (20 ml), dried (Na 2
SO
4 ), and the solvents were removedin vacuo. The residue (0.22 g) was dissolved in tetrahydrofuran (7 ml), and methylmagnesium bromide (3 M solution in ether; 0.66 ml) was added under nitrogen. The mixture was stirred at ambient temperature for 2 hours, then further 15 methylmagnesium bromide (3 M solution in ether; 0.42 ml) and toluene (5 ml) were added. The mixture was stirred at ambient temperature for 5 minutes and at 90-950C for 5 hours, then it was cooled to ambient temperature and diluted with water (30 ml). The product was extracted into ethyl acetate (2 x 30 ml), and the combined extracts were washed with water (30 ml) and saturated aqueous sodium 20 chloride solution (30 ml), dried (MgSO 4 ), and the solvents were removed in vacuo. A mixture of the residue, fumaric acid (0.037 g) and ethanol (5 ml) was heated under reflux for 5 minutes, then the hot solution was decanted from a small trace of undissolved solid and allowed to cool to ambient temperature. The resulting solid was collected by filtration, washed with ether (10 ml) and dried in vacuo at 600C to 25 give 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]-1-methyl ethanol fumarate as an off-white solid (0.057 g), m.p. 180-1820C. Example 10 30 Ethylmagnesium chloride (2M solution in ether; 1.4 ml) was added dropwise at ambient temperature to a stirred solution of 3-(benzo[b]thiophen-3-yl)-5,6-dihydro imidazo[2,1-b]-thiazole-2-carboxaldehyde (0.52 g) in tetrahydrofuran (30 ml), then the mixture was stirred at ambient temperature for 30 minutes. Further 35 ethylmagnesium chloride (2M solution in ether; 0.5 ml) was added, the mixture was stirred at ambient temperature for 1 hour, then it was quenched by the addition of WO 00/71549 PCT/EP00/04279 48 water (30 ml). The product was extracted into ether (50 ml) followed by ethyl acetate (2 x 50 ml), then the combined extracts were washed with saturated aqueous sodium chloride solution (2 x 30 ml), dried (Na 2 SO4), and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica in Biotage 5 Flash 40i ® equipment using a 99:1 mixture of dichloromethane and methanol as eluant. Appropriate fractions were combined and the solvents removed in vacuo to leave 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]propan-1l-ol as an orange solid (0.24 g), m.p. 92-94oC. 10 Example 11 Triethylamine (50 ml) was added dropwise at ambient temperature to a stirred suspension of 3-(5-methoxybenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -bj thiazole hydrobromide (1 g; prepared in a manner similar to that described in 15 WO 97/02269) in dichloromethane (25 ml), then the mixture was stirred at ambient temperature for 10 minutes. Water (25 ml) was added, then the organic phase was separated, washed with water (25 ml), dried (Na 2 SO4), and the solvents were removed in vacuo to leave 3-(5-methoxybenzo[b]thiophen-3-yl)-5,6-dihydro imidazo[2,1-b]thiazole as a brown solid (0.65 g) which was used without further 20 purification. Phenyltrimethylammonium tribromide (1.5 g) was added in portions at 0oC under nitrogen to a stirred solution of 3-(5-methoxybenzo[b]thiophen-3-yl)-5,6 dihydroimidazo[2,1-b]thiazole (0.65 g) in tetrahydrofuran (25 ml), the mixture was 25 stirred at 0oC for 16 hours, then it was allowed to warm to ambient temperature. Triethylamine (50 ml) and water (50 ml) were added, then the organic phase was separated, dried (Na 2
SO
4 ), and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using a 99:1:0.1 mixture of ethyl acetate, methanol and triethylamine as eluant. Appropriate fractions were combined 30 and the solvents were removed in vacuo. The residue was crystallised from methanol and the resulting solid was collected by filtration and dried in vacuo at ambient temperature to give 2-bromo-3-(5-methoxybenzo[b]thiophen-3-yl)-5,6 dihydroimidazo[2,1-b]thiazole as an off-white solid (0.05 g), m.p. 210'C (decomposes).
WO 00/71549 PCTIEP00/04279 49 Example 12 Phenyltrimethylammonium tribromide (1.0 g) was added in portions at 0 5 50C under nitrogen over 15 minutes to a stirred solution of 3-(5 chlorobenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole (0.8 g; prepared in a manner similar to that described in WO 97/02269) in tetrahydrofuran (20 ml), then the mixture was stirred at ambient temperature for 18 hours. Water (30 ml) and triethylamine (5 ml) were added, then the product was extracted into 10 dichloromethane (2 x 20 ml), and the combined extracts were washed with water (4 x 20 ml), dried (MgSO 4 ), and the solvents were removed in vacuo to leave 2 bromo-3-(5-chlorobenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazole as a yellow solid (0.72 g), m.p. 205 - 2080C (decomposes). 15 Example 13 A mixture of 3-acetylbenzolb]thiophene (25 g), dimethylamine hydrochloride (15.05 g), paraformaldehyde (5.7 g), concentrated hydrochloric acid (1 ml) and ethanol (75 ml) was heated under reflux for 18 hours then allowed to cool to ambient 20 temperature. The resulting solid was collected by filtration and dried in vacuo at ambient temperature to give 1-(benzo[b]thiophen-3-yl)-3-(dimethylamino)propan-1 one hydrochloride as a pink solid (15.7 g), m.p. 169- 1710C. The solvent was removed in vacuo from the filtrate, and the residue was triturated with ether (100 ml). The resulting solid was collected by filtration and dried in vacuo at ambient 25 temperature to give a second crop of 1-(benzo[b]thiophen-3-yl)-3-(dimethylamino) propan-1-one hydrochloride as a pink solid (13.8 g). A mixture of 1-(benzo[b]thiophen-3-yl)-3-(dimethylamino)propan-1-one hydrochloride (29.4 g) and water (600 ml) was basified to pH 9.0 by the addition of 30 saturated aqueous sodium carbonate solution, the mixture was stirred at ambient temperature for 1 hour, then the free base was extracted into ether (3 x 100 ml). The combined extracts were dried (MgSO 4 ) and the solvent was removedin vacuo. The residue was dissolved in methanol (50 ml), then the solution was cooled in ice, and iodomethane (15.7 ml) was added dropwise. The mixture was stirred at ambient 35 temperature for 1 hour, then the resulting solid was collected by filtration, washed well with ether, and dried in vacuo at ambient temperature to give [3-(benzo[b]- WO 00/71549 PCTIEP00/04279 50 thiophen-3-yl)-3-oxopropyl]trimethylammonium iodide as a pink solid (28.7 g), m.p. 165 - 1671C. A mixture of [3-(benzo[b]thiophen-3-yl)-3-oxopropyl]trimethylammonium 5 iodide (5.0 g), sodium hydrogencarbonate (5.0 g), ether (150 ml) and water (130 ml) was stirred at ambient temperature for 4 hours, then the product was extracted into ether (3 x 150 ml). The combined extracts were dried (MgSO 4 ) and the solvent was removed in vacuo to leave 1-(benzo[b]thiophen-3-yl)propenone as a pink solid (2.1 g) which was used without further purification. 10 A solution of 1-(benzo[b]thiophen-3-yl)propenone (0.75 g) and benzyl alcohol (0.41 ml) in dichloromethane (2 ml) was cooled to 0OC, and concentrated sulphuric acid (2 drops) was added. The mixture was stirred at 00C for 3hours, then allowed to stand at 40C for 18 hours. Further benzyl alcohol (0.82 ml) was added, the 15 mixture was stirred at 00C for 7 hours, then it was diluted with dichloromethane (20 ml), washed with saturated aqueous sodium hydrogencarbonate solution (2 x 10 ml) and water (10 ml), and dried (MgSO 4 ). The solvent was removed in vacuo, and the residue was purified by preparative-scale thin layer chromatography on a silica-coated glass plate using dichloromethane as eluant. Appropriate sections 20 of silica were removed from the developed plate, and the product was extracted by trituration with dichloromethane (30 ml). The extract was filtered, and the solvent removed in vacuo to leave 1-(benzo[b]thiophen-3-yl)-3-benzyloxypropan-1-one as an orange oil (0.49 g) which was used without further purification. 25 Phenyltrimethylammonium tribromide (0.4 g) was added in portions under nitrogen to a stirred solution of 1-(benzo[b]thiophen-3-yl)-3-benzyloxypropan-1-one (0.43 g) in tetrahydrofuran (5 ml), the mixture was stirred at ambient temperature for 18 hours, then it was filtered and the solvent was removed in vacuo to leave 1-(benzo[b]thiophen-3-yl)-3-benzyloxy-2-bromopropan-l-one as a yellow oil (0.56 g) 30 which was used without further purification. A mixture of 1-(benzo[b]thiophen-3-yl)-3-benzyloxy-2-bromopropan-1-one (0.54 g), 2-imidazolidinethione (0.15 g), ethanol (3 ml) and acetic acid (1 ml) was heated under reflux under nitrogen for 18 hours, then the solvents were removed in 35 vacuo. The residue was triturated with ice-cold ethanol (5 ml) and the resulting solid WO 00/71549 PCTIEP00/04279 51 was collected by filtration, washed with ethanol (5 ml), and dried in vacuo at 600C to give 3-(benzo[b]thiophen-3-yl)-2-ethoxymethyl-5,6-dihydroimidazo[2,1 -b]thiazole hydrobromide as a cream solid (0.19 g), m.p. > 2500C. 5 Example 14 Vinylmagnesium chloride (1 M solution in tetrahydrofuran; 6.7 ml) was added dropwise at 00C under nitrogen to a stirred suspension of 3-(benzo[b]thiophen-3-yl) 5,6-dihydroimidazo[2,1-b]thiazole-2-carboxaldehyde (0.64 g) in tetrahydrofuran 10 (30 ml), then the mixture was stirred at 00C for 10 minutes and at ambient temperature for 30 minutes. Water (50 ml) was added, and the mixture was concentrated in vacuo to remove tetrahydrofuran, then the product was extracted into ethyl acetate (3 x 30 ml). The combined extracts were washed with saturated aqueous sodium chloride solution (2 x 25 ml), dried (MgSO 4 ), and the solvents were 15 removed in vacuo. The residue was purified by flash chromatography over silica in Biotage Flash 40i ® equipment using 1 - 5% mixtures of methanol in dichloromethane as eluant. Appropriate fractions were combined and the solvents were removed in vacuo to leave 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 b]thiazol-2-yl]prop-2-en-1-ol as a pale yellow foam (0.12 g), m.p. 60-650C. 20 Example 15 1-Propynylmagnesium bromide (0.5 M solution in ether; 10.5 ml) was added dropwise at 0oC under nitrogen to a stirred suspension of 3-(benzo[b]thiophen-3-yl) 25 5,6-dihydroimidazo[2, 1 -b]thiazole-2-carboxaldehyde (0.5 g) in tetrahydrofuran (30 ml), then the mixture was stirred at 00C for 10 minutes and at ambient temperature for 30 minutes. Water (60 ml) and ethyl acetate (100 ml) were added, then the organic phase was separated, washed with saturated aqueous sodium chloride solution (2 x 25 ml), dried (MgSO4), and the solvents were removed in 30 vacuo. The residue was purified by flash chromatography over silica in Biotage Flash 40i @ equipment using 1 - 5% mixtures of methanol in dichloromethane as eluant. Appropriate fractions were combined and the solvents were removed in vacuo to leave 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yl]but 2-yn-1-ol as a white solid (0.11 g), m.p. 190 - 2000C (decomposes). 35 WO 00/71549 PCT/EP00/04279 52 Example 16 n-Butyllithium (2.5 M solution in hexanes; 4.7 ml) was added dropwise at 0oC under nitrogen to a stirred solution of methyltriphenylphosphonium bromide (4.2 g) in 5 tetrahydrofuran (30 ml), then the mixture was stirred at 0OC for 5 minutes and at ambient temperature for 30 minutes. 3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo [2,1-b]thiazole-2-carboxaldehyde (3.05 g) was added in portions, then the mixture was heated under reflux for 3 hours and allowed to cool to ambient temperature. Ethyl acetate (75 ml) and water (50 ml) were added, then the organic phase was 10 separated, washed with saturated aqueous sodium chloride solution (50 ml), dried (MgSO 4 ), and the solvents were removed in vacuo. The residue was diluted with 2.5 M hydrochloric acid (75 ml), the mixture was stirred at ambient temperature for 3 hours, then it was filtered to remove a gummy semisolid. The filtrate was shaken with ethyl acetate (25 ml), then the organic phase was separated, dried (MgSO 4 ), 15 and the solvent was removed in vacuo to leave slightly impure 3-(benzo[b]thiophen 3-yl)-2-vinyl-5,6-dihydroimidazo[2,1-b]thiazole hydrochloride as a white solid (0.85 g). Further product was isolated by extraction with dichloromethane (2 x 50 ml), drying (MgSO 4 ), and removal of the solvent in vacuo to leave 3 (benzo[b]thiophen-3-yl)-2-vinyl-5,6-dihydroimidazo[2,1-b]thiazole hydrochloride as a 20 white solid (0.49 g), m.p. 221 - 223oC. Example 17 3-(Benzo[b]thiophen-3-yl)-2-bromo-5,6-dihydroimidazo[2,1-b]thiazole hydro 25 bromide (2 g) was added in portions under nitrogen at 0 - 5oC over 10 minutes to a stirred solution of ethylmagnesium chloride (2 M solution in ether; 7.2 ml) in tetrahydrofuran (20 ml), then the mixture was stirred at 0 - 50C for 30 minutes. Allyl bromide (0.87 ml) was added dropwise, the mixture was stirred at ambient temperature for 18 hours, then it was quenched by the addition of saturated aqueous 30 ammonium chloride solution (15 ml) followed by water (10 ml). The product was extracted into ethyl acetate (50 ml), then the extract was washed with water (25 ml) and saturated aqueous sodium chloride solution (25 ml), dried (MgSO 4 ), and the solvent was removed in vacuo. The residue was purified by flash chromatography over silica using 5 - 7% mixtures of methanol in dichloromethane as eluant. 35 Appropriate fractions were combined and the solvents removed in vacuo to give a WO 00/71549 PCT/EP00/04279 53 brown gum (0.36 g). The gum was dissolved in ethanol (2 ml), and a solution of fumaric acid (0.13 g) in ethanol (2 ml) was added. The resulting solid was collected by filtration, washed with ethanol (10 ml) and dried in vacuo at 750C to give 2-allyl-3 (benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole fumarate as an off-white 5 solid (0.22 g), m.p. 163 - 16409C. Example 18 n-Butyllithium (2.5 M solution in hexanes; 1 ml) was added dropwise under 10 nitrogen at -70oC over 10 minutes to a stirred solution of 3-(benzo[b]furan-3-yl)-5,6 dihydroimidazo[2,1-b]thiazole (0.5 g; prepared in a manner similar to that described in WO 97/02269) in tetrahydrofuran (6 ml), then the mixture was stirred at -700C for 30 minutes. Dimethylformamide (0.2 ml) was added, the mixture was stirred at -700C for 5 minutes, then it was allowed to warm to ambient temperature. Saturated 15 aqueous ammonium chloride solution (30 ml) was added, and the product was extracted into dichloromethane (3 x 30 ml). The combined extracts were washed with water (30 ml), dried (Na 2
SO
4 ), and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using a 9:1 mixture of dichloromethane and methanol as eluant. Appropriate fractions were combined, and 20 the solvents were removed in vacuo to leave 3-(benzo[b]furan-3-yl)-5,6 dihydroimidazo[2,1-b]thiazole-2-carboxaldehyde as a brown solid (0.24 g), m.p. 192- 1950C. 3-(Benzo[b]furan-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazole-2-carboxaldehyde 25 (0.17g) was dissolved in methanol (6ml) by gentle warming, then sodium borohydride (0.035 g) was added and the mixture was stirred at ambient temperature for 30 minutes. Water (50 ml) was added, the mixture was stirred at ambient temperature for 1 hour, then the resulting solid was collected by filtration, washed with water (10 ml) and dried in vacuo at 600C to give [3-(benzo[b]furan-3-yl)-5,6 30 dihydroimidazo[2,1-b]thiazol-2-yl]methanol as a white solid (0.08 g), m.p. 184- 1870C.
WO 00/71549 PCTIEP00/04279 54 Example 19 A stirred mixture of 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b] thiazole-2-carboxaldehyde (0.5 g), isopropylamine (1 ml), ethanol (50 ml) and acetic 5 acid (1 drop) was heated under reflux for 4 hours, then the solvent was removedin vacuo. The residue was triturated with ether (30 ml), and the resulting solid was collected by filtration, washed with ether (10 ml) and dried in vacuo at ambient temperature to give N-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2 ylmethylidene]-1-methylethylamine as a pale brown solid (0.38 g), m.p. 180- 1820C. 10 Example 20 Benzyltrimethylammonium chloride (8 g) was added in portions at ambient temperature to a stirred solution of iodine trichloride (10 g) in dichloromethane 15 (120 ml), then the mixture was stirred at ambient temperature for 2.5 hours. The resulting solid was collected by filtration and dried in vacuo at ambient temperature to give benzyltrimethylammonium tetrachloroiodate as a yellow solid (16.2 g) which was used without further purification. 20 Benzyltrimethylammonium tetrachloroiodate (5 g) was added in portions at 0OC over 10 minutes to a stirred solution of 3-(benzo[b]thiophen-3-yl)-5,6-dihydro imidazo[2,1-b]thiazole (3 g) in acetone (125 ml), then the mixture was stirred at 00C for 1 hour. The resulting solid was collected by filtration, triturated with hot propan-2 ol (150 ml) and crystallised from ethanol (150 ml) to give an off-white solid (0.74 g). 25 Concentration of the mother liquor to 75 ml gave a second crop of solid (0.41 g). The two crops of solid were combined, triturated with hot ethanol (40 ml), and the resulting solid was collected by filtration, washed with ethanol (10 ml) and dried in vacuo at 600C to give 3-(benzo[b]thiophen-3-yl)-2-chloro-5,6-dihydroimidazo[2,1 b]thiazole hydrochloride 0.5 hydrate as an off-white solid (0.91 g), m.p. 255- 2570C. 30 Example 21 3-(Benzo[b]thiophen-3-yl)-2-bromo-5,6-dihydroimidazo[2,1-b]thiazole hydro bromide (6 g) was added in portions under nitrogen at 0- 50C over 10 minutes to a 35 stirred solution of ethylmagnesium chloride (2 M solution in ether; 21.6 ml) in tetrahydrofuran (100 ml), then the mixture was stirred at 0- 50C for 1 hour. This WO 00/71549 PCTIEP00/04279 55 mixture was added over 10 minutes at 50 - 700C to a stirred solution of N-methoxy N-methylacetamide (5 g) in tetrahydrofuran (50 ml), then stirring at 700C was continued for a further 2.5 hours. The mixture was cooled in ice, then saturated aqueous ammonium chloride solution (100 ml), water (100 ml) and ethyl acetate 5 (150 ml) were added. The organic layer was separated, washed with a mixture of saturated aqueous sodium chloride solution (100 ml) and water (100 ml), dried (MgSO 4 ), and the solvents were removed in vacuo. The residue was triturated with ether (3 x 50 ml), and the resulting solid was collected by filtration, washed with ether (30 ml) and dried in vacuo to give a yellow solid (1.84 g). A sample (0.25 g) of the 10 solid was crystallised from ethanol (3.5 ml), and the resulting solid was collected by filtration, washed with ethanol (5 ml), and dried in vacuo at 750C to give 2-acetyl-3 (benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole as a yellow solid (0.043 g), m.p. 203- 205oC. 15 Example 22 Sodium hydride (60% dispersion in mineral oil; 0.15 g) was added in portions at ambient temperature over 10 minutes to a stirred suspension of [3-(benzol[b] thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yl]methanol (1 g) in dimethylform 20 amide (20 ml), then the mixture was stirred at ambient temperature for 45 minutes. lodomethane (240 ptl) was added, and stirring at ambient temperature was continued for a further 2 hours. Water (25 ml) and ethyl acetate (50 ml) were added, then the organic phase was separated, washed with water (4 x 25 ml) and saturated aqueous sodium chloride solution (25 ml), dried (MgSO 4 ), and the solvents were removed in 25 vacuo. The residue was purified by flash chromatography over silica using 5- 8% mixtures of methanol in dichloromethane as eluant. Appropriate fractions were combined and the solvents were removed in vacuo. The residue was dissolved in warm ethanol (3 ml), added to a solution of fumaric acid (0.085 g) in warm ethanol (2 ml), and the mixture was allowed to cool to ambient temperature. The resulting 30 solid was collected by filtration, washed with ethanol (3 ml), and dried in vacuo at 750C to give 3-(benzo[b]thiophen-3-yl)-2-(methoxymethyl)-5,6-dihydroimidazo[2,1 b]thiazole fumarate as a white solid (0.23 g), m.p. 175- 1760C.
WO 00/71549 PCTIEP00/04279 56 Example 23 3-(Benzo[b]thiophen-3-yl)-2-bromo-5,6-dihydroimidazo[2,1-b]thiazole hydro bromide (5 g) was added in portions under nitrogen at 0-50C over 30 minutes to a 5 stirred solution of ethylmagnesium chloride [2.0 M solution in ether (15 ml)] in tetrahydrofuran (75 ml), then the mixture was stirred at ambient temperature for 1 hour. The mixture was cooled to 0 oC, dimethyl disulphide (1.8 ml) was added, then the mixture was stirred at ambient temperature for 24 hours, and quenched by the cautious addition of saturated aqueous ammonium chloride solution (50 ml). The 10 product was extracted into ethyl acetate (150 ml), then the extract was washed with water (50 ml) and saturated aqueous sodium chloride solution (50ml), dried (Na 2
SO
4 ), and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica in Biotage Flash 40i ® equipment using a 19:1 mixture of ethyl acetate and methanol as eluant. Appropriate fractions were 15 combined and the solvents were removed in vacuo. The residue was triturated with ether (20 ml) and the resulting solid was collected by filtration and dried in vacuo to leave 3-(benzo[b]thiophen-3-yl)-2-(methylthio)-5,6-dihydroimidazo[2,1-b]thiazole (1.9g) as an off-white solid, m.p. 129 - 131 oC. 20 Example 24 n-Butyllithium (2.5 M solution in hexanes; 1.7 ml) was added under nitrogen to an ice-cold, stirred suspension of methyltriphenylphosphonium bromide (1.5 g) in tetrahydrofuran (25 ml), then the mixture was stirred at ambient temperature for 30 25 minutes. A solution of 2-acetyl-3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 b]thiazole (1.6 g) in tetrahydrofuran (15 ml) was added, the mixture was heated under reflux for 4h, allowed to stand at ambient temperature for 18 hours, then it was quenched by the addition of water (50 ml). The product was extracted into ethyl acetate (50 ml), then the extract was washed with saturated aqueous sodium 30 chloride solution (50 ml), dried (MgSO 4 ), and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using 5- 6% mixtures of methanol in dichloromethane as eluant. Appropriate fractions were combined and the solvents were removed in vacuo to leave 3-(benzo[b]thiophen-3-yl)-2-(1 methylvinyl)-5,6-dihydroimidazo[2,1-b]thiazole (0.14 g) as a brown solid, m.p. 76 oC. 35 WO 00/71549 PCT/EP00/04279 57 Examples 25-33 Examples 25 - 33 were prepared as part of a High Speed Analogue library using the following general method: 5 The appropriate commercially-available Grignard reagent (3 molar equivalents) was added to a solution of 3-(benzo[b]thiophen-3-yl)-5,6 dihydroimidazo[2,1-b]thiazole-2-carboxaldehyde (approximately 50 mg) in tetrahydrofuran (4 ml), the mixture was stirred at ambient temperature for 1 hour, 10 water (1 ml) was added, then the mixture was left exposed to the atmosphere for 18 hours to allow the solvent to evaporate. Dichloromethane (4 ml) was added and the solution was pipetted onto a ChemElute (CE 1103; pH9) cartridge, allowed to stand for 15 minutes, then the product was eluted from the cartridge with dichloromethane (3 x 4 ml). The solvent was removed in vacuo to leave the required product which 15 was analysed by high performance liquid chromatography on a Hypersil BDS C18 column (100 x 4.6mm) using gradient elution with mixtures of acetonitrile and 0.1M ammonium acetate buffer according to the following time schedule: Ammonium Time (minutes) Acetonitrile (%) acetate (%) 0 10 90 8 -9 100 0 11 10 90 20 All of the products of the following Examples gave satisfactory mass spectra: Hplc retention time and % purity are reported for each Example. Example 25 25 1 -[3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]-2-methylpropan 1-ol (Retention time: 3.28 minutes - Purity: 80%).
WO 00/71549 PCT/EP00/04279 58 Example 26 1-[3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]butan-1 -ol (Retention time: 3.29 minutes - Purity: 100%). 5 Example 27 1-[3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yi]-2-methylbut-3-en 1-ol (Retention time: 3.42 minutes - Purity: 100%). 10 Example 28 1-[3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]-3-methylbutan-1 ol (Retention time: 3.61 minutes - Purity: 90%). 15 Example 29 1-[3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]pentan-1 -ol (Retention time: 3.68 minutes - Purity: 100%). 20 Example 30 1-[3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]prop-2-yn-1 -ol (Retention time: 2.71 minutes - Purity: 100%). 25 Example 31 1-[3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]but-3-en-1 -ol (Retention time: 3.12 minutes - Purity: 96%). 30 Example 32 1-[3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]-2-methylprop-2 en-1-ol (Retention time: 3.13 minutes - Purity: 97%). 35 WO 00/71549 PCTIEP00/04279 59 Example 33 1-[3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]pent-4-en-1 -ol (Retention time: 3.44 minutes - Purity: 85%). 5 Example 34 In a manner similar to that described in Example 4, 3-(benzo[b]thiophen-3-yl) 5,6-dihydroimidazo[2,1-b]thiazole-2-carboxaldehyde (prepared via the methodology 10 described in Example 6) was reacted with 2-methoxyphenylmagnesium bromide and the product was recrystallised from a mixture of methanol and propan-2-ol to give [3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yl](2-methoxyphenyl) methanol as a white solid, m.p. 195- 197 oC. 15 Example 35 n-Butyllithium (2.5M solution in hexanes; 73.8 ml) was added dropwise over 45 minutes at 0 - 4 oC under nitrogen to a stirred mixture of methyltriphenylphosphonium bromide (65.7 g) and tetrahydrofuran (680 ml), then the mixture was stirred at 4 0C for 10 minutes and at ambient temperature for 30 20 minutes. 3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazole-2 carboxaldehyde (48 g; prepared in a manner similar to that described in Example 6) was added in portions at ambient temperature, then the mixture was heated under reflux for 3 hours, cooled to ambient temperature, and added to water (500 ml). The product was extracted into ethyl acetate (3 x 400 ml), then the combined extracts 25 were washed with water (400 ml), dried (MgSO 4 ), and the solvents were removedin vacuo. The residue was triturated with ethyl acetate (300 ml) and the resulting solid was collected by filtration and recrystallised from ethyl acetate to give an off-white solid. The liquors from the trituration and recrystallisation were combined and concentrated to give a further crop of solid. This was repeated until no further solid 30 was isolable. All of the crops of solid were combined and repeatedly recrystallised from ethyl acetate until >99% pure (by hplc) to give 3-(benzo[b]thiophen-3-yl)-2-vinyl 5,6-dihydroimidazo[2,1-b]thiazole as an off-white solid (43.5 g). The majority of the solid (41 g) was dissolved in warm methanol (500 ml) and added to a saturated solution of fumaric acid (16.7 g) in methanol, then the solvent was removedin vacuo. 35 The residue was stirred with ether (500 ml) for 3 hours and the resulting solid was WO 00/71549 PCT/EP00/04279 60 collected by filtration and dried in vacuo at ambient temperature for 24 hours to give 3-(benzo[b)thiophen-3-yl)-2-vinyl-5,6-dihydroimidazo[2,1-b]thiazole fumarate (56.8 g) as a white solid, m.p. 161 - 162 0C. 5 Example 36 In a manner similar to that described in Example 35, 3-(benzo[b]thiophen-3 yl)-5,6-dihydroimidazo[2,1-b]thiazole-2-carboxaldehyde was reacted with ethyltriphenylphosphonium bromide and n-butyllithium to give crude product which was purified by flash chromatography over silica using a 19:1 mixture of 10 dichloromethane and methanol as eluant. Appropriate fractions were combined and the solvents removed in vacuo to give a 3.7:1 mixture of E- and Z-3 (benzo[b]thiophen-3-yl)-2-prop-1l-enyl-5,6-dihydroimidazo[2,1-b]thiazole as a yellow solid, m.p. 62 - 68 C. 15 Example 37 In a manner similar to that described in Example 6, 3-(benzo[b]thiophen-3-yl) 6,7-dihydro-5H-thiazolo[3,2-a]pyrimidine (prepared in a manner similar to that described in WO 97/02269) was brominated, then reacted with ethylmagnesium chloride followed by dimethylformamide to give 3-(benzo[b]thiophen-3-yl)-6,7 20 dihydro-5H-thiazolo[3,2-a]pyrimidine-2-carboxaldehyde. This was reduced with sodium borohydride in a manner similar to that described in Example 2 to give [3 (benzo[b]thiophen-3-yl)-6,7-dihydro-5H-thiazolo[3,2-a]pyrimidin-2-yl]methanol as an off-white solid, m.p. 174 - 176 oC. 25 Example 38 A mixture of 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole-2 carboxaldehyde (0.5 g; prepared in a manner similar to that described in Example 6), hydroxylamine hydrochloride (0.16 g) and formic acid (1.3 ml) was heated at 90 - 95 OC for 25 hours, then diluted with ether (50 ml). The resulting solid was collected by 30 filtration, washed with ether (30 ml) and purified by flash chromatography over silica WO 00/71549 PCT/EP00/04279 61 using 95:5 followed by 85:15 mixtures of dichloromethane and methanol as eluants. Appropriate fractions were combined, and the solvents were removed in vacuo to leave 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole-2-carbonitrile 0.3 formate (0.12 g) as a white solid, m.p. 195 - 196 0C. 5 Example 39 A solution of diethyl benzylphosphonate (1.5 ml) in tetrahydrofuran (10 ml) was added dropwise at ambient temperature under nitrogen to a stirred suspension of sodium hydride (60% dispersal in mineral oil; 0.26 g) in tetrahydrofuran (15 ml), 10 then the mixture was stirred at ambient temperature for 20 minutes. 3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole-2-carboxaldehyde (0.83 g; prepared in a manner similar to that described in Example 6) was added in one portion, the mixture was stirred at ambient temperature for 72 hours, then it was quenched by the addition of water (30 ml). The product was extracted into 15 dichloromethane (3 x 30 ml), the combined extracts were dried (MgSO 4 ), and the solvents were removed in vacuo. The residue was triturated with ether (20 ml) and the resulting solid was collected by filtration. The ethereal liquors were concentrated in vacuo and the residue was triturated with ether (10 ml) to give a second crop of solid. The combined solids were dried in vacuo to give 3-(benzo[b]thiophen-3-yl)-2 20 styryl-5,6-dihydroimidazo[2,1-b]thiazole (0.49 g) as a yellow solid, m.p. 153 - 155 OC. Example 40 In a manner similar to that described in Example 6, 3-(5-chloro benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole (prepared by basification of 25 the hydrobromide salt obtained in a manner similar to that described in WO 97/02269) was brominated, then reacted with ethylmagnesium chloride followed by dimethylformamide to give 3-(5-chlorobenzo[b]thiophen-3-yl)-5,6-dihydro imidazo[2,1-b]thiazole-2-carboxaldehyde as a yellow solid, m.p. 258 -260 oC, WO 00/71549 PCT/EP00/04279 62 Example 41 Sodium borohydride (0.06 g) was added to a stirred suspension of 3-(5 chlorobenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazole-2-carboxaldehyde (0.31 g) in ethanol (15 ml), the mixture was stirred at ambient temperature for 4 5 hours, then water (15 ml) was added. The resulting solid was collected by filtration, washed with ether (15 ml) and dried in vacuo at 60 oC to give [3-(5 chlorobenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]methanol (0.14 g) as a white solid, m.p. 204 - 206 oC. 10 Example 42 [3-(5-Chlorobenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl] methanol (0.6 g) was prepared in a manner similar to that described in Examples 40 and 41. However, on this occasion the product was impure. Consequently it was purified by preparative-scale hplc using mixtures of acetonitrile and aqueous 15 triethylammonium formate buffer as eluant. Appropriate fractions were combined and the solvents were removed in vacuo. The residue was triturated with water (2 x 3 ml) and the resulting solid was collected by filtration and dried in vacuo at 60 OC to give [3-(5-chlorobenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl] methanol formate (0.19 g) as an off-white solid, m.p. 171 - 173 OC. 20 Example 43 In a manner similar to that described in Example 23, 3-(benzo[b]thiophen-3 yl)-2-bromo-5,6-dihydroimidazo[2,1-b]thiazole hydrobromide (5 g) was reacted with ethylmagnesium chloride followed by diphenyl disulphide to give 25 3-(benzo[b]thiophen-3-yl)-2-(phenylthio)-5,6-dihydroimidazo[2,1-b]thiazole (0.6 g) as a yellow solid, m.p. 123 - 125 oC.
WO 00/71549 PCT/EP00/04279 63 Example 44 Methylamine (2M solution in tetrahydrofuran; 8.7 ml) and sodium triacetoxyborohydride (0.56 g) were added under nitrogen to a stirred solution of 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazole-2-carboxaldehyde (0.5 5 g; prepared in a manner similar to that described in Example 6) in tetrahydrofuran (20 ml), then the mixture was stirred at ambient temperature for 72 hours. Further methylamine solution (4.3 ml) was added, the mixture was stirred at ambient temperature for 48 hours, then it was quenched by the addition of saturated aqueous sodium hydrogencarbonate solution (50 ml). The product was extracted into ethyl 10 acetate (3 x 30 ml), the combined extracts were washed with water (30 ml) and saturated aqueous sodium chloride solution (30 ml), then they were dried (MgSO 4 ) and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using a 9:1 mixture of dichloromethane and methanol as eluant. Appropriate fractions were combined and the solvents were removed in 15 vacuo to give [3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]-N methylmethylamine (0.19 g) as a waxy solid, m.p. 102 - 104 0C. Example 45 A solution of oxalyl chloride (13 ml) in dichloromethane (20 ml) was added 20 dropwise at -10 - 0 0C under nitrogen to a stirred solution of cyclopropylacetic acid (5 g) and dimethylformamide (2 drops) in dichloromethane (20 ml), then the mixture was stirred at ambient temperature for 24 hours and the solvent was removed in vacuo to leave cyclopropylacetyl chloride as a brown oil which was used without purification. 25 Potassium carbonate (9.2 g) was added in portions at 0 - 5 oC over 10 minutes to a stirred solution of N,O-dimethylhydroxylamine hydrochloride (5.1 g) in the minimum volume of water, then dichloromethane (30 ml) was added. The above cyclopropylacetyl chloride was dissolved in dichloromethane (20 ml) and the solution was added dropwise at -5 - 0 oC to the dimethylhydroxylamine solution. The 30 mixture was stirred at 0 oC for 30 minutes and at ambient temperature for 2 hours, then the product was extracted into dichloromethane (3 x 50 ml). The combined extracts were dried (Na 2
SO
4 ) and the solvent was removed in vacuo to give WO 00/71549 PCT/EP00/04279 64 cyclopropyl-N-methoxy-N-methylacetamide (6.2 g) as a pale brown oil which was used without purification. A few drops of a solution of 3-bromobenzo[b]thiophene (8.7 g) in tetrahydrofuran (35 ml) were added under nitrogen to a mixture of magnesium 5 turnings (1.05 g), 2 crystals of iodine and tetrahydrofuran (5 ml), and the mixture was warmed gently to initiate the reaction. The remainder of the solution was then added at a rate sufficient to maintain gentle relux. When the addition was complete, the mixture was stirred at reflux temperature for 1.5 hours then allowed to cool to ambient temperature. A solution of cyclopropyl-N-methoxy-N-methylacetamide (6 g) 10 in tetrahydrofuran (35 ml) was added at ambient temperature, the mixture was stirred at reflux temperature for 5 hours, and allowed to stand at ambient temperature for 18 hours, then it was quenched by the addition of 2M hydrochloric acid (50 ml) and stirred at ambient temperature for 1 hour. The product was extracted into ethyl acetate (2 x 100 ml), the combined extracts were washed with water (2 x 30 ml) and 15 saturated aqueous sodium chloride solution (2 x 30 ml), then they were dried (MgSO 4 ) and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using a 1:3 mixture of dichloromethane and petroleum ether (b.p. 60 - 80 oC) as eluant. Appropriate fractions were combined and the solvents were removed in vacuo to give 1-(benzo[b]thiophen-3-yl)-2-cyclopropyl 20 ethan-1-one (4.15 g) as an orange oil which was used without further purification. Phenyltrimethylammonium tribromide (1.74 g) was added under nitrogen to a stirred solution of 1-(benzo[b]thiophen-3-yl)-2-cyclopropylethan-1-one (1 g) in tetrahydrofuran (15 ml), the mixture was stirred at ambient temperature for 18 hours, then it was filtered and the solvent was removed in vacuo. The residue was 25 dissolved in ethanol (12 ml), 2-imidazolidinethione (0.47 g) and acetic acid (4 ml) were added, the mixture was heated under reflux under nitrogen for 18 hours, then the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using a 1:3 mixture of dichloromethane and ether as eluant. Appropriate fractions were combined and the solvents were removed in 30 vacuo to leave 3-(benzo[b]thiophen-3-yl)-2-cyclopropyl-5,6-dihydroimidazo[2,1-b] thiazole hydrobromide (0.72 g) as an off-white solid, m.p. 181 - 183 OC.
WO 00/71549 PCT/EP00/04279 65 Example 46 A solution of iodine monochloride (1.83 g) in dichloromethane (5 ml) was added dropwise at ambient temperature to a stirred solution of 3-(benzo[b]thiophen 3-yl)-5,6-dihydroimidazo[2,1-b]thiazole (3.8 g; prepared in a manner similar to that 5 described in Example 6) in dichloromethane (200 ml) and the mixture was stirred at ambient temperature for 15 minutes. The resulting solid was colected by filtration, washed with dichloromethane (50 ml) and dried in air to give 3-(benzo[b]thiophen-3 yl)-2-iodo-5,6-dihydroimidazo[2,1-b]thiazole hydrochloride (1.3 g) as a pale yellow solid, m.p. 194.7 - 195.2 OC. 10 Example 47 A solution of dimethyl 2-oxopropylphosphonate (1.28 g) in tetrahydrofuran (10 ml) was added dropwise at ambient temperature under nitrogen to a stirred suspension of sodium hydride (60% dispersion in mineral oil; 0.46 g) in 15 tetrahydrofuran (15 ml), then the mixture was stirred at ambient temperature for 20 minutes. 3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazole-2-carbox aldehyde (2 g; prepared in a manner similar to that described in Example 6) was added in portions, the mixture was stirred at ambient temperature for 18 hours and at reflux temperature for 7 hours, then it was allowed to stand at ambient temperature 20 for 18 hours. The solvent was removed in vacuo, the residue was diluted with water (200 ml), and the product was extracted into dichloromethane (200 ml). The extract was dried (Na 2
SO
4 ), the solvent was removed in vacuo, then the residue was purified by flash chromatography over silica using a 19:1 mixture of dichloromethane and methanol as eluant. Appropriate fractions were combined and the solvents were 25 removed in vacuo to give 4-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 b]thiazol-2-yl]but-3-ene-2-one (1.15 g) as a yellow solid, m.p. 164 - 166 OC. Sodium borohydride (36 mg) was added to a stirred solution of 4-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]but-3-ene-2-one (0.28 g) in ethanol (10 ml), the mixture was stirred at ambient temperature for 3 30 hours, then the solvent was removed in vacuo. The residue was diluted with water (100 ml) and the product was extracted into dichloromethane (100 ml), then the extract was dried (Na 2
SO
4 ) and the solvent was removed in vacuo. The residue was triturated with ether (20 ml) and the resulting solid was collected by filtration and WO 00/71549 PCTIEP00/04279 66 dried in vacuo to give 4-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol 2-yl]but-3-en-2-ol (0.16 g) as an off-white solid, m.p. 161 - 162 oC. Example 48 5 In a manner similar to that described in Example 17, 3-(benzo[b]thiophen-3 yl)-2-bromo-5,6-dihydroimidazo[2,1-b]thiazole hydrobromide was reacted with ethylmagnesium chloride followed by 3-bromo-2-methylpropene and fumaric acid to give 3-(benzo[b]thiophen-3-yl )-2-(2-methylprop-2-enyl)-5,6-dihydroimidazo[2,1-b] thiazole fumarate as an off-white solid, m.p. 54 - 64 OC. 10 Example 49 A solution of tetraethyl (dimethylamino)methylenediphosphonate (2.32 g) in 1,4-dioxane (5 ml) was added dropwise at ambient temperature under nitrogen to a stirred suspension of sodium hydride (60% dispersion in mineral oil; 0.28 g) in 1,4 15 dioxane (5 ml), and the mixture was stirred at ambient temperature until the evolution of hydrogen ceased. 3-(Benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole-2 carboxaldehyde (2 g; prepared in a manner similar to that described in Example 6) was added, the mixture was stirred at 60 0C for 1.3 hours and at ambient temperature for 18 hours, then it was poured into water (50 ml). The product was 20 extracted into ethyl acetate (3 x 30 ml), the combined extracts were dried (MgSO 4 ), and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using a 93:7 mixture of dichloromethane and methanol as eluant. Appropriate fractions were combined and the solvents were removed in vacuo to give diethyl 2-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2 25 yl]-1-(dimethylamino)ethenylphosphonate (1.78 g) as a red oil which was used without further purification. A mixture of 2-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2 yl]-1-(dimethylamino)ethenylphosphonate (1.7 g) and concentrated hydrochloric acid (12 ml) was heated under reflux for 1 hour then cooled in ice. The product was 30 extracted into dichloromethane (3 x 30 ml), the combined extracts were dried (MgSO 4 ) and the solvent was removed in vacuo. The residue was dissolved in water WO 00/71549 PCT/EP00/04279 67 (30 ml), the solution was neutralised by the addition of an excess of saturated aqueous sodium hydrogencarbonate solution, and the product was extracted into dichloromethane (3 x 30 ml). The combined extracts were dried (MgSO 4 ) and the solvent was removed in vacuo. The residue was dissolved in ethanol (2 ml), oxalic 5 acid (15 mg) was added, and the solvent was removed in vacuo. The residue was triturated with ether (10 ml) and the resulting solid was collected by filtration and dried in vacuo to give ethyl [3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 b]thiazol-2-yl]acetate oxalate (40 mg) as an off-white solid, m.p.102 - 104 OC. 10 Example 50 sec-Butyllithium (1.25M solution in a 92:8 mixture of cyclohexane and hexane; 100 ml) was added dropwise at -70 0C under nitrogen to a stirred solution of 4-fluorophenyl methyl sulphide (22.0 g) in tetrahydrofuran, then the mixture was stirred at -70 oC for 65 minutes. Dimethylformamide (13.2 ml) was added dropwise 15 at -68 OC to -70 OC, the stirred mixture was allowed to warm to ambient temperature slowly over 20 hours, then it was added to a solution of acetic acid (10 ml) in water (500 ml). The product was extracted into ether (3 x 150 ml), then the combined extracts were washed with 2M hydrochloric acid (200 ml) and saturated aqueous sodium chloride solution (200 ml), dried (Na 2 SO4), and the solvents were removedin 20 vacuo. The residue (25 g), which was used without further purification, was estimated to consist predominantly of a 2:3 mixture of 4-fluorophenyl methyl sulphide and 2-fluoro-5-(methylthio)benzaldehyde respectively by nuclear magnetic resonance spectroscopy. 25 A stirred mixture of methyl thioglycolate (8.9 ml), crude 2-fluoro-5 (methylthio)benzaldehyde (25 g), dimethyl acetamide (250 ml) and N,N-diisopropyl ethylamine (42 ml) was heated at 140 - 150 oC under nitrogen for 3.5 hours, then the solvent was removed in vacuo. Water (650 ml) was added to the residue, then the product was extracted into dichloromethane (3 x 150 ml). The combined extracts 30 were washed with water (3 x 150 ml), dried (Na 2 SO4), and the solvent removedin vacuo. The residue was purified by trituration with ether (250 ml), then the resulting solid was collected by filtration, washed with ether (2 x 50 ml), and driedin vacuo to give methyl 5-(methylthio)benzo[b]thiophene-2-carboxylate (13.3 g) as a pale yellow solid, m.p. 89.7 - 90.4 °C.
WO 00/71549 PCTIEP00/04279 68 Sodium hydroxide (8 g) was dissolved in water (100 ml) then the solution was added to a stirred solution of methyl 5-(methylthio)benzo[b]thiophene-2-carboxylate (23.8 g; prepared in a manner similar to that described above) in methanol (300 ml). 5 The mixture was heated under reflux for 10 minutes then allowedto stand at ambient temperature for 3 days. The suspension was concentrated to a total volume of approximately 250 ml by heating, then water (100 ml) was added and the mixture hot filtered to remove insoluble material. A solution of concentrated hydrochloric acid (40 ml) in water (20 ml) was added to the filtrate and the resulting solid was collected 10 by filtration and washed with water, then dried in vacuo at 80 oC to give 5-(methylthio)benzo[b]thiophene-2-carboxylic acid (21 g) as a pale yellow solid, m.p. 186 - 186.5 oC. A mixture of copper powder (5.3 g), 5-(methylthio)benzo[b]thiophene-2 15 carboxylic acid (20 g) and quinoline (100 ml) was stirred and heated under reflux under nitrogen for 30 minutes, then hot filtered. The filtrate was added to a mixture of concentrated hydrochloric acid (100 ml), ice (500 g) and ether (200 ml), then the resulting solid was collected by filtration and washed with ether (200 ml). The aqueous phase was separated and further product extracted from it into ether (2 x 20 150 ml). The combined ethereal solutions were washed with 2M hydrochloric acid (200 ml) and water (200 ml), dried (Na 2 SO4), and the solvent removed in vacuo to give 5-(methylthio)benzo[b]thiophene (14.7 g) as a light brown solid which was used without further purification. 25 A solution of 5-(methylthio)benzo[b]thiophene (14.7 g) in dichloromethane (180 ml) was added at <0 oC under nitrogen to a stirred mixture of aluminium bromide (26.2 g), bromoacetyl bromide (7.12 ml) and dichloromethane (120 ml), the resulting dark red-brown solution was stirred at <0 oC for 30 minutes and at ambient temperature for 20 hours, then it was added to a mixture of ice (600 g) and 30 concentrated hydrochloric acid (50 ml). Dichloromethane (300 ml) was added and insoluble materials were removed by filtration (Celite ®). The aqueous phase was separated and further product extracted from it into dichloromethane (300 ml), then the combined dichloromethane solutions were dried (MgSO 4 ), and the solvent was removed in vacuo. The residue was dissolved in a mixture of acetic acid (200 ml) 35 and dichloromethane (200 ml), a solution of 2-imidazolidinethione (5.29 g) in acetic acid (200 ml) was added, then the dichloromethane was removed by distillation. The WO 00/71549 PCT/EP00/04279 69 remaining mixture was heated under reflux for two hours, then the total volume was reduced to approximately 200 ml by heating in vacuo. The hot solution was removed from insoluble material by decantation, then allowed to cool. Further solid precipitated and was removed as before, then the solvents were removed in vacuo 5 at 50 OC. The residue was mixed with water (300 ml) and 5M aqueous sodium hydroxide solution (300 ml) then the product was extracted into dichloromethane (300 ml). The extract was dried (Na 2 SO4), and the solvent was removed in vacuo. The residue was partially purified by flash chromatography over silica using ethyl acetate then an 8:1:1 mixture of ethyl acetate, methanol and triethylamine as 10 eluants. Appropriate fractions were combined and the solvents removedin vacuo to leave 3-[5-(methylthio)benzo[b]thiophen-3-yl]-5,6-dihydroimidazo[2,1-b]thiazole as a yellow-brown gum (3.6 g), which was used without further purification. A solution of bromine (1.87 g) in dichloromethane (10 ml) was added 15 dropwise at 15 - 20 oC to a stirred solution of 3-[5-(methylthio)benzo[b]thiophen-3 yl]-5,6-dihydroimidazo[2,1-b]thiazole (3.55 g) in dichloromethane (80 ml), the mixture was stirred at ambient temperature for 10 minutes, then the dichloromethane solution was separated by decantation from insoluble materials and concentrated in vacuo. The residue was triturated with dichloromethane (10 ml) and the resulting 20 solid was collected by filtration and dried in vacuo to give 2-bromo-3-[5-(methylthio) benzo[b]thiophen-3-yl]-5,6-dihydroimidazo[2,1-b]thiazole hydrobromide (2.97 g) as a yellow-brown solid, m.p. 260 - 265 0C. Example 51 25 Ethylmagnesium chloride (2.8M solution in tetrahydrofuran; 8.76 ml) was added at -10 oC under nitrogen to a stirred suspension of 2-bromo-3-[5-(methylthio) benzo[b]thiophen-3-yl]-5,6-dihydroimidazo[2,1-b]thiazole hydrobromide (2.9 g) in tetrahydrofuran (40 ml), then the mixture was stirred at ambient temperature for 90 30 minutes and cooled to -5 0C. Dimethylformamide (5 ml) was added, the resulting suspension was stirred for 2 hours at ambient temperature, then ethyl acetate (200 ml) and saturated aqueous ammonium chloride solution (200 ml) were added. The ethyl acetate layer was separated, dried (Na 2 SO4), and the solvents removed in vacuo to give 3-[5-(methylthio)benzo[b]thiophen-3-yl]-5,6-dihydroimidazo[2,1-b] 35 thiazole-2-carboxaldehyde (1.4 g) as a solid, m.p. 157-158.5 oC, which was used without further purification.
WO 00/71549 PCT/EP00/04279 70 Sodium borohydride (0.114 g) was added to a stirred solution of 3-[5-(methylthio)benzo[b]thiophen-3-yl]-5,6-dihydroimidazo[2,1 -b]thiazole-2-carbox aldehyde (0.664 g) in ethanol (40 ml), then the mixture was stirred at ambient 5 temperature for 24 hours and quenched by the addition of 5M hydrochloric acid (10 ml). The mixture was basified by the addition of an excess of 1M aqueous sodium hydroxide solution and concentrated in vacuo to remove ethanol, then the product was extracted into dichloromethane (3 x 30 ml). The combined extracts were dried (MgSO 4 ), the solvent was removed in vacuo, and the residue was purified by Biotage 10 flash chromatography over silica using a 34:3:3 mixture of ethyl acetate, industrial methylated spirit and triethylamine as eluant. Appropriate fractions were combined and the solvents were removed in vacuo, then the residue was triturated with ether (10 ml). The resulting solid was collected by filtration and dried in air to give {3-[5-(methylthio)benzo[b]thiophen-3-yl]-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yl} 15 methanol (0.13 g) as a beige solid, m.p. 164 - 167 oC. Example 52 In a manner similar to that described in Example 22, [3-(benzo[b]thiophen-3 20 yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]methanol (0.5 g) was reacted with sodium hydride and bromomethylcyclopropane followed by fumaric acid. In this case the salt formation was carried out in methanol solution and no solid product precipitated. Consequently, the solvent was removed in vacuo and the residue was triturated with ether (10 ml). The resulting solid was collected by filtration and dried in vacuo to 25 give 3-(benzo[b]thiophen-3-yl)-2-cyclopropylmethoxymethyl-5,6-dihydroimidazo [2,1-b]thiazole fumarate (40 mg) as a pale brown solid, m.p. 82 - 98 oC. Example 53 30 Sodium hydride (60% dispersion in mineral oil; 0.153 g) was added in portions at ambient temperature over 10 minutes to a stirred suspension of [3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]methanol (1 g) in dimethylformamide (50 ml), then the mixture was stirred at ambient temperature for 2 hours. 1-Chloroprop-2-yne (276 p1) was added, and stirring at ambient temperature 35 was continued for a further 2 hours. Further 1-chloroprop-2-yne (27 p1) was added and the mixture was stirred at ambient temperature for 18 hours. Water (50 ml) was WO 00/71549 PCT/EP00/04279 71 added, the product was extracted into ethyl acetate (3 x 50 ml), then the combined extracts were washed with water (4 x 25 ml) and saturated aqueous sodium chloride solution (25 ml), dried (MgSO 4 ), and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using 5 - 8% mixtures of 5 methanol in dichloromethane as eluant. Appropriate fractions were combined and the solvents were removed in vacuo. The residue was dissolved in methanol (15 ml), fumaric acid (0.185 g) was added, the mixture was stirred at ambient temperature for 5 hours, then it was warmed to dissolve the product and filtered to remove a small amount of insoluble material. The solvent was removed in vacuo to 10 give 3-(benzo[b]thiophen-3-yl)-2-prop-2-ynyloxymethyl-5,6-dihydroimidazo[2, 1 -b] thiazole fumarate (0.67 g) as a brown solid, m.p. 120 oC (softens 80 - 90 oC). Example 54 15 A solution of potassium hydroxide (4.87 g) in a mixture of ethanol (140 ml) and water (35 ml) was added in one portion at ambient temperature under nitrogen to a stirred solution of 2-methoxybenzenethiol (10.6 ml) in a mixture of ethanol (125 ml) and water (7.5 ml), then the mixture was stirred at ambient temperature for 3.5 hours. A solution of 1-chloro-4-phenoxybut-2-yne (15.7 g) in a mixture of ethanol 20 (125 ml) and water (7.5 ml) was added dropwise over 1.5 hours, then the mixture was stirred at ambient temperature for 18 hours, and the solvents were removedin vacuo. The residue was diluted with water (75 ml), the product was extracted into ethyl acetate (2 x 115 ml), then the combined extracts were washed with water (50 ml) and saturated aqueous sodium chloride solution (50 ml), dried (MgSO 4 ), and the 25 solvent was removed in vacuo to leave 1-(2-methoxyphenylthio)-4-phenoxybut-2-yne (24.7 g) as a yellow oil which was used without further purification. A solution of 3-chloroperoxybenzoic acid (70% purity; 9.1 g) in chloroform (210 ml) was added dropwise at 0 - 5 oC over 1.5 hours to a stirred solution of 30 1-(2-methoxyphenylthio)-4-phenoxybut-2-yne (10.5 g) in chloroform (95 ml), the mixture was stirred at ambient temperature for 18 hours, then it was washed with 5% aqueous sodium carbonate solution (3 x 120 ml) and water (3 x 80 ml) and dried (MgSO 4 ). The chloroform solution was stirred and heated under reflux for 7 hours and allowed to stand at ambient temperature for 18 hours, then it was washed with 35 5M aqueous sodium hydroxide solution (115 ml), water (4 x 110 ml) and saturated aqueous sodium chloride solution (100 ml) and dried (MgSO 4 ). The solvent was WO 00/71549 PCT/EP00/04279 72 removed in vacuo to leave 1-(7-methoxy-2,3-dihydrobenzo[b]thiophen-3-yl)-2 phenoxyethan-1-one (10.7 g) as a brown gum which was used without further purification. 5 A mixture of 1-(7-methoxy-2,3-dihydrobenzo[b]thiophen-3-yl)-2-phenoxy ethan-1 -one (10.7 g), acetic acid (100 ml) and concentrated sulphuric acid (12 drops) was heated at 90 - 95 OC for 3 hours then cooled to ambient temperature and poured onto water (800 ml). The product was extracted into dichloromethane (2 x 250 ml), the combined extracts were washed with 2M aqueous sodium hydroxide 10 solution (2 x 200 ml) and water (3 x 200 ml), then they were dried (MgSO 4 ) and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using a 1:1 mixture of dichloromethane and petroleum ether (b.p. 60 - 80 oC) as eluant. Appropriate fractions were combined and the solvents were removed in vacuo to give 1-(7-methoxybenzo[b]thiophen-3-yl)ethan-1-one (2 g) as a brown oil 15 which was used without further purification. Phenyltrimethylammonium tribromide (2.55 g) was added in portions at ambient temperature under nitrogen over 20 minutes to a stirred solution of 1-(7-methoxybenzo[b]thiophen-3-yl)ethan-1-one (1.4 g) in tetrahydrofuran (40 ml), 20 the mixture was stirred at ambient temperature for 1 hour, then it was filtered and the solvent was removed in vacuo. The residue was dissolved in ethanol (30 ml), 2-imidazolidinethione (0.69 g) and acetic acid (20 ml) were added, the mixture was heated under reflux for 18 hours, then it was cooled to ambient temperature. The resulting solid was collected by filtration, washed with ether (20 ml) and dried in 25 vacuo at 60 0C to give 3-(7-methoxybenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 b]thiazole hydrobromide (1.48 g) as a grey solid, m.p. 277 - 279 oC. 3-(7-Methoxybenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazole hydrobromide (1.48 g) was basified by the addition of 2M aqueous sodium hydroxide 30 solution (110 ml) and the free base was extracted into dichloromethane (150 ml). The extract was washed with water (2 x 70 ml), dried (MgSO 4 ), and the solvent was removed in vacuo. The residue was dissolved in dichloromethane (23 ml), then the stirred solution was cooled to 0 - 50C and a solution of bromine (0.68 g) in dichloromethane (4.7 ml) was added dropwise over 45 minutes. The mixture was 35 stirred at 0 -5 oC for 30 minutes and allowed to stand at ambient temperature for 18 WO 00/71549 PCT/EP00/04279 73 hours, then the resulting solid was collected by filtration, washed with dichloromethane (20 ml) and dried in vacuo to give 2-bromo-3-(7-methoxy benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazole hydrobromide (1.22g) as a white solid, m.p. 240 - 242 OC. 5 Example 55 Sodium hydride (60% dispersion in mineral oil; 0.38 g) was added in portions at ambient temperature over 10 minutes to a stirred suspension of [3-(benzo[b] 10 thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]methanol (2.5 g) in dimethyl formamide (50 ml), then the mixture was stirred at ambient temperature for 2 hours. 2-Bromopropane (0.9 ml) was added and stirring at ambient temperature was continued for 2 hours. Further 2-bromopropane (0.4 ml) was added and the mixture was stirred at ambient temperature for 72 hours. Sodium hydride (60% dispersion in 15 mineral oil; 0.07 g) was added, the mixture was stirred for 10 minutes, then 2-bromopropane (0.16 ml) was added and the mixture was stirred at ambient temperature for 18 hours. Water (100 ml) was added, the product was extracted into ethyl acetate (100 + 2 x 75 ml), then the combined extracts were washed with water (3 x 100 ml) and saturated aqueous sodium chloride solution (100 ml), dried 20 (MgSO 4 ), and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using a 1:19 mixture of methanol and dichloromethane as eluant. Appropriate fractions were combined and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using a 9:1 mixture of ethyl acetate and methanol as eluant. Appropriate 25 fractions were combined and the solvents were removed in vacuo to give 3-(benzo[b]thiophen-3-yl)-2-isopropoxymethyl-5,6-dihydroimidazo[2,1 -b]thiazole (0.12 g) as a yellow solid, m.p. 64 - 66 oC. Example 56 30 Sodium hydride (60% dispersion in mineral oil; 0.46 g) was added in portions at ambient temperature over 10 minutes to a stirred suspension of [3-(benzo[b] thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]methanol (3 g) in dimethyl formamide (80 ml), then the mixture was stirred at ambient temperature for 2 hours. 35 Bromomethylcyclobutane (1.7 g) was added dropwise and the mixture was stirred at ambient temperature for 2.5 hours. Further bromomethylcyclobutane (0.16 g) was WO 00/71549 PCT/EP00/04279 74 added dropwise and the mixture was stirred at ambient temperature for 1 hour. Further bromomethylcyclobutane (0.16 g) was added dropwise and the mixture was stirred at ambient temperature for 18 hours. Tic showed starting material still remained, so bromomethylcyclobutane (0.32 g) was added and the mixture was 5 stirred at ambient temperature for 2 hours and at 550C for 1 hour. Further sodium hydride (0.042 g) and bromomethylcyclobutane (0.8 g) were added and the mixture was stirred at 55 oC for 1 hour and at ambient temperature for 18 hours. Water (100 ml) was added, the product was extracted into ethyl acetate (100 + 3 x 75 ml), then the combined extracts were washed with water (4 x 75 ml) and saturated 10 aqueous sodium chloride solution (75 ml), dried (MgSO 4 ), and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using a 1:19 mixture of methanol and dichloromethane as eluant. Appropriate fractions were combined and the solvents were removed in vacuo. The residue was purified by flash chromatography over silica using a 3:1 mixture of petroleum ether 15 (b.p. 60 - 80 oC) and ethyl acetate followed by a 19:1 mixture of dichloromethane and methanol as eluants. Appropriate fractions were combined and the solvents were removed in vacuo. A sample (30 mg from 70mg) of the residue was further purified by preparative scale hplc on a C8 symmetry shield column using a 2:3 mixture of acetonitrile and triethylammonium formate buffer as eluant. Appropriate 20 fractions were combined and the solvents removed in vacuo to give 3-(benzo[b]thiophen-3-yl)-2-cyclobutylmethoxymethyl-5,6-dihydroimidazo[2,1 -b] thiazole (12 mg) as a brown gum, 1H-nmr (DMSO-d 6 ): 6 H 1.61 - 1.84 (6H, m, 3 x cyclobutane CH 2 ), 2.36 - 2.41 (1H, m, cyclobutane CH), 3.22 (2H, d, CH20), 3.49 3.61 (2H, m, CH 2 N), 3.98 - 4.05 (2H, m, CH 2 0), 4.11 -4.15 (2H, m, CH 2 N), 7.45 25 7.49 (2H, m, 2 x ArH), 7.77 - 7.81 (1H, m, ArH), 8.01 (1H, s, ArH), 8.08 - 8.11 (1H, m, ArH). Example A 30 The use of compounds of the present invention in the manufacture of pharmaceutical compositions is illustrated by the following description. In this description the term "active compound" denotes any compound of the invention but particularly any compound which is the final product of one of the preceding Examples. 35 WO 00/71549 PCT/EP00/04279 75 a) Capsules In the preparation of capsules, 10 parts by weight of active compound and 240 parts by weight of lactose are de-aggregated and blended. The mixture is filled 5 into hard gelatin capsules, each capsule containing a unit dose or part of a unit dose of active compound. b) Tablets 10 Tablets are prepared from the following ingredients. Parts by weight Active compound 10 Lactose 190 Maize starch 22 15 Polyvinylpyrrolidone 10 Magnesium stearate 3 The active compound, the lactose and some of the starch are de-aggregated, blended and the resulting mixture is granulated with a solution of the polyvinyl 20 pyrrolidone in ethanol. The dry granulate is blended with the magnesium stearate and the rest of the starch. The mixture is then compressed in a tabletting machine to give tablets each containing a unit dose or a part of a unit dose of active compound. c) Enteric coated tablets 25 Tablets are prepared by the method described in (b) above. The tablets are enteric coated in a conventional manner using a solution of 20% cellulose acetate phthalate and 3% diethyl phthalate in ethanol:dichloromethane (1:1). 30 d) Suppositories In the preparation of suppositories, 100 parts by weight of active compound is incorporated in 1300 parts by weight of triglyceride suppository base and the mixture formed into suppositories each containing a therapeutically effective amount of 35 active ingredient.
Claims (2)
- 3-(benzo~b]thiophen-3-yI)-5,6-dihydroimidazo[2, 1 -bjthiazole-2-carboxaldehyde; 5 [3-(benzo[bjthiophen-3-y)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yI] methanol; 3-(benzo[blthiophen-3-yl)-5, 6-dihydroimidazo[2, 1 -b]thiazole-2-carboxaldehyde oxime; 10 1 -[3-(benzo[b]thiophen-3-y)-5,6-dihydroiidazo[2, 1 -b]thiazol-2-yl]ethanol; 3-(benzo~b]thiophen-3-y)-2-bromo-5,6-dihydroimidazo[2, 1 -bithiazole; 15 3-(benzo[b]thiophen-3-yl-2-bromo-6,7-dihydro-5H-thiazoo[3,2-a]pyrimidile; 1 -[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yJ-1 -methylethanol; 1 -[3-(benzo[b]thiophen-3-yi)-5, 6-dihydroimidazo[2, 1 -b]thiazol-2-yI]propan-1 -o1; 20 2-bromo-3-(5-methoxybenzo[b~thiophen-3-y)-5,6-dihydrimfidaz0[2, 1 -b]thiazole; 2-bromo-3-(5-chlorobenzo[b]thiophel-3-y)-5,6-dihydroimidazo[2, 1 -blthiazole; 25 3-(benzo[b]thiophen-3-y)-2-ethoxymethyl-5,6-dihydroimidazo[2, 1 -b]thiazole; 1 -[3-(benzo[b]thiophen-3-yi)-5,6-dihydroimidaz0[2, 1 -b]thiazol-2-yI]prop-2-en-1 -ol; 1 -[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yl]but-2-yn-1 -ol; 30 3-(benzo[b]thiophen-3-yl)-2-vinyl-5,6-dihydroimidazo[2, 1 -b]thiazole; 2-allyl-3-(benzo[b]thiophen-3-y)-5,6-dihydroimidazo[2, 1 -b]thiazole; 35 [3-(benzo[b]furan-3-yl)-5, 6-dihydroimidazo[2, 1 -b]thiazol-2-yl]methanol; N-[3-(benzo[blthiophen-3-y)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-ylmethylidene]-1 methylethylamine; 40 3-(benzo[b]thiophen-3-y)-2-chloro-5,6-dihydroimidazo[2, 1 -b]thiazole; 2-acetyl-3-(benzo[b]thiophen-3-y)-5,6-dihydroimidazo[2, 1 -b~th jazole; 3-(benzo[blthiophen-3-yi)-2-(methoxymethyl)-5,6-dihydroimidazo[2, 1 -b]thiazole; 45 3-(benzobthiophen-3-yl)-2-(methylthio)-5,6-dihydroilidazo[2, 1 -b]thiazoie; 3-(benzolblthiophen-3-yl)-2-(1 -methylvinyl)-5,6-dihydroimidazo[2, 1 -b]thiazole; 50 1 -[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -bjthiazol-2-yI]-2-methylpropan-1 ol ; 1 -[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1-b]thiazol-2-yl]butan-1 -ol WO 00/71549 PCT/EPOO/04279 82 1 -[3-(benzo[b]thiophen-3-y)-5,6-dihydriidazo[2, 1 -b~t h iazo 1-2-yl]-2-m ethyl but-3-e n 1-ol ; 5 1 -3(benzo[b]thiophen-3-yD)-5,6-dihydroimidaz0[2, 1 -b]thiazol-2-yI]-3-methyibutan-1 a!; 1 -[3-(benzof~b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b~thiazo-2-yl]pentan-1 -ol;, 10 1 -[3-(benzo[b]thiophen-3-y)-5,6-dihydrimidaz[2, 1 -b]thiazol-2-yl]prop-2-yn- -01; 1 [-bnobtiohn3y)56diyriiao21 -blthiazol-2-yl]but-3-en-1 -ol ; 1 -[3-(benzo[b]thiophen-3-yi)-5,6-dihydroimidazo[2, 1 -b]th iazol-2-yI]-2-m ethyl pro p-2 15 en-I-ol; 1 -[3-(benza[b]thiophen-3-yI)-5,6-dihydroimidazo[2, 1 -b~thiazal-2-yI]pent-4-en-1 -al; [3-(benza[b~thiaphen-3-yI)-5,
- 6-dihydraimidaza[2, 1 -bjthiazol-2-yl](2 20 methoxyphenyl)methanol; 3-(benzo[bthiaphen-3-y)-2-prop-1 -enyl-5,6-dihydraimidazo[2, 1 -b]thiazole; [3-(benza[b]thiophen-3-y)-6,7-dihyd rQ-5H-thiazolo[3,2-apyrim id if-2-yl]methanl; 25 3-(benzo[b]thiophen-3-yl)-5,6-dihydrimidazo[2, 1 -b]thiazale-2-carbanitrile; 3-(benza[b]thiaphen-3-y)-2-styryI-5,6-dihydrimidazo[2, 1 -blthiazale; 30 3-(5-chlorabenzo[b]thiaphen-3-yD)-5,6-dihydrimidazo[2, 1 -b]thiazole-2 carbaxaldehyde; [3-(5-chlarobenzo[b]thiaphen-3-yI)-5,6-dihydrimidaz0[2,1 -b]thiazol-2-yI]methanol; 35 3-(benza[b]thiophen-3-yl)-2-(phenylthio)-5,6-dihydrimidazo[2,1 -b]thiazole; [3-(benza[blthiaphen-3-yl)-5 ,6-dihydraimidaza[2, 1 -b]thiazal-2-yI]-N methylmethylamine; 40 3-(benzo[b]thiaphen-3-y)-2-cyclopropyI-5,6-dihydroinlidazo[2 1 -blthiazale; 3-(benzo[b]thiaphen-3-yl)-2-iodo-5,6-dihydrimidazo[2, 1 -bjthiazole; 4-[3-(benzo[b]thiophen-3-yl)-5, 6-dihydroimidazo[2, 1 -b]thiazol-2-yI]but-3-en-2-ol;, 45 3-(benzo[b]thiaphen-3-yl)-2-(2-methylprp-2-el)-5,6-dihydriidaz[2, 1 -b]thiazale; ethyl [3-(benza[b]thiaphen-3-yI)-5 ,6-dihydraimidazo[2, 1-b]th iazal-2-y1] acetate; 50 2-broma-3-[5-(methylthio)benzoEblthiophefl-3-yI]-5,6-dihydroimidaz0[2, 1 -b]thiazole; {3-[5-(methylthio)benza[b]thiaphel-3-yl]-5, 6-dihydraimidazo[2, 1 -b]thiazol-2 yllm ethanol; WO 00/71549 PCT/EP00/04279 83 3-(benzo[b]thiophen-3-yl)-2-cyclopropylmethoxymethyl-5,6-dihydroimidazo[2, 1 b]thiazole; 3-(benzo[b]thiophen-3-yl)-2-prop-2-ynyloxymethyl-5,6-dihydroimidazo[2,1 -b]thiazole; 5 2-bromo-3-(7-methoxybenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazole; 3-(benzo[b]thiophen-3-yl)-2-isopropoxymethyl-5,6-dihydroimidazo[2,1-b]thiazole; and 10 3-(benzo[b]thiophen-3-yl)-2-cyclobutylmethoxymethyl-5,6-dihydroimidazo[2, 1 b]thiazole including pharmaceutically acceptable salts thereof and individual enantiomers, racemates or other mixtures of enantiomers. 15 19) A compound selected from 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazole-2-carboxaldehyde; [3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[ 2 ,1 -b]thiazol-2-yl]methanol; 20 3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[ 2 , 1 -b]thiazole-2-carboxaldehyde oxime; 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazol-2-yl]ethanol; 25 3-(benzo[b]thiophen-3-yl)-2-bromo-5,6-dihydroimidazo[2, 1 -b]thiazole; 3-(benzo[b]thiophen-3-yl)-2-bromo-6,7-dihydro-5H-thiazolo[3,2-a]pyrimidine; 30 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]-1 -methylethanol; 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]propan-1 -ol; 2-bromo-3-(5-methoxybenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazole; 35 2-bromo-3-(5-chlorobenzo[b]thiophen-3-yl)-5,6-dihydroimidazo[ 2 ,1-b]thiazole; 3-(benzo[b]thiophen-3-yl)-2-ethoxymethyl-5,6-dihydroimidazo[ 2 ,1-b]thiazole; 40 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[ 2 ,1 -b]thiazol-2-yl]prop-2-en-1 -ol; 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]but-2-yn-1 -ol; 3-(benzo[b]thiophen-3-yl)-2-vinyl-5,6-dihydroimidazo[2, 1 -b]thiazole; 45 2-allyl-3-(benzolb]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazole; [3-(benzo[b]furan-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]methanol; 50 N-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[ 2 ,1 -b]thiazol-2-ylmethylidene]-1 methylethylamine; WO 00/71549 PCT/EP00/04279 84 3-(benzo[b]thiophen-3-yl)-2-chloro-5,6-dihydroimidazo[2,1-b]thiazole; 2-acetyl-3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2, 1 -b]thiazole; 5 3-(benzo[b]thiophen-3-yl)-2-(methoxymethyl)-5,6-dihydroimidazo[2,1 -b]thiazole; 3-(benzo[b]thiophen-3-yl)-2-(methylthio)-5,6-dihydroimidazo[2, 1 -b]thiazole; 10 3-(benzo[b]thiophen-3-yl)-2-(1 -methylvinyl)-5,6-dihydroimidazo[2,1 -b]thiazole; 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]-2-methylpropan-1 ol; 15 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]butan-1-ol; 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]th iazol-2-yl]-2-methylbut-3-en 1-ol; 20 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]-3-methylbutan-1 ol; 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]pentan- 1-ol; 25 1-[3-(benzo[b]thiophen-3-yi)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]prop-2-yn-1- o; 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1-b]thiazol-2-yl]but-3-en-1-ol ; 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]-2-methylprop-2 30 en-1-ol; and 1-[3-(benzo[b]thiophen-3-yl)-5,6-dihydroimidazo[2,1 -b]thiazol-2-yl]pent-4-en-1 -ol; 35 and pharmaceutically acceptable salts thereof. 20) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, as claimed in any previous claim, together with a 40 pharmaceutically acceptable diluent or carrier. 21) A compound of Formula I, as claimed in any previous claim, for use as a medicament. 45 22) A compound of Formula I, as claimed in any previous claim for use in the treatment of depression, anxiety, psychoses, schizophrenia, tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, cerebral ischaemia, obsessive-compulsive behaviour, panic attacks, social phobias, WO 00/71549 PCT/EP00/04279 85 eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, and stress, and as an aid to smoking cessation. 5 23) A compound of Formula I, as claimed in any previous claim for use in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke, brain trauma, cerebral ischaemia, head injuries and haemorrhage. 10 24) Use of a compound of Formula I, as claimed in any of claims 1 to 19, in the manufacture of a medicament for use in the treatment of depression, anxiety, psychoses, schizophrenia, tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, cerebral ischaemia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, 15 snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, and stress, and as an aid to smoking cessation and in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke, brain trauma, cerebral ischaemia, head injuries and haemorrhage. 20 25) A method of treating depression, anxiety, psychoses, schizophrenia, tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, cerebral ischaemia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, snacking and binge eating, non 25 insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, stress, and seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke, brain trauma, cerebral ischaemia, head injuries and haemorrhage comprising the administration of a therapeutically effective amount of a compound of Formula I, as claimed in any of claims 1 to 19, to a patient in need 30 thereof. 26) A method of reducing the craving to smoke in human beings which comprises the administration of a therapeutically effective amount of a compound of Formula 1, as claimed in any of claims 1 to 19, to a patient in need thereof. 35 WO 00/71549 PCT/EP00/04279 86 27) A method of reducing weight gain after smoking cessation in human beings which comprises the administration of a therapeutically effective amount of a compound of Formula I, as claimed in any of claims 1 to 19, to a patient in need thereof. 5 28) A compound of Formula I, as claimed in any of claims 1 to 19, for use in the treatment or prevention of metabolic diseases and conditions arising therefrom, in particular non exercise activity thermogenesis and increased metabolic rate, sexual dysfunction, sleep apnoea, premenstrual syndrome, urinary incontinence, 10 hyperactivity disorders, hiatial hernia and reflux esophagitis, pain, especially neuropathic pain, weight gain associated with drug treatment, chronic fatigue syndrome, osteoarthritis and gout, cancers associated with weight gain, menstrual dysfunction, gallstones, orthostatic hypotension and pulmonary hypertension. 15 29) A compound of Formula I, as claimed in any of claims 1 to 19, for use in the prevention of cardiovascular disease, in reducing platelet adhesiveness, in aiding weight loss after pregnancy or in aiding weight loss after smoking cessation. 30) The use of a compound which is a 5-HT1A agonist and which is also 20 monoamine reuptake inhibitor particularly a noradrenaline reuptake inhibitor in the treatment of obesity and related co-morbid conditions without causing cardiovascular side effects. 31) A method of treating obesity without causing cardiovascular side-effects 25 comprising the administration of a compound which is a 5-HT1A agonist and which is also a monoamine reuptake inhibitor particularly a noradrenaline reuptake inhibitor to a patient in need thereof. 32) A compound of Formula I as claimed in any one of claims 1 to 19 for use in 30 the treatment obesity and related co-morbid conditions. 33) A process for the preparation of compounds of Formula I comprising: a) dehydrating a compound of Formula II WO 00/71549 PCT/EP00/04279 87 RS H NN (RR)g I 2 n A R s in which A,R 1 ,R 2 ,R 3 ,R 4 ,Rs, g and n are as hereinbefore defined, optionally in the presence of an acid at a temperature in the range 0-200OC; or 5 b) by reacting a compound of Formula Ill H N> S =< (CR 2 R 3 ) In N / H in which R 2 ,R 3 and n are as hereinbefore defined, with a compound of Formula IV 10 CO.CHR 4 .Z (R1)g 9 IV W A R 5 in which Z is a leaving group and A,R 1 ,R 4 ,R 5 and g are as hereinbefore defined, at a temperature in the range 0-200 0 C, optionally in the presence of an acid, and optionally in the presence of a solvent, without isolation of the intermediate of 15 Formula II; or c) reacting a compound of Formula V S N (Rj) / L(CR2R3 n A R 20 WO 00/71549 PCT/EP00/04279 88 in which A, R 1 , R 2 , R 3 , Rs, n and g are as hereinbefore defined, with a halogenating agent at a temperature in the range -50-200oC optionally in the presence of a solvent to give compounds of Formula I in which R 4 represents halo or 5 d) reacting a compound of Formula VI O S N VI (R )g A R 5 in which A, R 1 , R 2 , Ra, R 5 , n and g are as hereinbefore defined and Ry is H with an organometallic reagent of formula RxMgX or RxLi in which Rx is a C1-5 alkyl group, an 10 alkenyl group containing 2-5 carbon atoms, an alkynyl group containing 2-5 carbon atoms or (2-C 1 - 3 alkoxyphenyl) and X is halo, in the presence of a solvent, at a temperature in the range of -500C to the boiling point of the solvent used to give compounds of Formula I in which R 4 represents a group of Formula -CH(OH)Rx in which Rx is as hereinbefore defined; or 15 e) reacting a compound of Formula VI in which A, R 1 , PR, R 3 , Rs, g and n are as hereinbefore defined and Ry is a C1.5 alkyl group, an alkenyl group containing 2-5 carbon atoms, an alkynyl group containing 2-5 carbon atoms or (2-C 1 - 3 alkoxyphenyl) with a reducing agent in the presence of a solvent, at a temperature in the range of 20 0 0 C to the boiling point of the solvent used to give compounds of Formula I in which R 4 represents a group of Formula -CH(OH)Ry in which Ry is a C15 alkyl group, an alkenyl group containing 2-5 carbon atoms, an alkynyl group containing 2-5 carbon atoms or (2-C 1 .- 3 alkoxyphenyl) ; or 25 f) reacting a compound of Formula VI in which A, R 1 , R 2 , R 3 , R 5 , g and n are as hereinbefore defined and Ry is H with a reducing agent, in a solvent, at a temperature in the range of -500C to the boiling point of the solvent used to give compounds of Formula I in which R 4 is hydroxymethyl; or WO 00/71549 PCT/EP00/04279 89 g) reacting a compound of Formula VI in which A, R 1 , R, R 3 , R 5 , g and n are as hereinbefore defined and Ry is H with hydroxylamine or a salt thereof optionally in the presence of a solvent, at a temperature in the range of 0-250oC to give compounds of Formula I in which R 4 is hydroxyiminomethyl; or 5 h) reacting a compound of Formula VI in which A, R 1 , R, R 3 , R 5 , g and n are as hereinbefore defined and Ry is H with hydroxylamine or a salt thereof in the presence of formic acid at a temperature in the range of 0-2500C to give compounds of Formula I in which R 4 is cyano; or 10 i) reacting a compound of Formula VI in which A, R 1 , R 2 , R, R 5 , g and n are as hereinbefore defined and Ry is H with an amine of Formula RaNH 2 wherein Ra represents a C1-4 alkyl group optionally in the presence of a solvent, optionally in the presence of an acid catalyst, at a temperature in the range 0-2500C to give 15 compounds of Formula I in which R 4 represents a C 1 4alkyliminomethylene group; or j) reacting a compound of Formula I in which R 4 represents a C1. 4 alkyliminomethylene group, and A, R 1 , R 2 , R 3 , R 5 , g and n are as hereinbefore defined, with a reducing agent in the presence of a solvent, at a temperature in the 20 range of 00C to the boiling point of the solvent used to give compounds of Formula I in which R 4 represents a C 1 4 alkylaminomethylene group; or k) reacting a compound of Formula VI in which A, R 1 , R 2 , R 3 , R 5 , g and n are as hereinbefore defined and Ry represents hydrogen with an amine of formula RaNH 2 25 wherein Ra represents a C1-4 alkyl group and a reducing agent, in the presence of a solvent, at a temperature in the range 00C to the boiling point of the solvent used to give compounds of Formula I in which R 4 represents a C 1 -4alkylaminomethylene group; or 30 1) reacting a compound of Formula VI in which Ry is a C1.5 alkyl group, and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, with an organometallic reagent of formula RxMgX or RxLi in which Rx is a CI-.5 alkyl group and X is halo, in the presence of a solvent, at a temperature in the range of -500C to the boiling point of the solvent WO 00/71549 PCT/EP00/04279 90 used to give compounds of Formula I in which R 4 represents a group of formula -C(OH)RxRy in which Rx and Ry are each independently a C1.5 alkyl group; or m) reacting a compound of Formula VI, as hereinbefore defined except that Ry is 5 ORz in which Rz is a C1-6alkyl group, with an organometallic reagent of formula RxMgX or RxLi in which Rx is a C1.2 alkyl group and X is halo, in the presence of a solvent, at a temperature in the range of -50 0 C to the boiling point of the solvent used to give compounds of Formula I in which R 4 represents a group of formula -C(OH)RxRy in which Rx and Ry are the same C1-2 alkyl group; or 10 n) reacting compounds of Formula VI, in which Ry represents hydrogen or a C1-4 alkyl group, and A, R1, R 2 , R 3 , R 5 , n and g are as previously defined, with a phosphonium salt of formula RzPh 3 P+Br- in which Rzrepresents a C1-5 alkyl group or a benzyl group in the presence of a base, in a solvent at a temperature in the range 15 -780C to the boiling point of the solvent used to give compounds of Formula I in which R 4 represents a C2-6 alkenyl group in which the double bond is attached to the carbon alpha to the thiazole ring or a styryl group; or o) reacting a compound of Formula I in which R 4 represents halo and A, R 1 , R 2 , R 3 , 20 R 5 , n and g are as previously defined or a compound of Formula V, with a compound of formula RbMgX or RbLi in which Rb is a 01-6 alkyl group and X is halo, in the presence of a solvent at a temperature in the range -780C to the boiling point of the solvent used, and then reacting the product obtained with an acylating agent of Formula RcCON(CH 3 )OCH 3 in which Rc represents a C1.-5 alkyl group in a solvent, at 25 a temperature in the range 00C to the boiling point of the solvent used to give compounds of Formula I in which R 4 represents a 02.-6 alkanoyl group; or p) reacting a compound of Formula I in which R 4 represents a hydroxyC 1 - 3 alkyl group, and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, with a C1-3 alkylating 30 agent, in the presence of a base, in a solvent, at a temperature in the range of -50 to 1500C to give compounds of Formula I in which R 4 represents a 01-3 alkoxyC1. 3 alkyl group; or q) reacting a compound of Formula I in which R 4 represents a hydroxyC 1 - 3 alkyl 35 group, and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, with a C4.7 WO 00/71549 PCT/EP00/04279 91 cycloalkylalkylating agent, in the presence of a base, in a solvent, at a temperature in the range of -50 to 1500C. to give compounds of Formula I in which R 4 represents a C4-7cycloalkylalkoxyC. 3 alkyl group; or 5 r) reacting a compound of Formula I in which R 4 represents a hydroxyC 1 - 3 alkyl group, and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, with a C3-.7 alkynylalkylating agent in the presence of a base, in a solvent, at a temperature in the range of -50 to 1500C to give compounds of Formula I in which R 4 represents a C3.7 alkynylalkoxyC 1 . 3 alkyl group; or 10 s) reacting a compound of Formula I in which R 4 represents a mercaptoC1- 3 alkyl group, and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, with a C1- 3 alkylating agent, in the presence of a base, in a solvent, at a temperature in the range of -50 to 1500C to give compounds of Formula I in which R 4 represents a C1-3 alkylthioC1-3 15 alkyl group; or t) reacting a compound of Formula I in which R 4 represents halo or a compound of Formula V with a metallating agent of formula RMgX or RLi in which R is a C1-6 alkyl group and X is halo, in a solvent, at a temperature in the range of -1000C to the 20 boiling point of the solvent used to give an intermediate complex, which is reacted with a disulphide of formula RdS-SRd in which Rd is a 01-3 alkyl group or an aryl group, at a temperature in the range of -1000C to the boiling point of the solvent used to give compounds of Formula I in which R 4 represents a C1-3 alkylthio group or an arylthio group and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined; or 25 u) reacting a compound of Formula I in which R 4 represents halo with an C1.3 alkoxide salt, optionally in the presence of a solvent, optionally in the presence of a catalyst, at a temperature in the range of 0-3500C to give compounds of Formula 1 in which R 4 represents a C1-3 alkoxy group and A, R 1 , R 2 , R 3 , R 5 , n and g are as 30 previously defined; or v) reacting a compound of Formula I in which R 4 represents halo, for example bromo or chloro, and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, or a compound of Formula V with a compound of formula RbMgX or RbLi in which Rb is a WO 00/71549 PCT/EP00/04279 92 C1-6 alkyl group and X is halo, for example bromo or chloro, in the presence of a solvent, at a temperature in the range -780C to the boiling point of the solvent used, and then reacting the product obtained with an alkenylating agent, for example a C3 6 alkenylmethyl halide, in a solvent, at a temperature in the range 0oC to the boiling 5 point of the solvent used, to give compounds of Formula I in which R 4 represents a C 3 - 6 alkenyl group in which the double bond is not attached to the carbon alpha to the thiazole ring; or w) reacting compounds of Formula VI, in which Ry represents hydrogen and A, R 1 , 10 R 2 , R 3 , R 5 , n and g are as previously defined, with a phosphonate of formula Me 2 NCH[PO(ORz) 2 ] 2 in which Rzrepresents a C1-4 alkyl group in the presence of a base, in a solvent, at a temperature in the range -780C to the boiling point of the solvent used, then subjecting the resulting intermediate product to partial hydrolysis in the presence of an acid, to give compounds of Formula I in which R 4 is a C3 15 6 alkoxycarbonylalkyl group; or x) reacting compounds of Formula VI, in which Ry represents hydrogen and A, R 1 , R 2 , R 3 , R 5 , n and g are as previously defined, with a compound of Formula (RzO) 2 POCH2CORc in which Rz represents a C1-2 alkyl group and Rc represents a 20 C1-3 alkyl group in the presence of a base, in a solvent, at a temperature in the range -780C to the boiling point of the solvent used, then subjecting the resulting intermediate product to reaction with a reducing agent, in a solvent, at a temperature in the range -200C to the boiling point of the solvent used, to give compounds of Formula I in which R 4 is a C 4 - 6 hydroxyalkenyl group in which the double bond is 25 attached to the carbon alpha to the thiazole ring.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9911863 | 1999-05-21 | ||
GBGB9911863.0A GB9911863D0 (en) | 1999-05-21 | 1999-05-21 | Therapeutic agents |
PCT/EP2000/004279 WO2000071549A1 (en) | 1999-05-21 | 2000-05-11 | Thiazoloderivatives and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
AU5065700A true AU5065700A (en) | 2000-12-12 |
Family
ID=10853913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU50657/00A Abandoned AU5065700A (en) | 1999-05-21 | 2000-05-11 | Thiazoloderivatives and pharmaceutical compositions containing them |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1178993A1 (en) |
JP (1) | JP2003500410A (en) |
KR (1) | KR20020033626A (en) |
CN (1) | CN1361783A (en) |
AU (1) | AU5065700A (en) |
BG (1) | BG106227A (en) |
BR (1) | BR0010827A (en) |
CA (1) | CA2374926A1 (en) |
CZ (1) | CZ20014171A3 (en) |
GB (1) | GB9911863D0 (en) |
HU (1) | HUP0201376A2 (en) |
IL (1) | IL146540A0 (en) |
MX (1) | MXPA01011895A (en) |
NO (1) | NO20015667L (en) |
PL (1) | PL352282A1 (en) |
SK (1) | SK16852001A3 (en) |
TR (1) | TR200200164T2 (en) |
WO (1) | WO2000071549A1 (en) |
ZA (1) | ZA200110022B (en) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0005789D0 (en) * | 2000-03-11 | 2000-05-03 | Knoll Ag | Therapeutic agents |
GB0023610D0 (en) * | 2000-09-27 | 2000-11-08 | Knoll Ag | Therapeutic agents |
UA76130C2 (en) * | 2000-11-20 | 2006-07-17 | Merck Patent Gmbh | Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome |
JP2005501861A (en) | 2001-08-22 | 2005-01-20 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Combinations of 1,4-benzothiepine 1,1-dioxide derivatives with other active substances and their use |
KR100915108B1 (en) | 2001-08-31 | 2009-09-03 | 사노피-아벤티스 도이칠란트 게엠베하 | Diarylcycloalkyl derivatives as PPAR activators and a pharmaceutical composition comprising the same |
US7399777B2 (en) | 2001-08-31 | 2008-07-15 | Sanofi-Aventis Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals |
US6884812B2 (en) | 2001-08-31 | 2005-04-26 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals |
US7223796B2 (en) | 2002-04-11 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use |
US7078404B2 (en) | 2002-04-11 | 2006-07-18 | Sanofi-Aventis Deutschland Gmbh | Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use |
US7049341B2 (en) | 2002-06-07 | 2006-05-23 | Aventis Pharma Deutschland Gmbh | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use |
US7262220B2 (en) | 2002-07-11 | 2007-08-28 | Sanofi-Aventis Deutschland Gmbh | Urea- and urethane-substituted acylureas, process for their preparation and their use |
DE10231370B4 (en) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophene glycoside derivatives, medicaments containing these compounds and methods of making these medicaments |
PL373329A1 (en) | 2002-07-12 | 2005-08-22 | Sanofi-Aventis Deutschland Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
US20040157922A1 (en) | 2002-10-04 | 2004-08-12 | Aventis Pharma Deutschland Gmbh | Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments |
US7208504B2 (en) | 2002-10-12 | 2007-04-24 | Sanofi-Aventis Deutschland Gmbh | Bicyclic inhibitors of hormone sensitive lipase |
DE10258007B4 (en) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatic fluoroglycoside derivatives, medicaments containing these compounds and methods for the preparation of these medicaments |
US20040242583A1 (en) | 2003-01-20 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use |
US7179941B2 (en) | 2003-01-23 | 2007-02-20 | Sanofi-Aventis Deutschland Gmbh | Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use |
DE10306250A1 (en) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals |
US7196114B2 (en) | 2003-02-17 | 2007-03-27 | Sanofi-Aventis Deutschland Gmbh | Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use |
US7148246B2 (en) | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
DE10308353A1 (en) | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as medicines |
DE10308355A1 (en) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl-substituted alkanoic acid derivatives, process for their preparation and their use as medicaments |
DE10308352A1 (en) | 2003-02-27 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Branched side chain arylcycloalkyl derivatives, process for their preparation and their use as medicaments |
DE10308351A1 (en) | 2003-02-27 | 2004-11-25 | Aventis Pharma Deutschland Gmbh | 1,3-substituted cycloalkyl derivatives having acidic, usually heterocyclic groups, processes for their preparation and their use as medicaments |
US7501440B2 (en) | 2003-03-07 | 2009-03-10 | Sanofi-Aventis Deutschland Gmbh | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use |
DE10314610A1 (en) | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | New diphenylazetidinone with improved physiological properties, process for its preparation, medicaments containing these compounds and its use |
US7094800B2 (en) | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
US7008957B2 (en) | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
US7094794B2 (en) | 2003-07-28 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
DE10335092B3 (en) | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituted benzoylureido-o-benzoylamides, process for their preparation and their use |
US7241787B2 (en) | 2004-01-25 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments |
US7498341B2 (en) | 2004-01-31 | 2009-03-03 | Sanofi Aventis Deutschland Gmbh | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
US7402674B2 (en) | 2004-01-31 | 2008-07-22 | Sanofi-Aventis Deutschland Gmbh, | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
US7470706B2 (en) | 2004-01-31 | 2008-12-30 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
DE102004005172A1 (en) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazole derivatives as inhibitors of the hormone sensitive lipase |
EP1586573B1 (en) | 2004-04-01 | 2007-02-07 | Sanofi-Aventis Deutschland GmbH | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
DE102005026762A1 (en) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases |
CN101443314B (en) | 2006-03-13 | 2014-04-09 | 杏林制药株式会社 | Aminoquinolones as GSK-3 inhibitors |
DE102006028862A1 (en) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-amino-imidazo [1,2-a] pyridine |
RU2009108280A (en) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use |
DE102007002260A1 (en) | 2007-01-16 | 2008-07-31 | Sanofi-Aventis | Use of substituted pyranonic acid derivatives for the preparation of medicaments for the treatment of the metabolic syndrome |
DE102007008420A1 (en) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | benzimidazole derivatives |
AU2008299903B2 (en) | 2007-09-11 | 2013-08-29 | Kyorin Pharmaceutical Co., Ltd | Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors |
KR101597841B1 (en) | 2007-09-12 | 2016-02-26 | 교린 세이야꾸 가부시키 가이샤 | Spirocyclic aminoquinolones as gsk-3 inhibitors |
DE102007048716A1 (en) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo [1,2-a] pyrimidine derivatives |
DE102007054497B3 (en) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | New crystalline hydrate form of dodecanedioic acid 4-((2S,3R)-3-((S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl)-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl)-benzylamide ((2S,3R,4R,5R)-pentahydroxy-hexyl)-amide useful e.g. to treat hyperlipidemia |
US9393002B2 (en) | 2008-02-18 | 2016-07-19 | Covidien Lp | Clip for implant deployment device |
US8317808B2 (en) | 2008-02-18 | 2012-11-27 | Covidien Lp | Device and method for rolling and inserting a prosthetic patch into a body cavity |
US9044235B2 (en) | 2008-02-18 | 2015-06-02 | Covidien Lp | Magnetic clip for implant deployment device |
US9398944B2 (en) | 2008-02-18 | 2016-07-26 | Covidien Lp | Lock bar spring and clip for implant deployment device |
US9301826B2 (en) | 2008-02-18 | 2016-04-05 | Covidien Lp | Lock bar spring and clip for implant deployment device |
US9034002B2 (en) | 2008-02-18 | 2015-05-19 | Covidien Lp | Lock bar spring and clip for implant deployment device |
EP2247245B1 (en) | 2008-02-18 | 2017-06-28 | Covidien LP | A device for deploying and attaching a patch to a biological tissue |
US9833240B2 (en) | 2008-02-18 | 2017-12-05 | Covidien Lp | Lock bar spring and clip for implant deployment device |
US9393093B2 (en) | 2008-02-18 | 2016-07-19 | Covidien Lp | Clip for implant deployment device |
US8758373B2 (en) | 2008-02-18 | 2014-06-24 | Covidien Lp | Means and method for reversibly connecting a patch to a patch deployment device |
US8808314B2 (en) | 2008-02-18 | 2014-08-19 | Covidien Lp | Device and method for deploying and attaching an implant to a biological tissue |
DE102008017590A1 (en) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
RU2011102262A (en) * | 2008-06-21 | 2012-07-27 | КенБер ЛЛСи (US) | NUTRIGENOMIC METHODS AND COMPOSITIONS |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
EP2792307B1 (en) | 2008-10-20 | 2017-10-04 | Covidien LP | A device for attaching a patch to a biological tissue |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
MX2011009414A (en) | 2009-03-11 | 2011-10-19 | Kyorin Seiyaku Kk | 7-cycloalkylaminoquinolones as gsk-3 inhibitors. |
WO2011021082A1 (en) | 2009-08-17 | 2011-02-24 | PolyTouch Medical, Inc. | Means and method for reversibly connecting an implant to a deployment device |
EP2467093B1 (en) | 2009-08-17 | 2019-08-28 | Covidien LP | Articulating patch deployment device |
JP2013503135A (en) | 2009-08-26 | 2013-01-31 | サノフイ | Novel crystalline heteroaromatic fluoroglycoside hydrate, pharmaceutical comprising the compound and use thereof |
EP2482823A2 (en) | 2009-10-02 | 2012-08-08 | Sanofi | Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120053A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683700B1 (en) | 2011-03-08 | 2015-02-18 | Sanofi | Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use |
EP2683701B1 (en) | 2011-03-08 | 2014-12-24 | Sanofi | Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use |
EP2766349B1 (en) | 2011-03-08 | 2016-06-01 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120051A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN114113064B (en) * | 2021-12-27 | 2023-09-08 | 郑州大学 | Light-responsive oxidase based on benzodithiazole, preparation method thereof and application of light-responsive oxidase in colorimetric detection of glutathione in foods |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9513467D0 (en) * | 1995-07-01 | 1995-09-06 | Knoll Ag | Therapeutic agents |
GB9705428D0 (en) * | 1997-03-15 | 1997-04-30 | Knoll Ag | Therapeutic agents |
-
1999
- 1999-05-21 GB GBGB9911863.0A patent/GB9911863D0/en not_active Ceased
-
2000
- 2000-05-11 KR KR1020017014892A patent/KR20020033626A/en not_active Application Discontinuation
- 2000-05-11 HU HU0201376A patent/HUP0201376A2/en unknown
- 2000-05-11 MX MXPA01011895A patent/MXPA01011895A/en unknown
- 2000-05-11 BR BR0010827-8A patent/BR0010827A/en not_active IP Right Cessation
- 2000-05-11 IL IL14654000A patent/IL146540A0/en unknown
- 2000-05-11 WO PCT/EP2000/004279 patent/WO2000071549A1/en not_active Application Discontinuation
- 2000-05-11 TR TR2002/00164T patent/TR200200164T2/en unknown
- 2000-05-11 EP EP00935009A patent/EP1178993A1/en not_active Withdrawn
- 2000-05-11 AU AU50657/00A patent/AU5065700A/en not_active Abandoned
- 2000-05-11 JP JP2000619805A patent/JP2003500410A/en not_active Withdrawn
- 2000-05-11 CZ CZ20014171A patent/CZ20014171A3/en unknown
- 2000-05-11 CA CA002374926A patent/CA2374926A1/en not_active Abandoned
- 2000-05-11 SK SK1685-2001A patent/SK16852001A3/en unknown
- 2000-05-11 PL PL00352282A patent/PL352282A1/en not_active Application Discontinuation
- 2000-05-11 CN CN00810653A patent/CN1361783A/en active Pending
-
2001
- 2001-11-20 NO NO20015667A patent/NO20015667L/en not_active Application Discontinuation
- 2001-12-05 ZA ZA200110022A patent/ZA200110022B/en unknown
- 2001-12-17 BG BG106227A patent/BG106227A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TR200200164T2 (en) | 2002-04-22 |
PL352282A1 (en) | 2003-08-11 |
EP1178993A1 (en) | 2002-02-13 |
BR0010827A (en) | 2002-06-04 |
CN1361783A (en) | 2002-07-31 |
HUP0201376A2 (en) | 2002-08-28 |
NO20015667D0 (en) | 2001-11-20 |
SK16852001A3 (en) | 2002-05-09 |
ZA200110022B (en) | 2003-05-28 |
KR20020033626A (en) | 2002-05-07 |
JP2003500410A (en) | 2003-01-07 |
CA2374926A1 (en) | 2000-11-30 |
BG106227A (en) | 2002-08-30 |
GB9911863D0 (en) | 1999-07-21 |
IL146540A0 (en) | 2002-07-25 |
CZ20014171A3 (en) | 2002-06-12 |
MXPA01011895A (en) | 2004-03-19 |
NO20015667L (en) | 2002-01-21 |
WO2000071549A1 (en) | 2000-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5065700A (en) | Thiazoloderivatives and pharmaceutical compositions containing them | |
US6900216B2 (en) | Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents | |
EP0970090B1 (en) | Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use | |
KR102307413B1 (en) | Multicyclic compounds and methods of use thereof | |
EP1881827B1 (en) | Fused thiazole derivatives as kinase inhibitors | |
AU4565200A (en) | Substituted imidazothiazoles as antidepressant agents | |
WO2002026747A1 (en) | Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidine derivatives with 5-ht receptor affinity | |
US5869492A (en) | Condensed thiazole derivatives, having 5-HT receptor affinity | |
MXPA97009509A (en) | Therapeutic agents | |
CZ9903260A3 (en) | Therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |